The effects of the HIV-1 Tat protein and morphine on the structure and function of the hippocampal CA1 subfield by Marks, William D.
Virginia Commonwealth University 
VCU Scholars Compass 
Theses and Dissertations Graduate School 
2017 
The effects of the HIV-1 Tat protein and morphine on the structure 
and function of the hippocampal CA1 subfield 
William D. Marks 
SUNY College at Buffalo 
Follow this and additional works at: https://scholarscompass.vcu.edu/etd 
 Part of the Molecular and Cellular Neuroscience Commons, Pharmacology Commons, Systems 
Neuroscience Commons, Toxicology Commons, and the Virology Commons 
 
© The Author 
Downloaded from 
https://scholarscompass.vcu.edu/etd/5168 
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It 
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars 
Compass. For more information, please contact libcompass@vcu.edu. 
The effects of the HIV-1 Tat protein and morphine on the structure and function of 
the hippocampal CA1 subfield 
 
 
 
 
 
 
A dissertation submitted in partial fulfillment of requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University 
 
 
 
 
 
 
 
By 
William D. Marks 
Master of Arts, State University of New York College at Buffalo 
Bachelor of Science, Franciscan University of Steubenville 
 
 
 
 
 
 
 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
December 2017  
ii 
 
 
 
Acknowledgements 
 
 A great deal of gratitude is owed to a great many people who have been 
instrumental in this work and beyond. I would first like to thank my advisor, Dr. Kurt 
Hauser for his insight, energy, and his patience along the way. His enthusiasm and 
candor was most helpful, and, I feel, has given me valuable insight into life as a scientist 
beyond the lab bench. I am likewise grateful to Dr. Pamela Knapp, whose keen eye for 
experimental design and readiness to help made the setbacks I experienced (inevitable 
in any project) more manageable than they would have been otherwise. I also would 
like to thank Dr. Rory McQuiston and Dr. Thomas Reeves for their help, without which 
none of the electrophysiological studies presented here would have been possible. Also 
instrumental in getting this work done properly were Dr. Jason Paris, Dr. Virginia 
McLane, Mr. Aaron Barbour, and Ms. Jean Moon. 
 Thanks are due also to the two men who inspired and encouraged me from a 
very young age to pursue the natural sciences; my late grandfather, Mr. Arthur Marks, 
who went out of his way to make sure I had every chance to be exposed to the wonders 
of the natural world, and Dr. Norman Paolini Jr. who taught me to experiment with the 
things around me (much to my parents chagrin), for example, by growing fungi in petri 
dishes lightly coated with grape jelly (which I of course carried in my pockets for 
warmth). 
 A great many thanks are due to my closest friends, Ms. Eileen Bartolozzi, Ms. 
Maria Lang, Mr. Eric Smith, Dr. Michael Del Do, Mr. Zachary Curry, and Mr. Adam 
iii 
 
 
 
DePriest. Your friendship over these past few years has been a constant source of 
inspiration, humor, and comfort.  
 To the members of the Hauser/Knapp collective past and present; I am incredibly 
glad to have met you all. You have made the -myriad- frustrations of graduate education 
more bearable. It’s hard to imagine a more vibrant and enjoyable workplace, and I am 
seriously concerned that no place I go on from here will ever match y’all!  
 I would also like to thank the Catholic community of Richmond, especially the 
parishes at the Cathedral of the Sacred Heart, St. Benedict’s and St. Mary’s, and all the 
amazing people I’ve gotten to know through CatholicRVA. Finally, and most importantly, 
I give my thanks to God, who sustains and strengthens me -Ad Majorem Dei Gloriam-. 
  
  
iv 
 
 
 
Table of Contents 
Acknowledgements ..........................................................................................................ii 
List of Figures ................................................................................................................. vii 
List of Tables ...................................................................................................................ix 
List of Abbreviations ........................................................................................................ x 
Abstract ........................................................................................................................... 1 
Chapter 1: Introduction .................................................................................................... 3 
The human immunodeficiency virus ............................................................................. 3 
HIV-1 structure and viral proteins ................................................................................. 4 
HIV-1 Tat ...................................................................................................................... 5 
Transmission and Epidemiology of HIV Infection ......................................................... 7 
AIDS ............................................................................................................................. 7 
Infection of the CNS ..................................................................................................... 9 
The HIV Associated Neurocognitive Disorders .......................................................... 10 
Neuronal pathology ................................................................................................. 10 
Astrocytic pathology and contribution to neuroAIDS ............................................... 13 
Microglial and MDM pathology and contribution to neuroAIDS ............................... 17 
Oligodendrocytic and myelin pathology .................................................................. 20 
Global effects of HIV on the central nervous system .............................................. 21 
The Hippocampus and HIV ........................................................................................ 24 
v 
 
 
 
Comorbidity of HIV infection and opioid abuse disorder ............................................ 28 
The opiate receptors, morphine, and the hippocampus ............................................. 29 
Morphine effects in the hippocampus ........................................................................ 32 
Interactions between HIV and opiate use ................................................................... 33 
Hypotheses and Aims ................................................................................................ 36 
Chapter 2: The effects of HIV Tat on CA1 interneuron microcircuitry and spatial memory
 ...................................................................................................................................... 38 
Introduction ................................................................................................................ 38 
Materials and methods ............................................................................................... 41 
Results ....................................................................................................................... 47 
Discussion .................................................................................................................. 51 
Chapter 3: The effects of Tat and Morphine on the structure and function of CA1 ........ 73 
Introduction ................................................................................................................ 73 
Materials and Methods ............................................................................................... 75 
Results ....................................................................................................................... 82 
Discussion .................................................................................................................. 90 
Chapter 4: General Discussion and future directions .................................................. 118 
Future directions ...................................................................................................... 133 
Concluding remarks ................................................................................................. 141 
References .................................................................................................................. 146 
vi 
 
 
 
Vita .............................................................................................................................. 184 
 
  
vii 
 
 
 
List of Figures 
Figure 2. 1: Barnes  maze performance between Tat- and Tat+ mice .......................... 59 
Figure 2. 2: Effects of Tat on novel object recognition task performance ...................... 61 
Figure 2. 3: Tat effects on nNOS and NPY expressing CA1 interneurons .................... 62 
Figure 2. 4: nNOS and NPY subcellular localization ..................................................... 64 
Figure 2. 5: Effects of Tat on PV and SST expressing CA1 interneurons ..................... 65 
Figure 2. 6: PV and SST subcellular localization ........................................................... 67 
Figure 2. 7: Tat does not affect amount of PV or SST+ neurites in CA1 ....................... 69 
Figure 2. 8: Interneurons affected by Tat are part of a memory microcircuit ................. 70 
 
Figure 3. 1: Effects of Tat and morphine on Barnes maze performance in mice ........... 96 
Figure 3. 2: Representative Barnes maze track traces.................................................. 98 
Figure 3. 3: Visual representation of planned comparisons design for 
electrophysiological analysis ......................................................................................... 99 
Figure 3. 4: Firing frequency of CA1 pyramidal cells after exposure to Tat and/or 
morphine-treated mice (in vivo) in which morphine is present during electrophysiological 
recordings (ex vivo) ..................................................................................................... 100 
Figure 3. 5: Membrane properties of CA1 pyramidal cells in Tat and/or morphine-treated 
mice (in vivo) in which morphine is present during electrophysiological recordings (ex 
vivo) ............................................................................................................................. 101 
Figure 3. 6: Firing frequency of CA1 pyramidal cells from Tat and/or morphine-treated 
mice (in vivo) in which morphine is withheld during electrophysiological recordings (ex 
vivo) ............................................................................................................................. 103 
viii 
 
 
 
Figure 3. 7: Membrane properties of CA1 pyramidal cells from Tat and/or morphine-
treated mice (in vivo) in which morphine is withheld during electrophysiological 
recordings (ex vivo) ..................................................................................................... 105 
Figure 3. 8: Examples of a 3D-reconstructed biocytin-filled CA1 pyramidal cells ........ 107 
Figure 3. 9: Effects of Tat and morphine on the morphology of the portion of the 
pyramidal cell dendrite within the stratum oriens (SO) ................................................ 108 
Figure 3. 10: Effects of Tat and morphine on the morphology of the portion of the 
pyramidal cell dendrite within the stratum radiatum (SR) ............................................ 110 
Figure 3. 11: Effects of Tat and morphine on the morphology of the portion of the 
pyramidal cell dendrite within the stratum lacunosum-moleculare (SL-M)................... 112 
Figure 3. 12: Assessment of gephyrin puncta within the aspinous portion of pyramidal 
cell basilar and apical dendrites .................................................................................. 114 
 
Figure 4. 1: TdTomato x VIP expressing mice ............................................................ 143 
 
  
ix 
 
 
 
List of Tables 
Table 1. 1 Selected listing of regional effects of HIV/HIV proteins within the CNS ........ 37 
 
Table 2. 1: Raw exploration time and motor behavior among Tat- and Tat+ mice ........ 72 
 
Table 3. 1: Membrane properties of CA1 pyramidal cells after exposure to Tat and 
morphine ..................................................................................................................... 115 
Table 3. 2: Membrane properties of CA1 pyramidal cells from Tat- and Tat+ animals in a 
withdrawal like state .................................................................................................... 116 
Table 3. 3 Correlations between morphological and electrophysiological findings ...... 117 
 
Table 4. 1: Effects of Tat and morphine on hippocampal cytokine levels .................... 144 
Table 4. 2: Protein extracted from hippocampal samples ............................................ 145 
 
 
 
 
 
 
  
x 
 
 
 
List of Abbreviations 
AIDS- autoimmune deficiency syndrome 
AEG- astrocyte elevated gene 
CA- cornu ammonis 
CNS- central nervous system 
CSF- cerebrospinal fluid 
DG- dentate gyrus 
DOR- delta opiate receptor 
EC- entorhinal cortex 
EPSP- excitatory post synaptic potential 
GABA- Gama-aminobutyric acid 
GP120- glycoprotein 120 
GUD- genital ulcer disease 
HAND- HIV associated neurocognitive disorders 
HIV- Human immunodeficiency virus 
HIVE- HIV encephalopathy 
IHC- immunohistochemistry/immunohistochemical 
IDU- intravenous drug user 
IPSP- inhibitory postsynaptic potential 
IS1- interneuron specific interneuron type 1 
IS3- interneuron specific interneuron type 3 
IV- intravenous 
KOR- kappa opiate receptor 
xi 
 
 
 
LTP- long term potentiation 
MOR- mu opiate receptor 
MSM- Men who have sex with men 
nNOS- neuronal nitric oxide synthase 
NO- nitric oxide 
NPY- neuropeptide Y 
NR- nucleus reuniens 
OLM- Oriens-lacunosum moleculare projecting cell 
PFC- prefrontal cortex 
P-TEFb- positive transcription elongation factor 
PV- parvalbumin 
ROS- reactive oxygen species 
SIV- simian immunodeficiency virus 
SL-M- Stratum lacunosum-moleculare 
SO- stratum oriens 
SP- stratum pyramidale 
SR- stratum radiatum 
SST- somatostatin 
Syt2- synaptotagmin 2 
Tat- transactivator of transcription 
TAR- Transctivator response element 
VIP- vasoactive intestinal peptide 
 
 
Abstract 
THE EFFECTS OF THE HIV-1 TAT PROTIEN AND MORPHINE ON THE 
STRUCTURE AND FUNCTION OF THE HIPPOCAMPAL CA1 SUBFIELD 
By William D Marks, MA, Ph.D.c. 
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 HIV is capable of causing a set of neurological diseases collectively termed the 
HIV Associated Neurocognitive Disorders (HAND). Worsening pathology is observed in 
HIV+ individuals who use opioid drugs. Memory problems are often observed in HAND, 
implicating HIV pathology in the hippocampus, and are also known to be exacerbated 
by morphine use. HIV-1 Tat was demonstrated to reduce spatial memory performance 
in multiple tasks, and individual subsets of CA1 interneurons were found to be 
selectively vulnerable to the effects of Tat, notably nNOS+/NPY- interneurons of the 
pyramidal layer and stratum radiatum, PV+ neurons of the pyramidal layer, and SST+ 
neurons of stratum oriens. Each of these interneuron subsets are hypothesized to form 
part of a microcircuit involved in memory formation. Electrophysiological assessment of 
hippocampal pyramidal neurons with Tat and morphine together revealed that Tat 
caused a reduction in firing frequency, however, chronic morphine exposure did not 
have any effect. When morphine was removed after chronic exposure, non-interacting 
effects of Tat and morphine withholding on firing frequency were observed, suggesting 
that a homeostatic rebalancing of CA1 excitation/inhibition balance takes place in 
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response to chronic morphine exposure independently of any Tat effects. Additionally, 
differential morphological effects of Tat and morphine were observed in each of the 
three major dendritic compartments, with SR being less affected, suggesting complex 
circuit responses to these insults reflecting local change and potentially changes in 
inputs from other brain regions. Behaviorally, Tat and morphine interactions occur in 
spatial memory, with morphine potentially obviating Tat effects.   
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Chapter 1: Introduction 
 
 
The human immunodeficiency virus 
The Human Immunodeficiency virus (HIV)-1 is a Lentivirus, within the larger 
group of retroviruses, that was first isolated and identified as the cause of acquired 
immunodeficiency syndrome (AIDS) in 1983 following the initial identification of the 
disease in 1981 (Barre-Sinoussi et al, 1983; Gallo et al, 1983; Weiss, 1993; Sharp & 
Hahn, 2011). A second species, HIV-2, was identified in 1986 (Clavel et al, 1986). 
Although cases of AIDS and AIDS-related illnesses became common in the 1980s, 
evidence of HIV infection can be seen as far back as 1959 (Weiss, 1993; Zhu et al, 
1998; Worobey et al, 2008). The two major forms of the virus (HIV-1 and HIV-2) are 
believed to have diverged relatively recently from the simian immunodeficiency virus 
(SIV), with some studies suggesting the divergences occurred between 1880 and 1970 
depending on the specific viral group (e.g. HIV-1 M or HIV-2 B), with 1940 being the 
favored date for development of HIV-1 group M, the pandemic form of the virus. These 
events are attributed to a number of interacting factors favorable to the transition and 
initial spread of HIV, including low rates of circumcision, high rates of genital ulcer 
disease (GUD), and unsafe injection practices  (Chitnis et al, 2000; Marx et al, 2001; 
Sharp et al, 2001; de Sousa et al, 2010; Sharp & Hahn, 2011). The transfer of SIV/HIV 
to humans is believed to be due to a number of cross-species events, in which SIV 
strains infecting various subgroups of apes were able to make the leap to humans, with 
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the animal vector differing between the origin of HIV-1 and HIV-2 (Marx et al, 2001; 
Sharp & Hahn, 2011). 
HIV-1 and HIV- 2 are related, but distinct viruses, with disparate evolutionary 
origin and differing virulence and transmission rates. Specifically, HIV-1 is more virulent, 
and more transmissible than HIV-2. As a result, HIV-1 is the major cause of HIV 
infection and AIDS worldwide, with HIV-2 infections being found only in West Africa 
(Sharp et al, 2001; Reeves & Doms, 2002; Gilbert et al, 2003; Sharp & Hahn, 2011). 
The rest of this work will focus on the details of HIV-1 and HIV-1 infections. HIV-1 can 
be further divided into four distinct groups; M, N, O, and P. HIV-1 group M represents 
the majority of HIV-1 infections worldwide, and is considered the pandemic form of the 
virus. Groups N and O each make up less than 1% of total HIV-1 infections. HIV-1 
group P is newly discovered, and has infected only a handful of individuals (Sharp & 
Hahn, 2011). Group M can be further divided into 9 major groups, termed clades, (A, B, 
C, D, F, G, H, J, and K) as well as a number of circulating recombinant forms (Taylor et 
al, 2008; Sharp & Hahn, 2011).  
HIV-1 structure and viral proteins 
HIV has a single stranded RNA genome consisting of three main genomic 
elements; gag, pol, and env. These regions produce a number of different proteins from 
a relatively short genomic strand utilizing a combination of overlapping open reading 
frames, differential splicing, and post-translational modifications. The structure of the 
genomic RNA is also known to play a role in multiple facets of viral function, through 
use of binding sites and superstructures (King, 1994; Paillart et al, 2002; Kuiken et al, 
2010). The genomic RNA is packaged within the lipid membrane-covered capsid which 
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is comprised of several proteins (p24/CA-capsid, p17/MA-matrix, p7/NC-nucleocapsid, 
and p6) which are cleavage products of p55, the product of the Gag gene. These 
proteins form specific functions in the formation of the capsid structure, binding of the 
genome, interaction with viral and host proteins as well as binding of the membrane 
envelope, which the virus takes upon budding from its cellular host (King, 1994; Kuiken 
et al, 2010). The product of the Env gene is broken down to gp41 and gp120, which 
insert into the viral membrane and play a critical role in binding to and infecting cells  
(Kuiken et al, 2010). The Pol gene product is the proenzyme for several components 
necessary for viral integration and replication; Protease, Reverse Transcriptase, RNAse 
H, and Integrase (King, 1994; Kuiken et al, 2010). The remaining proteins are encoded 
by individual genes; Rev, Vif, Vpr, Vpu, Nef, Tev, and finally Tat, which is the main 
focus of the work to be presented this document (Kuiken et al, 2010).  
HIV-1 Tat 
The HIV-1 transactivator of transcription (Tat) protein is critical for viral 
replication. Tat will interact with host positive transcription elongation factor b (P-TEFb) 
during the initiation of viral replication, and bind to the viral TAR genomic element. 
Formation of this complex causes the phosphorylation and subsequent activation of 
Abbreviation, and RNA Polymerase II, allowing for whole-genome transcription of the 
virus to occur (Kim & Sharp, 2001; Sobhian et al, 2010; Debaisieux et al, 2012). Low 
level production of Tat is achieved by reverse transcriptase production following 
infection of a cell. This small initial amount of Tat allows for viral replication to occur 
more rapidly (Kim & Sharp, 2001). The length of the Tat protein is variable depending 
on specific viral strain, ranging from 80-103 residues (Walker & Burton, 2008; 
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Debaisieux et al, 2012). There are several highly conserved residues and domains 
within the various Tat protein sequences. Notable domains include a Zn2+ binding 
domain, a highly basic domain, and the N-terminal domain which is strongly acidic 
(Bayer et al, 1995; Debaisieux et al, 2012). Internal interactions within the Tat protein 
are fluid, and influenced by a number of extrinsic factors, and as such the secondary 
structure of the Tat protein is highly variable, with the basic domain usually being 
available for binding interactions. Binding via the basic domain stabilizes the Tat protein, 
and Tat binding interactions tend to be very tight (Zhang et al, 2000; Pantano et al, 
2002; Pantano et al, 2004; Rayne et al, 2010; Debaisieux et al, 2012).In addition to its 
role in binding, the basic domain of the Tat protein serves as a targeting sequence 
which facilitates passage through plasma membranes. Tat can also be actively secreted 
via vesicular transport, meaning that cellular lysis is not necessary to release Tat into 
the extracellular space. (Frankel & Pabo, 1988; Green & Loewenstein, 1988; Rayne et 
al, 2010; Debaisieux et al, 2012). Additionally, truncated Tat fragments can pass 
through the membrane to interact with intracellular components (Soulas et al, 2009). 
The flexibility in structure and lack of spatial restriction give Tat the ability to interact with 
a wide variety of molecules outside of the Transactivation response (TAR) element, 
including various cell surface receptors, conferring on Tat the ability to induce a number 
of pathological states associated with AIDS and NeuroAIDS even in the absence of 
active viral replication. The unique properties of Tat make it highly pathogenic, as well 
as a candidate for re-engineering to deliver targeted therapeutics to otherwise difficult-
to-reach targets (Bayer et al, 1995; Nath et al, 1996; Debaisieux et al, 2012; Cohen-
Avrahami et al, 2014). 
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Transmission and Epidemiology of HIV Infection 
 HIV is spread by blood and sexual fluids, specifically, seminal, vaginal, and rectal 
fluids. Early on in the AIDS crisis, several high-risk groups emerged; men who have sex 
with men (MSMs), those receiving blood transfusions, and intravenous (IV) drug users. 
Sexual transmission, however, is not limited to MSMs. Any sexual contact involving 
sexual fluids coming in contact with a mucous membrane can transmit HIV (van der 
Graaf & Diepersloot, 1986; CDC, 2016). Several other conditions of infection were also 
noted; healthcare workers may become infected due to needlestick events, and HIV can 
be transmitted mother-to-child in several ways; perinatally due to bodily fluid contact 
events during the birthing process, and rarely across the placenta or by breastmilk (van 
der Graaf & Diepersloot, 1986). Casual contact does not spread HIV, and while viral 
particles have been found in other bodily fluids, transmission is uncommon unless blood 
is present in the fluids, and fluid-to-blood contact occurs (van der Graaf & Diepersloot, 
1986; CDC, 1987; CDC, 2016). Cerebrospinal fluid (CSF) can contain measurable 
levels of HIV viral particles, however, the likelihood of actual transmission by CSF 
contact is low outside of occupational exposure (CDC, 1987; Bell et al, 1998; Nath, 
2015).  Recent estimates by the World Health Organization (WHO) suggest 36.7 million 
people worldwide are living with HIV infection, with 18.2 million HIV+ individuals on 
antiretroviral therapy (WHO, 2016).  
AIDS 
The disease caused by HIV infection is called Autoimmune Deficiency Syndrome 
(AIDS). When sufficient contact between the blood or sexual fluids of the infected 
individual and the new host occurs, the virus will infect the CD4+ T cells and CD4/CD8+ 
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macrophages of the peripheral immune system via interactions with CCR5 or CXCR4, 
depending on viral tropism (Berger et al, 1998; Coakley et al, 2005; Zhou & Saksena, 
2013). Shortly after infection, an initial drop in CD4+ cells will occur as the immune 
system is attacked by the virus. Symptoms during this phase appear similar to a flu-like 
viral infection; fever, lethargy, etc., although the overt symptoms of viral infection may 
not present in all patients (WHO, 2017). This phase soon resolves as the immune 
system produces antibodies to the virus and suppresses the infection, restoring the 
CD4+ cell count to near pre-infection levels. At this point, the patient enters a relatively 
symptom free period of latency (Shah et al, 2010; Elliot et al, 2012). The latency period 
of the HIV virus lasts an average of 8 years, and since the viral genome is integrated 
into the host genome, the virus continues to be actively replicated within infected cells 
(Harris & Bolus, 2008; Elliot et al, 2012; CDC, 2017). Over this 8 year period, the 
patients CD4+ cell count will steadily decline. A patient’s status changes from being HIV 
positive to having AIDS when their CD4+ cell count drops below 200 (Crum-Cianflone et 
al, 2009), with the number of CD4+ cells remaining being negatively correlated with 
post-AIDS seroconversion survival (Jacobson et al, 1993). At this point, the patients’ 
immune system is compromised, and they become susceptible to a wide variety of 
opportunistic infections that healthy individuals are generally able to handle, and 
infections that are typically mild can become terminal (Gilmore et al, 1983). In addition, 
the immune response to naturally occurring aberrations in cell growth is also affected. 
As such, many patients develop a specific type of tumor known as Kaposi’s sarcoma 
(Gilmore et al, 1983; Bohlius et al, 2014). There are also neurological complications to 
HIV infection. Early on in the initial HIV epidemic period, the neurological effects, 
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although sometimes quite severe, were less of a concern, as patients who contracted 
HIV and developed AIDS died rapidly from various infections. However, as the lifespan 
of HIV patients was extended by the use of antiretroviral therapies and the 
immunological disease became more manageable, the treatment and study of the 
neurological disease became more practical (Gelman et al, 2013).  
Infection of the CNS 
HIV enters into the brain and establishes a reservoir quickly after infection 
(Masliah et al, 2000). The infection of the CNS is thought to occur via the “Trojan horse 
model”, in which infected CD8+ monocytes cross over the blood brain barrier, allowing 
the virus access to an area where it would typically be unable to cross on its own 
(Peluso et al, 1985; Haase, 1986; Meltzer et al, 1990; Zhou & Saksena, 2013). While 
the evidence most strongly supports the Trojan horse model, other less likely alternative 
methods for viral entry have been proposed (Harouse et al, 1989; Kaul et al, 2001; Zhou 
et al, 2008; Zhou & Saksena, 2013). Alternative theories include transcytosis, in which 
viral particles in the blood are taken up into vacuoles by endothelial cells, and then 
released into the brain (Kaul et al, 2001; Liu et al, 2002; Bobardt et al, 2004), and 
primary infection of the choroid plexus which then spreads to the rest of the CNS via the 
cerebrospinal fluid, or CSF (Harouse et al, 1989; Chen et al, 2000). Regardless of the 
viral entry mechanism, once introduced, HIV will infect microglia, the resident immune 
cells of the brain, as well as astrocytes. Neurons, however, are not infected by HIV 
(Soulas et al, 2009).  
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The HIV Associated Neurocognitive Disorders 
Soon after the discovery of AIDS, it was realized that severe neurological 
impairments could accompany the disease (Snider et al, 1983; Levy et al). Presently, 
there are three broad classifications of HIV-associated neurocognitive disorders 
(HAND); asymptomatic neurocognitive impairment (ANI), Mild neurocognitive disorder 
(MND), and HIV associated dementia (HAD), in order of increasing severity (Antinori et 
al, 2007; McArthur et al, 2010), with some of the most severe cases exhibiting HIV 
encephalopathy (HIVE) (Everall et al, 2009). Greater understanding leading to treatment 
of HAND, especially the more severe varieties, is crucial, as it is not prevented entirely 
by combined antiretroviral therapy (cART) (Sacktor et al, 2002; Tozzi et al, 2005). In 
fact, as longevity of AIDS patients is increasing, the number of AIDS patients living with 
HAND is increasing, although there are declines in the prevalence of HAD as well as 
HIVE (McArthur, 2004; Ellis et al, 2007; Everall et al, 2009; Heaton et al, 2011). 
Neuroinflammation is considered to be the main cause for development of HAND (Glass 
et al, 1995; Persidsky & Gendelman, 2003; Everall et al, 2009; Levine et al, 2016). The 
presentation of HAND differs among patients, but tends to involve some common 
symptomatology, which include deficits in various types of memory, learning and 
attention, verbal function, mood disorders, generalized processing speed deficits, motor 
dysfunction, and difficulties in processing visual information or performing spatial 
manipulations (Antinori et al, 2007; Dawes et al, 2008; Levine et al, 2016). The severity 
of HAND sometimes progressives to the point of inability to care for oneself or function 
in society (Antinori et al, 2007).   
Neuronal pathology 
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Excitotoxicity is one of the main neuronal pathologies caused by HIV infection, 
and also commonly presents in other neurodegenerative diseases, seizure disorders, 
and traumatic brain injuries (Haughey et al, 2001; Avignone et al, 2005; Mattson et al, 
2005; Li et al, 2008; Mehta et al, 2013). Excitotoxicity occurs when a neuron becomes 
overactivated by glutamate signaling, which can be due to excessive glutamate release, 
lack of glutamate clearance, or improper inhibitory feedback. Excitotoxicity is not a 
single process, but rather an umbrella term used to describe the general effects which 
can be driven by many pathological states, and have subtle differences in cellular and 
systems presentation. (Bouilleret et al, 2000; Mehta et al, 2013).  While excitotoxic 
damage does not appear to be immediately deadly in neurons in vivo, a long-term 
buildup of damage over time can lead to a loss of function and eventually death by the 
activation of caspases, but not wholesale sudden necrosis. This sustained cumulative 
damage is believed to explain why neurological symptoms take so long to appear after 
the onset of AIDS (Coleman et al, 2004). An example of this can be seen in the loss of 
dendritic spines in hippocampal neurons of transgenic mice with an active Tat 
transgene without evidence of decreased neuronal number, or significant increase in 
evidence of cell death (Fitting et al, 2013). Interestingly, some components of Tat-
induced excitotoxic injury appear to be reversible (Kim et al, 2008).  The HIV proteins 
Tat and gp120 can induce excitotoxity (Haughey & Mattson, 2002). Tat binding to the 
LRP receptor on neurons, which is associated with the NMDA receptor, causes an 
abnormal association of PSD-95 and nNOS to the NMDA/LRP complex. Interestingly, 
this can lead to apoptotic events in neurons that lack NMDA receptors as well as due to 
increased nitric oxide (NO) production (Eugenin et al, 2007; King et al, 2010).  This 
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complex plays a role in the phosphorylation of several sites on the NMDA receptor 
subunit 2A through the activation of Src kinase, the most important being Y1325.   
Gp120 can also potentiate excitotoxicity; exposure potentiates calcium signaling 
of NMDA receptors, with a greater effect driven by interactions with subunit 2B (King et 
al, 2010; Krogh et al, 2014; Zhou et al, 2016). Tat can also directly bind the receptor 
itself and act as an agonist, causing further toxicity (Li et al, 2008). The calcium 
dysregulation that comes with excitotoxic injury will also cause mitochondrial 
dysfunction, which may explain the shortening and loss of complexity seen in neurites 
after HIV infection or exposure to HIV proteins (Iskander et al, 2004). Additionally, Tat 
can act directly as a COX inhibitor, but only after it permeabilizes the mitochondrial 
membrane, which will further contribute to mitochondrial failure. (Iskander et al, 2004; 
Lecoeur et al, 2012).  The HIV viral proteins Vpr and Tat may also have an effect on 
neurons by altering miRNA expression. A study by Mukerjee et al (2011) showed that 
Vpr is taken up by cultured neurons, leading to disturbances in calcium levels, 
increased oxidative stress, synaptic dysfunction and damage to the mitochondria. The 
group found an increase in miRNAs against several critical mRNAs, a number of which 
(CACNB1, STIM1, IRIBT) are involved in calcium control within neurons. Others are 
involved in synaptic plasticity (SIRT-1), general cellular processes and maintenance 
(CREB) and maintaining structural integrity of processes (NEFM). Most of these mRNAs 
were decreased compared to control in neurons exposed to Vpr. In Tat-treated cells, the 
group found upregulation of miRNAs against many of the same mRNAs that are 
targeted in the case of Vpr exposure. The data on miRNAs are presently contested, 
however, due to questions of reproducibility (Chang et al, 2011; Mukerjee et al, 2011; 
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Witwer, 2014). In addition to the direct effects of HIV on neurons there are also 
bystander effects that cause neuronal injury which can be due to the direct effect of HIV 
proteins on glia, the natural immune response, or other pathological processes 
(González-Scarano & Martín-García, 2005; Fitting et al, 2010b; Ton & Xiong, 2013; 
Zhou & Saksena, 2013).  Some of these effects will be discussed in the subsequent 
sections, which deal with HIV effects on glial cells. 
Astrocytic pathology and contribution to neuroAIDS 
Astrocytes perform a number of key roles in the brain including trophic support, 
clearance of the synaptic cleft, and formation of the blood brain barrier. It is not 
surprising that once these cells are infected, they play a significant role in the 
progression of neurological disease. The onset of astrocytosis occurs rapidly once HIV 
has entered the brain (An et al, 1999), and can be induced by direct infection of 
astrocytes, or by independent extracellular action of viral proteins. This condition leads 
to the production of pro-inflammatory cytokines and other neurotoxic factors (Ton & 
Xiong, 2013; Zhou & Saksena, 2013). 
There are many cytokines known to be released by astrocytes in HIV infection, 
for example IL-1β, IL-6, IL-8 and TNF-α.A significant portion of these secreted products 
are also produced by microglia (González-Scarano & Martín-García, 2005; Ton & 
Xiong, 2013). To go into detail for each one of them would require its own review and so 
this section will cover some of the more current research on astrocyte cytokine 
production and effects in response to HIV infection and other general insults. The basic 
profile of astrocyte cytokine production in the absence of an insult was recently profiled 
in cultured human cells. The basic expression profile includes G-CSF, GM-CSF, GROα, 
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IL-6, IL-8, MCP-1, MIF, and Serpin E1. The cultured astrocytes were then subjected to 
insult via IL-1β and TNF-α. These cytokines caused expression of six other cytokines by 
activation of an NF-κB pathway; IL-1β, TNF-α, RANTES, MIP-1α, IP-10, and IL-1ra, 
along with other factors traditionally involved in cell adhesion, chemotaxis, and 
immunity. Additionally, the basally-expressed cytokines G-CSF, GM-CSF, GROα, and 
IL-6 were increased relative to their control levels while MCP-1 and MIF were 
decreased. The authors believe that there are still more astrocyte derived cytokines 
involved in neuroinflammation than what they found in their study (Choi et al, 2014). It is 
important to note that the basal production of cytokines by astrocytes in different brain 
regions will vary.  In a 2010 study by Fitting et al, cultured astrocytes taken from mouse 
cortex, cerebellum and spinal cord were probed for basal levels of cytokine production, 
and then challenged with combinations of Tat, gp120, and with morphine (Fitting et al, 
2010b). This study noted several more cytokines produced by resting astrocytes than 
the previously-discussed study; KC, eotaxin, IL-9, MIP-1α, MIP-1β, and IFN-γ, although 
this may be a species difference (Fitting et al, 2010b; Choi et al, 2014). Basal cortical 
production of most cytokines was much lower than that observed in cerebellum or spinal 
cord. The secretory response of activated astrocytes to HIV proteins independent of 
morphine also varies by region and specific HIV protein. Only IL-1β production was 
independent of brain region. Exposure to Tat elevated most cytokine production in all 
assayed brain regions, but the cerebellar astrocytes had a much weaker response than 
astrocytes of the cortex or spinal cord. In contrast gp120 did not significantly affect 
cytokine release despite causing an increase in intracellular calcium levels (Fitting et al, 
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2010b). CXCL8/IL-8 is also found to be upregulated in astrocytes following HIV infection 
(Mamik & Ghorpade, 2012).    
Aside from direct damage to neurons, HIV proteins along with cytokines can 
cause astroglia to produce other toxic compounds. For example, gp-120 induced 
production of arachidonic acid (Samikkannu et al, 2011).  The oncogene AEG (astrocyte 
elevated gene)-1 has been found to play a role in cytokine cascades that lead to 
neuronal injury. It is found to be upregulated in astrocytes which are exposed to Tat and 
complete HIV-1 virions, along with pro-inflammatory cytokines commonly observed in 
neuroAIDS TNF-α, and IL-1β. Not only do these insults increase expression of AEG-I, 
they cause it to translocate from the cytoplasm to the nucleus where it interacts with NF-
κB, leading to the downregulation of EAAT2, a glutamate transporter, and upregulated 
YY1, which acts to repress EAAT2. Constitutive overexpression of AEG-1 causes the 
same effects, but the process is exacerbated when IL-1β is introduced, presumably 
because it precipitates nuclear translocation. Altogether, this novel pathway which 
culminates in decreased glutamate clearance highlights one of the ways in which 
released cytokines can cause indirect excitotoxic injury to neurons (Vartak-Sharma et 
al, 2014).  
Disruption of the blood brain barrier is also a contributing factor in the 
progression of HAND. Astrocytic cytokines play a role in facilitating the passage of 
infected immune cells across the BBB. In addition to having direct neurotoxic effects, 
the increased expression of CXCL10 in HIV has been shown to have a chemotactic 
effect on peripheral blood mononuclear cells (Mehla et al, 2012).  CX3CL1/fractalkine 
has been shown, with leukotrienes, to facilitate contact of HIV infected monocytes and 
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brain macrophages and transfer of infection. This process itself does not induce 
disruption of the blood brain barrier (Bertin et al, 2014). Additionally, IL-6 has also been 
shown to act as a chemoattractant to circulating lymphocytes (Almolda et al, 2014).  
This may be an important process for establishing the reservoir in the brain after initial 
infection and exacerbating inflammatory damage as the creation of a more permissive 
barrier due to decreases seen in expression of tight junction proteins, increased matrix 
metallopeptidase-9 activity in brain endothelial cells, and endothelial cell apoptosis is 
coupled with the increased attraction of immune cells from the blood stream (Andras et 
al, 2003; Kim et al, 2003; Xu et al, 2012; Zhou & Saksena, 2013; Rao et al, 2014; 
Leibrand et al, 2017; Patel et al, 2017). 
Finally, the overall health of the astrocytes can contribute to neuronal pathology, 
as astrocytes play a key role in supporting neuronal health. Astrocytes form the first line 
of defense against aberrant ROS production in the brain (Desagher et al, 1996; 
Masanetz & Lehmann, 2011; Ferrucci et al, 2013). Exposure of astrocytes to HIV-1 VPR 
causes an increase in oxidative stress along with increased cytokine production.  VPR 
also causes decreases in ATP and glutathione levels, which would normally help to 
alleviate oxidative stress. It was also found that there was a decrease in GAPDH 
expression and therefore decreased glycolytic activity after VPR exposure, resulting in 
neuronal apoptosis. Astrocytes normally secrete glutathione which is taken up by 
neurons. Neurons exposed to conditioned medium taken from VPR-treated astrocytes 
showed increased apoptosis compared to neurons exposed to control astrocyte 
conditioned medium. This is likely due to the neurons’ inability to reduce oxidative stress 
due to the lack of secreted glutathione (Desagher et al, 1996; Ferrucci et al, 2013).  The 
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HIV-1 protein Nef, which is expressed in infected astrocytes also decreases fitness.  
Under normal circumstances, immune cells put out reactive oxygen species in addition 
to inflammatory cytokines, and astrocytes play a strong role in protecting neurons from 
damage due to ROS production acting as a buffer and providing glutathione.  Astrocytes 
transfected with Nef and exposed to a medium containing 10 μM hydrogen peroxide 
were much more likely to die in a four hour incubation than astrocytes not transfected. 
This effect may be due to the loss of glutathione production (Desagher et al, 1996; 
Masanetz & Lehmann, 2011; Ferrucci et al, 2013). 
Microglial and MDM pathology and contribution to neuroAIDS 
  Microglia and monocyte-derived macrophages (MDMs) also contribute to the 
progression of neuroAIDS. Microglia are the resident immune cells of the brain, and are 
known to produce cytokines, ROS, and other soluble factors against potential insults. 
Many of the pro-inflammatory cytokines that are produced by astrocytes are also 
produced by microglia and MDMs, with microglia representing the main source of pro-
inflammatory cytokines (Rock et al, 2004; Ghorpade et al, 2005; González-Scarano & 
Martín-García, 2005; Almolda et al, 2014; Rao et al, 2014). Microglia respond rapidly to 
HIV infection. Infection of cultured microglia with HIV causes the production of pro-IL-1β 
and other inflammatory products as early as four hours after exposure to the virus 
(Walsh et al, 2014). It is important to note that the production of inflammatory molecules 
is only one of the reasons that the increased attraction of immune cells across the BBB 
and activation of microglia play such a significant role in the progression of neuroAIDS 
pathology (Andras et al, 2003; Kim et al, 2003; González-Scarano & Martín-García, 
2005; Xu et al, 2012; Almolda et al, 2014; Rao et al, 2014). It is also important to note 
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that in HIV patients receiving antiretroviral therapy, microglia remain activated and 
continue to produce inflammatory molecules. This phenomenon correlates with mild 
neurocognitive decline in otherwise asymptomatic patients (Garvey et al, 2014). 
Much like astrocytes, microglia also have different characteristics and responses 
depending on where in the brain they are located. In a comparison of microglia collected 
from a patient with HAD against seronegative patients, tissue samples were collected 
from multiple brain regions (cortex, basal ganglia, striatum, cerebellum, brain stem, and 
hippocampus). Microglia in all the regions observed were activated in the HIV patient, 
and increased microglial numbers were seen in the cortical white matter, basal ganglia, 
cerebellum and brain stem. In all areas, immunohistochemical (IHC) tissue analysis 
showed that there were microglia (identified by CD68 and vimentin IHC reactivity) 
positive for HIV-1 p24, indicating infection, although the number of cells varied region to 
region and correlated with presence of microglial nodules and immune activation. 
Microglia also formed multinucleated giant cells post-infection. Comparison of the 
amount of viable glial cells showed no significant differences. In all brain regions 
surveyed, microglia in the HIV+ patient showed less production of TNF-α both basally 
and induced, indicating a decreased immune reaction rather than a die-off of microglia 
(Ghorpade et al, 2005). In addition to a decreased immune response, increases in 
production of IL-8 (CXCL8) by astrocytes and microglia can contribute to increasing viral 
genome integration rates and replication rates within infected microglia and 
macrophages. The replication rates increase with longer exposure to the factors 
involved and infection of new cells, leading to a downward spiral effect (Huang et al, 
2011; Mamik & Ghorpade, 2012; Mamik & Ghorpade, 2014).  
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These cells also play a role in exacerbating neuronal excitotoxicity.  Microglia 
infected by HIV produce an increased amount of glutamate due to an increased 
expression of microglial glutaminase in culture. This effect is also found in patients 
suffering from HAD (Huang et al, 2011).  Additionally, the production of TNF-α and IL-1β 
by microglia and MDMs causes upregulation of glutaminase in human neuronal cultures 
(Ye et al, 2013). Other microglial/monocyte produced compounds can strengthen the 
effect. For example, activated microglia and monocytes produce quinolinic acid, a 
metabolite of tryptophan that acts as an NMDA agonist at the glutamate binding site. 
This agonism has been shown to enhance excitotoxicity. The production of quinolinic 
acid is more robust in MDMs (Kerr et al, 1998; Guillemin et al, 2005). Another MDM 
secreted factor that promotes excitotoxicity is Platelet activating factor (PAF), which can 
also be secreted by astrocytes (Gelbard et al, 1994). 
Microglia can also play a more direct role in neural damage than simply secreting 
toxic factors. In mice injected intracranially with Tat, microscopy on tissue slices 
indicated that activated microglia produce filopodia, and form contacts with dendritic 
spines, presynaptic terminals, and extend into excitatory and inhibitory synaptic clefts, 
which may disrupt the synapses in a process called synaptic stripping.  The filopodia 
had phagosomes which contained parts of the synaptic structures, and the surrounding 
area showed evidence of proteolytic degradation, indicating that microglia may be 
actively breaking down synapses in response to HIV proteins (Tremblay et al, 2013). 
This could be a potential mechanism contributing to the loss of dendritic spines 
observed in neurons when combined with the problem of failing metabolic support which 
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leads to loss of dendritic length and arborization (Iskander et al, 2004; Vander Jagt et al, 
2008; Tremblay et al, 2013).   
Oligodendrocytic and myelin pathology 
While oligodendrocytes are not believed to be infected by HIV (Zhou & Saksena, 
2013), they do have receptors for many of the inflammatory cytokines released by 
astrocytes, MDMs, and microglia, making them susceptible to damage by the 
pathological processes that occur in neuroAIDS (González-Scarano & Martín-García, 
2005). In individuals infected with HIV, a condition called vacuolar myelopathy (VM) can 
arise in white matter. A post-mortem assessment of AIDS patients revealed that in white 
matter tracts of the spinal cord, there was significant vacuolation, demyelination, and 
increased presence of macrophages, and there was no correlation with astrocyte 
activation (Gyorkey et al, 1987; Tran et al, 1995). In some regions of the brain, but not 
all, myelin thickness around axons has been observed to decrease, as has the volume 
of the anterior corpus callosum from loss of both nerve fibers and myelin 
(Wohlschlaeger et al, 2009). There is a significant reduction in oligodendrocyte process 
length observed in an in vivo Tat injection model, and losses in oligodendrocyte 
membrane area in the HIV-1 Tat transgenic mouse model (Hauser et al, 2009; Zou et 
al, 2015). Additionally, oligodendrocytes exposed to Tat alone show an upregulation in 
caspase production, but no increase in apoptosis rate (Hauser et al, 2009). This is likely 
related to increases in Ca2+ influx into the oligodendrocytes mediated the interaction of 
Tat with the AMPA and NMDA receptors (Zou et al, 2015).  
MRI often shows “white matter pallor”, which might indicate demyelination or an 
area of edema, perhaps due to increased leak through the blood brain barrier in HIV 
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patients. In a 2001 study using MRI diffusion tensor imaging, an MRI method for white 
matter, microstructural abnormalities were seen in early stage HIV positive patients in 
the frontal cortex and the internal capsule, however newer data suggest other 
disturbances can occur in any CNS white matter tract (Pomara et al, 2001; Xuan et al, 
2013). The altered myelination may lead to decreased conduction velocity along white 
matter tracts as is the case in the HIV infected peripheral nervous system (Kokotis et al, 
2007), and such changes would undoubtedly contribute to aspects of HAND.  
One of the pathological conditions that arises in oligodendrocytes/white matter is 
the production of self-antibodies against myelin proteins as seen in multiple sclerosis 
(Maimone et al, 2009; Lackner et al, 2010). In a comparison of HIV patients, MS 
patients, and control subjects, myelin basic protein antibodies were found in the CSF of 
HIV patients at higher levels than MS patients while none were found in control 
subjects.  Patients who had both HIV and MS had equivalent antibody levels to MS free 
HIV patients (Maimone et al, 2009). Antibodies against myelin oligodendrocyte 
glycoprotein (MOG) were found in the CSF of AIDS patients, but not of patients 
suffering from other neurological conditions. Furthermore, the antibodies of HAND 
patients were more specific than those in asymptomatic patients. Additionally the 
antibodies against MOG were found before and after effective antiretroviral therapy 
(Lackner et al, 2010).  
Global effects of HIV on the central nervous system 
Throughout the brain, there appears to be a decrease in volume across multiple 
regions. This atrophy is observed in adults and in children, and correlates with 
decreases in CD4+ cell count and cognitive decline, but not with duration of infection 
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(Johann-Liang et al, 1998; Thompson et al, 2006; Chiang et al, 2007; Andronikou et al, 
2014). Concurrent with brain atrophy is an expansion of ventricular volume by an 
average of 2.18 times the observed volume in control patients as detected by MRI. The 
expansion is not uniformly distributed within the ventricles, with the occipital and frontal 
horns expanding more than the temporal horn (Thompson et al, 2006). These effects 
are persistent even with effective ART, as is the progression of neurocognitive 
impairment (Gongvatana et al, 2013; Hua et al, 2013).  Elevated quinolinic acid in the 
CSF is linked to the atrophy observed in the brain, specifically in those regions that are 
susceptible to excitotoxic injury (Heyes et al, 2001). Histologically, it has been observed 
that in patients with HAD, the spatial distribution of astrocytes changes as the disease 
progresses. Astrocytes cluster near interneurons, and away from large pyramidal cells, 
with the level of clustering correlating to the severity of the disease. The clustering was 
determined by identifying specific cell types in slices and measuring the closeness to 
the interneurons by applying concentric rings of a known distance and observing the 
number of cells present within these rings (Roberts et al, 2013). Additionally, there is 
deposition of amyloid-β plaques as in Alzheimer’s disease, with higher levels of 
amyloid-β in cases of HIVE, and a correlation between amyloid-β deposition and age. 
While amyloid-β deposition is not necessarily causative of HAND symptoms, it can 
serve as a marker of disruption in protein clearance (Esiri et al, 1998; Achim et al, 2009; 
Soontornniyomkij et al, 2012).  
While there are global changes, a wide variety of pathologies are observed in 
most brain subregions, giving rise to the various behavioral facets of NeuroAIDS (Table 
1) (Nath, 2015). These differences in pathology are due to numerous factors both 
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anatomical and cellular which influence the nature of HIV-host interactions. A variety of 
genes, with the most notable being MAP2 and syanaptophysin (SYP), have been 
identified as being correlated with HAND severity and increased HIV RNA levels across 
multiple brain regions (Masliah et al, 1997; Moore et al, 2006; Levine et al, 2016). Due 
to the complex interplay between genes in individuals, the response to HIV-induced 
neuroinflammation may vary from patient to patient, in part explaining the differential 
presentation of HAND in individual cases (Lojek & Bornstein, 2005; Dawes et al, 2008; 
Fazeli et al, 2014; Levine et al, 2016). Anatomically, the relative closeness of a structure 
to the ventricles is suspected to be a factor, as viral particles, produced toxins like 
quinolinic acid, and pro-inflammatory factors are found to be elevated in the CSF (Kerr 
et al, 1998; Petito et al, 1999; Heyes et al, 2001; Thompson et al, 2006; Tate et al, 
2011; Ances et al, 2012; Andronikou et al, 2014; Choi et al, 2014). At the cellular level, 
HIV Tat has been shown to have disparate effects on the astrocytes of different regions 
(Fitting et al, 2010b). There have been observations of regional heterogeneity in 
astrocytic and microglial subpopulations genetically and functionally (Hochstim et al, 
2008; Chaboub & Deneen, 2012; Martin et al, 2015; Covelo & Araque, 2016; Grabert et 
al, 2016). This is in addition to the wide array of neuronal phenotypes found in the 
structures of the CNS (Klausberger & Somogyi, 2008; Bikoff et al, 2016), So it should 
come as no surprise that the great variety in CNS cell subtypes within discrete brain 
regions would create  unique responses to HIV infection and its sequelae (Fitting et al, 
2010b; Nath, 2015). 
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The Hippocampus and HIV  
The region of interest in the studies to be discussed is the hippocampus. This 
structure can be found in each hemisphere of the brain, and is folded up beneath the 
edge of the cortex. While the neocortex has six layers, the hippocampus has 3-4 
depending on the subfield of interest. The hippocampal formation is defined as the 
hippocampus proper (the Dentate gyrus and cornu ammonis regions) and several 
associated structures, usually referring to the subiculum, entorhinal cortex, and fimbria 
of the hippocampus. The two main regions of the hippocampus proper can be further 
divided into anatomically and functionally distinct domains. The dentate gyrus can be 
divided by layers, the principal cell layer, or granule cell layer forms a chevron-like 
structure opening onto the end of cornu ammonis (CA). The layer within the chevron is 
called the hilus. This layer contains axonal projections to the CA. On the outer edge of 
the dentate gyrus is the molecular layer, which borders the interior edge of the 
CA/subiculum border. The CA structure is divided into three main regions, CA3, CA2, 
and CA1 (Ranson, 1932; Amaral & Lavenex, 2007). The CA3 region can be divided into 
4 layers; in order from the outside border with the alveus; the SO, stratum pyramidale or 
pyramidal layer, stratum lucidum, and the stratum lacunosum-moleculare (SL-M). The 
stratum lucidum is unique to CA3. Outside of this difference, the layered structure of 
CA2 and CA1 is very similar to CA3. The overall flow of information in the hippocampus 
follows a defined path from the entorhinal cortex to the dentate gyrus via axons known 
as the perforant path. The dentate gyrus projections to CA3 are termed the mossy 
fibers, and the projections from CA3 to CA1/2 are referred to as the Schaffer collaterals. 
CA1 pyramidal neurons primarily project to the entorhinal cortex, completing the 
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processing loop through the hippocampus. In addition to this main loop, several back-
and-co-projections occur, allowing for more complex processing(Amaral & Lavenex, 
2007). Most notably, some perforant path axons also project directly to CA3 and CA1 
(Deng et al, 2010). Within the hippocampal subfields, a wide variety of cell types interact 
to build defined regional microcircuits that allow for complex processing of information to 
occur (Amaral & Lavenex, 2007; Klausberger & Somogyi, 2008; Deng et al, 2010; 
Muller & Remy, 2014). Originally thought to simply be a high-order olfactory processing 
center (Ranson, 1932),this region of the brain is responsible for a number of functions, 
including spatial and social memory (Okuyama et al, 2016), as well  as having some 
involvement in emotional processes. 
The hippocampus has been shown to be vulnerable to the effects of HIV and HIV 
protiens. Learning, memory and spatial awareness, which are among the deficits 
observed in neuroAIDS, are mediated in part by the hippocampus (Castelo et al, 2006). 
A 2013 study by Fitting et al showed that in Tat transgenic mice, a loss of dendritic 
spines and inhibitory synaptic proteins within pyramidal layer of the CA1, indicating the 
loss of a specific subset of GABAergic interneurons, correlated with reduced 
hippocampal LTP and a reduction of both spatial learning and contextual fear 
conditioning. Another study also showed increased evidence of autophagy in 
hippocampal astrocytes (Vander Jagt et al, 2008). Similarly, Vpr also causes memory 
impairment. Vpr transfected astrocytes injected into the hippocampus of rats caused a 
decrease in long-term memory formation and an increase of neurons undergoing 
chromatolysis in CA1 and CA3 (Torres & Noel, 2014). These memory deficits exist in 
human patients as well. In a study consisting of only women, three different measures 
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of memory were found to be impaired; verbal episodic memory, visual memory, and 
working memory both in short and long term. Neuroimaging of the hippocampi in these 
subjects showed a lesser response during the encoding process, and a heightened 
response when attempting to recall after a delay in stimulus presentation (Maki et al, 
2009). An earlier study also showed that regions of the hippocampus exhibit a reduced 
response during encoding, but increased activity was observed in the frontal and 
parietal cortices (Castelo et al, 2006). Hippocampal tissue is also susceptible to the 
accelerated aging processes associated with HIV infection and experiences a decrease 
in volume (Ances et al, 2012; Pfefferbaum et al, 2014), It likewise sees increased 
deposition of α-synuclein and β-amyloid (Kallianpur et al, 2012). In addition to its 
contribution to memory, dysfunction in the hippocampus also contributes to the 
depressive disorders seen in HIV patients resulting from the activation of indoleamine 
2,3 dioxygenase (IDO) via p38 MAPK in response to inflammatory cytokine secretion 
(Fu et al, 2011). 
The excitotoxic effects of HIV proteins are evident in the hippocampus. 
Synaptosome preparations of hippocampal neurons from Tat transgenic mice 
demonstrate an increased K+ evoked glutamate release but no change in GABA 
release (Zucchini et al, 2013), suggesting that Tat effects on GABAergic transmission 
within the hippocampus involve more than simply altered release mechanisms (Marks et 
al, 2016). In culture, hippocampal neurons have been demonstrated to lose synaptic 
terminals as a result of Tat-induced excitotoxicity, as indicated by a decrease in 
synaptophysin levels (Shin & Thayer, 2013). In addition to this, the remaining synaptic 
terminals are also affected. Neurons treated with Tat are more likely to generate 
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inhibitory synapses than excitatory synapses (Hargus & Thayer, 2013). These effects 
on synaptic integrity and formation are also based on excitotoxicity, and mediated by 
the binding of Tat to LRP, and formation of the LRP-PSD95-NMDA-nNOS complex 
rather than the apoptotic processes of excitotoxicity (Eugenin et al, 2007; King et al, 
2010; Hargus & Thayer; Shin & Thayer, 2013). This may appear to conflict with the 
results from Fitting et al (2013) which show a decrease in inhibitory synaptic formation 
in CA1, however with the wide variety of hippocampal neuronal types, it is likely that 
there is a differential effect on a specific subset in that specific region (Klausberger & 
Somogyi, 2008; Fitting et al, 2013). This effect can be seen in an earlier study on the 
differential neuronal toxicity of Tat and gp120 in the hippocampus by Fitting et al. in 
2008 (Fitting et al, 2008). Tat or gp120 were injected bilaterally into the hippocampi of 
newborn rats to assess long term toxicity. Neuron numbers were found to be decreased 
by Tat in CA 2/3, dentate gyrus, and subiculum, while gp120 only reduced neuron 
number in CA2/3, suggesting differential sensitivity of neuron subsets in those regions. 
Differential effects were also noted in glia, with astrocyte number being increased in the 
dentate gyrus and subiculum by Tat, and oligodendrocyte numbers being increased 
only in the dentate gyrus (Fitting et al, 2008). In addition, the hippocampus has been 
shown to have a reduced capacity to respond to oxidative stress in an HIV-transgenic 
rat model via the 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid; ABTS) assay 
(Pang et al, 2013). 
  The hippocampus is different from other regions, in that research indicates 
that it has a greater likelihood of recovery following injury resulting in loss of neurons. 
The hippocampus is one of the few regions in which neurogenesis continues into 
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adulthood. This neurogenesis is inhibited by HIV (Lee et al, 2011; Avraham et al, 2015), 
however, in a gp120 transgenic model, treating with an SSRI can rescue adult 
neurogenesis (Lee et al, 2011). In animals with a deletion of the gene encoding FAAH, 
the enzyme responsible for breakdown of endocannabinoids, neurogenesis in adult 
mice was not affected by gp120 (Avraham et al, 2015), raising hope for potential 
development of treatments. In fact, the damage caused to the hippocampus might not 
be irreversible.  Within CA1, the chromatolysis induced by HIV proteins does not 
necessarily lead to neuronal death (Torres & Noel, 2014). The cellular deficits observed 
in CA1 do not appear to include loss of neuronal cells, but simply their impairment 
(Fitting et al, 2008; Fitting et al, 2013; Zucchini et al, 2013) . A 2008 paper by Kim et 
al.(Kim et al, 2008) also showed that in hippocampal cultures, synaptic loss via 
excitotoxicity is due to the LRP-PSD95-NMDA-nNOS complex rather than the apoptotic 
events of excitotoxicity (Eugenin et al, 2007; Kim et al, 2008; King et al, 2010; Hargus & 
Thayer, 2013; Shin & Thayer, 2013).  It additionally showed that the process is 
reversible by treatment with receptor associated protein (RAP), which is an LRP 
blocker, after Tat treatment, while NMDA antagonists did not reverse the effect after Tat 
administration. The authors of this paper suggest that this reversible loss of synaptic 
structures is a compensatory mechanism meant to mitigate the effects of the excitotoxic 
state (Kim et al, 2008).  
Comorbidity of HIV infection and opioid abuse disorder 
 A growing problem worldwide is the coincidence of HIV infection with opioid 
abuse disorder (Bruce & Altice, 2007). HIV infection can occur through the sharing of 
needles between injection drug users (IDUs), resulting in the transfer of small amounts 
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of blood between individuals and allowing the chance of HIV infection (van der Graaf & 
Diepersloot, 1986). The sharing of needles between users is a significant contributor to 
infections in individuals not engaging in risky sexual contact (Friedland, 1985; van der 
Graaf & Diepersloot, 1986; NIDA, 2017), and there is a significant overlap in the 
populations of individuals that are IDUs and those that engage in risky sexual behaviors 
(Bruce & Altice, 2007). Between 40 and 45% of IDUs are also HIV positive (Francis, 
2003), and while opiates are not the only drugs injected intravenously, they do make up 
a large proportion of total injection drug use (Bruce & Altice, 2007). Even in the absence 
of injection drug use and the risk of increased infection, there is still a risk posed by the 
abuse of prescription opioids, which may or may not be prescribed to an HIV infected 
individual. Around 8% of HIV-Infected patients may be on long term, physician-
prescribed courses of opiates. In an analysis of individuals whose tissue had been 
donated to a national brain tissue bank, over half of the HIV positive patients that were 
prescribed opiates were determined to exhibit improper use, however the lack of 
longitudinal data on these individuals leaves this value open to interpretation (Robinson-
Papp et al, 2012; Silverberg et al, 2012).  
The opiate receptors, morphine, and the hippocampus 
There are three main classes of opiate receptor; mu (MOR), kappa (KOR), delta 
(DOR), with a fourth, the nociceptin opioid receptor (NOP), having close sequence 
homology, but little functional overlap with the other three. All of these receptors are G-
protein coupled receptors that respond to a group of peptide neurotransmitters 
collectively known as the endogenous opioids, including enkephalins and endorphins 
(Butour et al, 1997; Gutstein & Akil, 2006; Bodnar, 2012). The three main receptors 
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have distinct functions and ligand affinities, with differential cell signaling cascades and 
behavioral outcomes associated with the activation of each receptor (Gutstein & Akil, 
2006; Bodnar, 2012; Beckman, 2014). Activation of the opioid receptor system in 
general is associated with analgesia, however, other effects beyond analgesia occur 
(Gutstein & Akil, 2006; Lutz & Kieffer, 2013; Stein, 2016). Activation of the MOR causes 
the activation of reward pathways, and underlies the abuse liability of many opiate 
drugs. At the same time, MOR activation can cause depressive effects (Lutz & Kieffer, 
2013; Stein, 2016). DOR acts in many ways as a mirror to MOR activity, with its 
activation effecting reward pathways, however, its role is modulatory and does not 
independently establish reward/dependence processes. As a result, many DOR 
agonists do not have the same abuse liability as MOR agonists. DOR activation also 
has been shown to have a mood elevating effect, and to be neuroprotective against 
excitotoxic damage (Gutstein & Akil, 2006; Kawalec et al, 2011; Lutz & Kieffer, 2013). 
Activation of the KOR runs counter to MOR/DOR activity, having dysphoric properties 
and having an anti-reward effect. KOR is involved in, and potentiated by stress 
processes (Lutz & Kieffer, 2013).   Morphine, the prototypical opiate drug, and a drug of 
abuse, has the strongest affinity for the MOR, with off-target interactions at both the 
DOR and KOR (Gutstein & Akil, 2006; Hauser et al, 2012; Lutz & Kieffer, 2013; 
Beckman, 2014). In addition to the neurological effects of morphine, activation of the 
opioid receptors in immune cells has been shown to modulate inflammatory processes, 
and therefore can affect neuroinflammation (Stein et al, 2003; Gutstein & Akil, 2006).   
As is common with most drugs of abuse, chronic use of opioid drugs leads 
toward development of tolerance and dependence. Anytime a drug is used over time in 
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a receptor system, the natural function of the system is supplanted by over- or under-
activation, hence giving the desired effect. Sometimes, these systems will either adjust 
to the new levels of receptor activation by increasing or decreasing the available 
receptors or ligands in an attempt to return to a homeostatic baseline, resulting in more 
and more need for (dependence on) the drug, as the amount of drug or neurotransmitter 
needed to obtain the desired effect increases (tolerance). Morphine has been shown to 
cause tolerance and dependence in patients with chronic or repeated use (Gutstein & 
Akil, 2006). Interestingly, tolerance to the various effects of morphine develop at 
differential rates, with tolerance to analgesia developing rapidly, but tolerance to motor 
effects having a more complex progression depending on dosage regimen rates (Vasko 
& Domino, 1978; Ling et al, 1989). This effect may be tied to differential development of 
tolerance by the different receptor groups (MOR vs DOR/KOR) or MOR subtypes (Ling 
et al, 1989; Angelopoulos et al, 1995).  The development of tolerance has been 
attributed to reductions in the available receptor at the cell surface, reduced availability 
of the endogenous opioid peptides, or a shift in agonist efficacy (Wimpey et al, 1989). 
While multiple mechanisms exist, the one described here is of particular interest due to 
the strong potential for overlap with HIV-induced excitotoxicity (King et al, 2010). In 
healthy neurons, the activation of the MOR by morphine activates Akt/PKB, which in 
turn activates nNOS.  nNOS signaling leads to activation of PKC, which activates Src, 
resulting in phosphorylation of the NMDA NR2A subunit at Y1325, and increased 
calcium influx. This calcium influx triggers a feedback mechanism to reduce Akt and 
nNOS activity to reduce phosphorylation of NR2A. This process also leads to 
phosphorylation of MOR over time, resulting in receptor internalization and the 
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development of morphine tolerance (Wimpey et al, 1989; Sanchez-Blazquez et al, 
2010). The inhibition of NOS has been demonstrated to reduce the development of 
tolerance due to MOR activation, but not KOR (Kolesnikov et al, 1993; Lue et al, 1999). 
The specific agonist studied is important, as some drugs but not others precipitate 
receptor internalization despite having similar activity at the receptor, making it an 
important consideration in drug replacement therapies used to treat opioid dependence 
(Kolesnikov et al, 1993; Fitting et al, 2015b) and in experimental paradigms. 
 
Morphine effects in the hippocampus 
Morphine is known to be neurotoxic on its own in cases of chronic and repeated 
exposure (Hauser et al, 2012; Liu et al, 2013; Razavi et al, 2014), and is especially 
detrimental to development of hippocampal neurons in pre- and postnatal development 
(Traudt et al, 2012; Bajic et al, 2013; Ghafari & Golalipour, 2014). Morphine’s effects on 
behavioral processes linked to the hippocampus are largely on development of 
conditioned place preference in relation to morphine cues, and are also involved in 
modulation of contextual fear conditioning (Razavi et al, 2014; Tan et al, 2015), but can 
also cause deleterious effects on spatial memory performance (Kitanaka et al, 2015). 
This is linked to the effects of morphine on synaptic plasticity within the hippocampus 
(Heidari et al, 2013; Portugal et al, 2014; Sadegh & Fathollahi, 2014; Tan et al, 2015), 
and notable alterations to the normal pattern of activity in the ability of the endogenous 
opioid system to modulate inputs and outputs (Wimpey et al, 1989; Harrison et al, 2002; 
Erbs et al, 2016).  Morphine has demonstrated effects on hippocampal glutamatergic 
and GABAergic neurotransmission that may interact synergistically to enhance 
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excitotoxicity.  Levels of glutamate were found to be increased after morphine 
sensitization, but decreased prior to the establishment of sensitization, and GABA levels 
were found to be initially decreased in the sensitization process, but then later become 
elevated following repeated exposure to morphine (Bodzon-Kulakowska et al, 2010; 
Farahmandfar et al, 2011a; Farahmandfar et al, 2011b; Zucchini et al, 2013).  The 
increase of glutamate levels does not necessarily relate to the amount of glutamate 
synthetase, but rather to its biochemical activity, which is an important point to keep in 
mind when considering the levels of expression of other enzymes (Bodzon-Kulakowska 
et al, 2010). Even with the increase in glutamatergic activity, and the tendency toward 
excitotoxic states with long term opiate exposure in the hippocampus, altering the levels 
of activation between the three receptor groups can offset the damaging effects of 
morphine (Kawalec et al, 2011; Fitting et al, 2015b). The effects of morphine in the 
hippocampus are largely discussed in terms of broad outputs. However, from a 
modulatory standpoint it is important to recognize that the endogenous opioid system in 
the hippocampus is largely involved with regulation of the Inhibitory interneuron 
network, with differential expression of opioid receptors occurring on different subsets of 
interneurons, and notable overlap between signaling modalities found in CA1 (eg 
somatostatin) and opioid receptor activity (Hatzoglou et al, 1995; Drake & Milner, 2002; 
Pfeiffer et al, 2002; Rácz & Halasy, 2002; McQuiston, 2008; Jorand et al, 2016). 
Interactions between HIV and opiate use 
The effects of HIV on brain function and immunosuppression in both the 
periphery and CNS can be exacerbated by the use of opiates (Bell et al, 1998; Anthony 
et al, 2008; Byrd et al, 2012; Hauser et al, 2012; Meyer et al, 2013; Edelman et al, 
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2017). Increased severity of cognitive deficits has been linked to interaction of HIV and 
drug abuse (Bell et al, 1998), and HIV encephalitis has been found more frequently in 
drug-abusing patients infected with HIV than in HIV-infected non-abusers (Byrd et al, 
2012). This is linked with increased inflammatory markers (Meyer et al, 2013), and 
coincides with increases in the viral load both in AIDS patients and in infected animal 
models (Anthony et al, 2008; Byrd et al, 2012; Hauser et al, 2012; McLane et al, 2014). 
The interaction between HIV and opiates can increase the severity of neuroAIDS, with 
increases in markers of disease severity such as multinucleated giant cells and HIV-1 
p2-positive microglia (Anthony et al, 2008; Hauser et al, 2012). In addition to increased 
severity, HIV will emerge from latency earlier in opiate-abusing individuals (Anthony et 
al, 2008; Hauser et al, 2012). In the HIV-1 Tat transgenic mouse model (Bruce-Keller et 
al, 2008), morphine has been demonstrated to exacerbate excitotoxic effects in cultured 
neurons from the striatum and from the enteric nervous system (Hauser et al, 2012; 
Fitting et al, 2014). The development of neuronal excitotoxicity after Tat exposure is 
likely due to multiple interactive pathways with multiple points of convergence. For 
example, exposure to Tat results in phosphorylation of site Y1325 on the NR2A subunit 
of NMDA (King et al, 2010). This site is also a target of phosphorylation in the cascade 
triggered by activation of the µ-opioid receptor (MOR) (Sanchez-Blazquez et al, 2010; 
Garzon et al, 2011). The influx of Ca2+ through open NMDA channels into the dendrites 
of neurons after combined HIV-1 Tat and morphine exposure contributes to excitotoxic 
injury (Fitting et al, 2014). The activation of GSK3β is another point of convergence for 
HIV pathology and opiate pathology. Inhibition of GSK3β can block both HIV-induced 
neurotoxicity in cultured cells as well as the synergistic effects of morphine exposure 
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(Masvekar et al, 2015). There is some evidence, however, that the use of opiates does 
not always result in a synergistic worsening of HIV induced neurotoxicity, and can in fact 
be mildly neuroprotective. When buprenorphine, a common replacement therapy used 
to treat opiate addiction is used instead of morphine at high doses in neuronal culture, 
interactive neurotoxicity occurs. In contrast, at low doses, a mild neuroprotective effect  
is noted  (Fitting et al, 2015b).  This could be due to multiple factors. Tat has been 
shown to alter expression of the mu opiate receptor and certain endogenous opioids in 
the striatum and hippocampus while leaving kappa- and delta-opioid receptor 
expression unchanged. Similarly, MOR association with downstream signaling 
components has been demonstrated to be altered by morphine in the striatum and 
amygdala (Fitting et al, 2010a; Hahn et al, 2016). The activity of buprenorphine at these 
other receptors is likely to have played a role in the mild neuroprotection observed 
(Ammon-Treiber et al, 2007; Fitting et al, 2010a; Fitting et al, 2015b). In fact, there is 
some evidence suggesting that under the right circumstances, even morphine itself can 
be mildly neuroprotective due to its off-target effects if the dosage and receptor type 
spread within a region is right, despite its normal pro-apoptotic effects (Ammon-Treiber 
et al, 2007; Kawalec et al, 2011; Razavi et al, 2014).  The extent to which this is true is 
likely to vary by brain region just as vulnerability to HIV pathologic processes vary, and 
to be affected by the degree to which different drugs affect internalization of the different 
opioid receptors (Ammon-Treiber et al, 2007; Fitting et al, 2010b; Gelman et al, 2012; 
Nath, 2015; Hahn et al, 2016). Additionally, HIV-1 Tat has been shown to increase the 
level of tolerance mice develop to chronic morphine exposure, while decreasing the 
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physical symptoms of withdrawal, perhaps through a series of compensatory 
mechanisms (Fitting et al, 2012; Fitting et al, 2016; Hahn et al, 2016).  
Hypotheses and Aims 
 Although a number of studies have focused on the comorbidity of HIV-1 infection 
and opiates in the brain, few of these studies have assessed these comorbid 
interactions within the hippocampus. Moreover, while the response of the hippocampus 
to opioid drugs is fairly well defined from a functional standpoint (Valentino & 
Dingledine, 1982; Bao et al, 2007; Saboory et al, 2007; McQuiston, 2008), the functional 
response to Tat in the hippocampus is not as well characterized, with few studies 
examining the functional effects of the protein within the area (Carey et al, 2012; Fitting 
et al, 2013; Kesby et al, 2016). At present, no studies focus specifically on the functional 
circuit outcomes of HIV-1 Tat and morphine interactions within the hippocampus. The 
studies laid out here are aimed at first addressing in greater detail the effects of Tat on 
the hippocampal formation. This facilitated a more robust comparison between its 
effects and the effects of morphine during the later phases of these studies, which are 
aimed at understanding the potential interactions between Tat and morphine on 
hippocampal structure and function. 
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CNS Region Effect 
 
 
Striatum 
Atrophy (Johann-Liang et al, 1998; Chiang et al, 2007; Andronikou et al, 2014) 
Calcification in juveniles (Andronikou et al, 2014) 
Decreased expression of DAT, VMAT2 (Midde et al, 2012; Theodore et al, 2012) 
MAO expression altered (Acharjee et al, 2014; Meulendyke et al, 2014) 
Decreased synaptogenesis (Gelman et al, 2012; Yuferov et al, 2013) 
Decreased dopamine levels (Kumar et al, 2011) 
SN Decreased dopamine levels (Kumar et al, 2011) 
Selective loss of dopaminergic/TH+ neurons (Agrawal et al, 2010) 
 
 
Frontal Cortex 
Regional atrophy (Thompson et al, 2005; Chiang et al, 2007; Hua et al, 2013) 
Accelerated aging (Khanlou et al, 2009; Pfefferbaum et al, 2014) 
Loss of synchronous firing in frontal eye field (Wilson et al, 2013) 
Increased ROS sensitivity (Zhang et al, 2012; Pang et al, 2013) 
Increased glutamate neurotransmission (Zucchini et al, 2013) 
Decreased GABA neurotransmission (Zucchini et al, 2013) 
 
 
Hippocampus 
Loss of dendritic spines (Fitting et al, 2013) 
Increased chromatolysis (Torres & Noel, 2014) 
Decreased activity during encoding tasks (Maki et al, 2009) 
Increased glutamate neurotransmission (Zucchini et al, 2013)  
Increased ROS sensitivity (Pang et al, 2013) 
Impaired adult neurogenesis (Lee et al, 2011; Avraham et al, 2015) 
 
Corpus callosum 
Regional atrophy (Johann-Liang et al, 1998; Thompson et al, 2006; Chiang et al, 2007; Tate et 
al, 2011; Ances et al, 2012; Hua et al, 2013; Andronikou et al, 2014)  
White matter pallor and volumetric disturbances (Gongvatana et al, 2009; Pfefferbaum et al, 
2009; Muller-Oehring et al, 2010; Tate et al, 2011; Zou et al, 2015) 
Axonal damage (Gongvatana et al, 2009; Pfefferbaum et al, 2009; Muller-Oehring et al, 2010; 
Tate et al, 2011; Zou et al, 2015) 
Amygdala Variable volumetric disturbance (Ances et al, 2012) 
 
Cingulate gyrus 
Atrophy (Heyes et al, 2001)  
Decreased synaptogenesis (Yuferov et al, 2013) 
Beta oscillations diminished (Becker et al, 2013) 
 
Cerebellum 
Regional atrophy (Abe et al, 1996) 
Increased neuronal glutamate toxicity (Savio & Levi, 1993) 
Increased pH (Patton et al, 2001) 
Decreased neuronal kinase activity (Everall & Barnes, 1999) 
 
Retina 
Activation of Müller glia (Krishnan & Chatterjee, 2014) 
Decreased neural and glial cell viability (Chatterjee et al, 2011; Krishnan & Chatterjee, 2014) 
Decreased thickness of RNFL (Plummer et al, 2001; Cheng et al, 2011) 
Abnormal pattern evoked firing patterns (Iragui et al, 1996) 
 
Optic nerve 
Demyelination/vacuolar myelopathy (Sadun et al, 1995) 
Axonal degeneration (Sadun et al, 1995) 
Abnormalities in Visually evoked potentials (Iragui et al, 1996; Mwanza et al, 2004; Mahadevan 
et al, 2006) 
 
Table 1. 1 Selected listing of regional effects of HIV/HIV proteins within the CNS 
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Chapter 2: The effects of HIV Tat on CA1 interneuron microcircuitry and spatial 
memory 
Parts of this chapter appear in the Journal of Neurovirology, and are reproduced with 
permission of Springer (License #4205710527260):  
J. Neurovirol. HIV-1 Tat causes cognitive deficits and selective loss of parvalbumin, 
somatostatin, and neuronal nitric oxide synthase expressing hippocampal CA1 interneuron 
subpopulations 22(6). 2016, 747-762, Marks WD, Paris JJ, Schier CJ, Denton MD, Fitting S, 
McQuiston AR, Knapp PE, Hauser KF. © Journal of NeuroVirology, Inc. 2016, with 
permission of Springer. 
PMID: 27178324 
 
Clarification of contributions: Novel object recognition testing was performed by Dr. 
Jason Paris 
 
Introduction 
Following the discovery of human immunodeficiency virus type 1 (HIV-1) and 
acquired  immunodeficiency syndrome (AIDS), a profile of progressive neurological 
symptoms came to be associated with HIV-1 infection (Snider et al, 1983; Levy et al, 
1985), now collectively referred to as HIV-associated neurocognitive disorders (HAND) 
(Antinori et al, 2007; McArthur et al, 2010). Although there is variation among patients, 
common symptoms include deficits in attention, learning, memory, and impaired motor 
function. The neurocognitive aspects of HAND can be severe enough to interfere with 
independent living (Antinori et al, 2007). Notably, combined antiretroviral therapy 
(cART) does not fully ameliorate these symptoms (Sacktor et al, 2002; McArthur, 2004; 
Tozzi et al, 2005; Ellis et al, 2007).  
HIV may contribute to the progressive neurocognitive impairment in combination 
antiretroviral therapy (cART)-controlled patients through the continued production of 
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neurotoxic HIV-1 proteins from cellular reservoirs within the central nervous system 
(CNS) (Johnson et al, 2013). Shortly after infection, HIV-1 can enter the brain and 
establish central reservoirs (Lane et al, 1996; An et al, 1999), infecting microglia or 
astrocytes, but not neurons (He et al, 1997; Brack-Werner, 1999; Kramer-Hammerle et 
al, 2005; Churchill et al, 2009; Li et al, 2011). Uninfected cells can be damaged by viral 
proteins, as well as by the host neuroinflammatory response to virions and free viral 
proteins (Nath et al, 1996; Kruman et al, 1998; Nath et al, 1999; Aksenov et al, 2001; 
Soulas et al, 2009; Zhou & Saksena, 2013; Nath & Steiner, 2014). Among these 
neurotoxic factors, the HIV-1 transactivator of transcription (Tat) protein is critical for 
HIV replication (Zhou & Saksena, 2013; Nath & Steiner, 2014) and can be secreted by 
infected cells (Ensoli et al, 1990; Thomas et al, 1994; Rayne et al, 2010; Debaisieux et 
al, 2012) even in the presence of cART (Johnson et al, 2013). Furthermore, Tat can 
bind to a large number of extracellular receptors due to its highly basic domain 
(Philippon et al, 1994; Zhou & Saksena, 2013), penetrate and traverse the plasma 
membrane, and interact with a number of intracellular factors (Debaisieux et al, 2012). 
Despite regional differences in CNS vulnerability to HIV-1 (Nath, 2015), few 
studies have examined why some brain regions and neuronal types are preferentially 
susceptible to the virus. A number of behavioral deficits, including attenuation of spatial 
learning and memory, which are common features of HAND, can be recapitulated by 
Tat exposure and may be attributed to cellular and functional deficits in the 
hippocampus (Li et al, 2004; Fitting et al, 2006; Fitting et al, 2013). Long-term 
potentiation (LTP) is lost when Tat is injected intrahippocampally or expressed 
endogenously (Behnisch et al, 2004; Li et al, 2004; Fitting et al, 2013). Despite the 
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pronounced loss of LTP and deficits in behavior, CA1 pyramidal cells showed only a 
modest decrease in the density of apical dendritic spines, but no loss in dendrite length 
or synaptic integrity at the ultrastructural level, and no alterations in the level of proteins 
involved in excitatory glutamatergic pre- and post-synaptic function (Li et al, 2004; 
Fitting et al, 2013). By contrast, there were selective alterations in proteins involved in 
inhibitory γ-aminobutyric acid-ergic (GABAergic) synaptic function, including a 
significant decline in synaptotagmin 2 (Syt2) expression (only within SR) and marked 
increases in the expression of gephyrin throughout CA1 (Fitting et al, 2013). These 
findings concur with human gene array data which show a high degree of correlation 
between the expression of genes associated with inhibitory GABAergic synaptic 
transmission, including GAD1 and GABAR1, and the severity of HAND, but showed less 
robust correlations with genes associated with glutamatergic neurotransmission 
(Gelman et al, 2012). 
GABAergic interneurons are a diverse population of specialized cells responsible 
for much of the processing that occurs in the hippocampus. With estimates of at least 
21 distinct interneuron subtypes in CA1, there are numerous potential targets for the 
development of hippocampal pathology (McBain & Fisahn, 2001; Klausberger & 
Somogyi, 2008; Lovett-Barron & Losonczy, 2014). While numerous studies have 
examined the effects of HIV-1 on glutamatergic transmission in the hippocampus, few 
studies have assessed whether GABAergic synapses are altered. Pathology within 
specific GABAergic interneuron subpopulations, and the hippocampal interneuron 
network as a whole, has been demonstrated in a number of neurological disorders 
(Korotkova et al, 2010; Toth et al, 2010; Hazra et al, 2013; Levenga et al, 2013), some 
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of which produce behavioral deficits similar to those observed in experimental models of 
neuro-acquired immunodeficiency syndrome (neuroAIDS) (Carey et al, 2012; Fitting et 
al, 2013). In HIV models, reductions in the number of hippocampal neurons expressing 
parvalbumin (PV) in CA3 and somatostatin (SST) in CA1 have been observed (Masliah 
et al, 1992; Fox et al, 1997); however, since multiple neuron types in CA1 and CA3 
express these markers, the identities of the affected interneuron subtypes remain 
unclear.  
Based on the collective findings above, we hypothesized that specific interneuron 
subpopulation(s) might be preferentially vulnerable to HIV-1 Tat and that deficits in one 
or more interneuron subtypes following Tat exposure would coincide with impaired 
cognitive performance on hippocampus-dependent behavioral tasks. Our data show 
that HIV-1 Tat exposure was accompanied by memory impairment in mice and resulted 
in a selective decrease in the proportion of nNOS positive (nNOS+), neuropeptide Y 
negative (NPY−) neurons in both the stratum pyramidale and SR, as well as decreases 
in somatostatin-positive (SST+) neurons in the SO and parvalbumin positive (PV+) 
neurons in the stratum pyramidale. 
 
Materials and methods 
Animals and treatments 
Male mice were used exclusively throughout these studies. Inducible, glial 
fibrillary acidic protein-driven transgenic Tat mice (aged 60–80 days) were used to 
identify the effects of HIV-1 Tat1–86 on hippocampal interneuron subpopulations and 
associated behavior (Bruce-Keller et al, 2008). In order to induce Tat expression, mice 
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expressing the tat and rtTA transgenes (Tat+) were fed doxycycline-containing chow 
(DOX; 6 mg/g, Harlan, Indianapolis, IN) for 12–14 days depending on the experiment. 
Control mice lacking the tat transgene, but expressing the rtTA gene (Tat−), were given 
the same DOX treatment. Animal procedures were approved by the Virginia 
Commonwealth University Institutional Animal Care and Use Committee and are in 
accordance with Association for Assessment and Accreditation of Laboratory Animal 
Care guidelines. 
 
Barnes maze 
Tat− (n = 13) and Tat+ (n = 8) mice were assessed for spatial learning and motor 
function in a Barnes maze test (Barnes, 1979). Mice consumed DOX chow for 7–8 days 
prior to 1 day of prehabituation, followed by 4 days of testing and 1 day of probe trials. 
For prehabituation, mice were placed in the escape hole (positioned in a randomly 
assigned location) for 2 min, then were placed in the brightly lit center of a Barnes maze 
(91 cm diameter, 90 cm height, with 20 holes each 5 cm diameter; Stoelting Co., Wood 
Dale, IL), and guided to the assigned escape hole where they remained for 2 min, then 
were placed under a glass cylinder next to the escape hole, and allowed up to 3 min to 
volitionally enter (mice that did not enter the hole were guided in and remained for 2 
min). On testing days (four trials per day over 4 days), mice were placed in the brightly 
lit center of the Barnes maze and were allowed up to 3 min to enter the escape hole. 
Mice that did not enter the hole were gently guided to the hole and allowed to remain for 
2 min. Shorter latencies to find the escape hole, a greater proportion of time spent in the 
correct quadrant of the maze, and fewer errors were considered indices of greater 
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learning (Camara et al, 2013). On day 5, a reversal probe trial was conducted wherein 
the maze was turned 180° such that the correct goal box was on the opposite end of the 
Barnes maze table, and the proportion of time spent in the new target quadrant, latency 
to find the new escape hole, and number of errors made were assessed. Distances and 
velocities traveled were used as an index of motor behavior. 
 
Novel object recognition 
Tat− (n = 14) and Tat+ (n = 14) mice were assessed for neurocognitive function 
in a novel object recognition test (Ennaceur & Delacour, 1988; Dere et al, 2007) after 14 
days on DOX. Briefly, mice were habituated to a testing room, placed in an open field 
(35 × 40× 40 cm; Stoelting Co., Wood Dale, IL), and allowed to explore two identical 
round objects (plastic toys in the shape of kiwis, oranges, potatoes, or tomatoes; each 
～6 × 3 cm) for a 10-min training trial. After a 4-h inter-trial interval, one of the previously 
explored objects was replaced with a novel cone-shaped object of similar size (a plastic 
toy in the shape of a half ear of corn or a half-pickle), which mice were allowed to 
explore for a 10-min retention trial. Across subjects, replacement of the familiar object 
on the left vs. right side of the apparatus was counterbalanced to control for potential 
side-preferences. For each trial, the time spent investigating the object in the novel 
position, as a function of the entire time spent investigating, was calculated: [(novel 
object time − familiar object time)/(novel object time + familiar object time)]. To assess 
motor behavior, the overall distance traveled, as well as the time and frequency spent 
rearing were recorded. 
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Vision testing 
Tat− (n =6) and Tat+ (n=6) mice were assessed for visual function based on prior 
methods 
(Wersinger et al, 2002) prior to DOX exposure, and at 7 and 14 days following DOX 
exposure. In brief, mice were suspended approximately 12 in. above a vertical ring-
stand and were gently lowered with the ring-stand approximately 2 in. from the left or 
right visual field (close enough to allow visual, but not whisker, contact with the ring-
stand). The left and right visual fields were assessed consecutively for each mouse. 
Visual responding was considered positive when mice reached with the forepaws for the 
rod when presented to both the left and right side (a response to only one visual field 
would have been considered a negative response). Two observers rated visual 
responses. 
 
Immunohistochemistry 
Brains were fixed in 4 % paraformaldehyde using transcardial perfusion, 
removed, halved, and embedded in Tissue-Tek O.C.T. compound (Sakura Finetek, 
Torrance, CA). Hemisected brains were sectioned in the sagittal plain at a thickness of 
16 μm for analysis of interneuron populations or in the coronal plane at a thickness of 
40 μm to determine the reference volume using stereology. A Leica CM1850 cryostat 
was used to cut the sections (Leica Biosystems, Buffalo Grove, IL). Sections were 
mounted on slides and then stored at −80 °C until use. Tissue sections for interneuron 
analyses were blocked, then incubated with individual primary antibodies (anti-PV, 
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Synaptic Systems, Cat. No. 195 004, guinea pig polyclonal, 1:1200; anti-nNOS, Abcam, 
ab1376, goat polyclonal, 1:5000; anti-NPY, Abcam, 
ab30914, rabbit polyclonal, 1:100; anti-SST, Santa Cruz Biotechnology, sc-13099, 
rabbit polyclonal, 1:50; anti-NeuN, Chemicon, MAB377, mouse monoclonal, 1:500) for 
18 h at 4 °C, and rinsed in phosphate-buffered saline (PBS). Solutions containing 
appropriate, fluorescently labeled secondary antibodies (goat anti-guinea pig IgG-Cy3, 
Abcam ab6965-100, 1:500; Abcam ab102370, 1:500; donkey anti-goat IgG-Alexa 
Fluor® 488, Invitrogen, A11055, 1:500; goat anti-rabbit IgG-Alexa Fluor® 647, 
Invitrogen A21244, 1:500; donkey anti-mouse IgG-Alexa Fluor® 594, Invitrogen, 
A21203, 1:500; goat antimouse IgG-488 Oregon green, Molecular Probes, 0-6380, 
1:500) were placed onto tissue sections for 2 h at room temperature. Slices were then 
rinsed 3 × 10 min in PBS. All tissue sections were incubated in PBS/Hoechst solution 
(0.5 μg/ml, Invitrogen, H3570) for 5–10 min, repeatedly rinsed in PBS, and mounted in 
ProLong Gold Antifade reagent (Invitrogen, P36930). 
 
Reference volume analysis 
Hoechst-stained 40-μm serial sections were sampled through the entire 
hippocampus. From a random starting position, sections at evenly spaced intervals 
were sampled to obtain an unbiased stereological assessment of hippocampal volume 
(Gundersen et al, 1988). In short, sections from halved brains were taken from Tat− (n = 
6) and Tat+ (n = 5) mice and imaged using a Zeiss Axio-Observer Z1 microscope, MRm 
digital camera, and a 10× objective (Zeiss, Oberkochen, Germany). Montages of the 
entire left hemisphere of the brain (5 × 6) were obtained utilizing a motorized stage 
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encoder (Zeiss) and a computerized tile reconstruction method (Zeiss, Axio-Vision 
software). Hippocampal volume was then estimated by overlaying a standardized grid 
over the image of the brain and performing a point count analysis (Gundersen et al, 
1988; Mouton, 2002). 
 
Imaging 
Hippocampi were imaged using a Zeiss LSM 700 microscope at 20× 
magnification (Zeiss, Oberkochen, Germany). Neurons, as noted by the presence of 
NeuN immunoreactivity within the nucleus, were counted in SO, stratum pyramidale, 
SR, and SL-M of CA1. Immunoreactivity for each protein was noted independently, and 
the markings were overlaid to confirm co-expression of proteins without bias. From 4 to 
10 sections (typically 7 to 8) were analyzed and averaged per animal, and 6 mice per 
experimental group were used for all experiments. All cell count data are presented as a 
percent of the total NeuN+ population in each layer. To examine the potential effects of 
the Tat transgene on the neuritic processes, densitometric analysis of PV+ dendrites 
and SST + axons was performed using ImageJ (NIH, Bethesda, MD). In addition, 
dendritic varicosities of PV+ interneurons were quantified on the five most pronounced 
dendrite segments from each image within SR from 2 to 3 sections per animal. 
Dendrites not reaching at least 50 μm in length or discontinuous dendrites were not 
analyzed. 
 
Statistical analyses 
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Behavioral endpoints were recorded and digitally encoded by an ANY-maze 
animal tracking system (Stoelting Co., Wood Dale, IL) and assessed via repeated-
measures analyses of variance (ANOVA) with novel object recognition trial (training trial 
or retention trial) or Barnes maze testing day (days 1–5) and mouse genotype (Tat− or 
Tat+) as the respective within-, and between-, subjects factors. Tukey’s honestly 
significant difference post hoc tests were used to assess group differences following 
main effects. Interactions were delineated via simple main effects and main effect 
contrasts with alpha corrected for multiple comparisons. Immunohistochemical 
endpoints were assessed with one-tailed Student’s t tests. Effects were considered 
significant when p<0.05. 
 
Results 
HIV-1 Tat expression impairs mnemonic performance 
Inducing HIV-1 Tat expression in the CNS of mice significantly impaired spatial 
learning in the Barnes maze test. Compared to Tat− controls, Tat+ mice demonstrated 
significantly longer latencies to find the escape hole [F(1,76)=9.39, p<0.05] and spent a 
significantly lower proportion of time [F(1,76)=8.17, p<0.05] in the correct quadrant of 
the Barnes maze (Fig. 1). Irrespective of genotype, all mice took significantly longer to 
find the escape hole following a 180° swap of the escape location on the probe trial day 
[F(4,76)=3.42, p<0.05] compared to any previous day’s performance (p = 0.0001–0.01; 
Fig. 1). No differences were observed in the number of errors made or the distance 
traveled between Tat− and Tat+ mice (Fig. 1); however, a difference in velocity was 
observed between Tat− and Tat+ mice  [F(1,76)=5.35, p<0.05] with a significant 
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reduction observed in the reversal probe trial [F(4,76)=8.45, p<0.05], compared to day 1 
performance (p < 0.0001). All mice demonstrated significantly decreased maze 
exploration (indicated by distance traveled) [F(4,76)=12.86, p<0.05] and made fewer 
errors [F(4, 76) = 11.37, p < 0.05] compared to day 1 (p = 0.0001–0.02; Fig. 1).  
Similarly, HIV-1 Tat expression significantly impaired cognitive performance in a 
novel object recognition task [F(1, 26) = 5.67, p < 0.05]. Compared to performance in 
the training trial, Tat− control mice spent a significantly greater proportion of time with a 
novel object in the retention trial (p = 0.0007; Fig. 2) indicating intact mnemonic 
performance. However, Tat+ mice demonstrated impaired object recognition during the 
retention phase (Fig. 2), spending significantly less time investigating the novel object 
compared to Tat− controls (p = 0.04). No significant differences were observed between 
Tat− or Tat+ mice on the total amount of time spent investigating objects nor on any 
motor measure investigated (Table 1). 
Given that a visual component is present in the Barnes maze and novel object 
recognition tasks, vision was assessed in a separate group of mice. All Tat− and Tat+ 
mice responded positively to a stimulus presented to the left and right fields of vision 
prior to DOX exposure and at 7 and 14 days following DOX exposure. 
 
Hippocampal volume is unchanged following Tat exposure 
Point count analysis of hippocampal volume revealed no difference between Tat− 
(16.71 ± 0.39 mm3) and Tat+ (17.62 ± 0.47 mm3) mice. Additionally, the volume of the 
CA1 subfield was unchanged between Tat− (9.97 ± 0.19 mm3) and Tat+ (10.74 ± 0.69 
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mm3) mice indicating that there was no difference in the volume of the hippocampus or 
in hippocampal area CA1 following 12–14 days of Tat induction. 
 
HIV-1 Tat expression is associated with reductions in specific CA1 nNOS-expressing 
interneuron subpopulations 
We investigated Tat effects on a subset of nNOS+/NPY+ cells known as ivy cells. 
These cells are found primarily in the stratum pyramidale as well as the SR of CA1 
(Fuentealba et al, 2008). To assess the vulnerability of nNOS+/NPY+ cells to HIV-1 Tat, 
hippocampal sections were immunolabeled for nNOS, NPY, and NeuN (Figs. 3 and 4). 
The distribution of nNOS and NPY immunoreactivity within CA1 was consistent with 
previous research (Morris, 1989; Jinno et al, 1999; Fuentealba et al, 2008). Significant 
reductions in the percentage of nNOS-expressing cells were observed in the stratum 
pyramidale [t(8) = 2.25, p < 0.05] and SR [t(8) = 2.43, p < 0.05] of Tat+ mice compared 
to Tat− mice (Fig. 3). Importantly, the reduction in nNOS+ interneurons was specifically 
restricted to the subpopulation of interneurons that did not possess NPY antigenicity in 
both the stratum pyramidale [t(8) = 2.36, p < 0.05] and SR [t(8) = 1.92, p < 0.05] after 
Tat exposure, indicating ivy cells were not selectively vulnerable. No significant 
differences were observed for NPY+ interneurons lacking nNOS in any layer of CA1. 
Tat induction did not significantly alter the percentage of NPY+ interneurons or 
interneurons coexpressing nNOS and NPY in any layer of the hippocampus (Fig. 3). 
 
The proportion of SST+ and PV+ neurons is reduced by HIV-1 Tat expression 
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To assess the vulnerability of PV+ and SST+ interneurons, hippocampal sections 
were immunolabeled for PV, SST, and NeuN (Figs. 5 and 6). PV immunoreactivity was 
nearly exclusive to stratum pyramidale and SO, consistent with previous research 
(Kosaka et al, 1987). Observations of SST immunoreactivity in SO, stratum pyramidale, 
and SR also agree with previous findings (Oliva et al, 2000); however, SST+ neurons 
occurring in the SR were not quantified as part of this study (Fig. 5). The percentage of 
PV+ neurons were significantly diminished in the stratum pyramidale of Tat+ mice 
compared to Tat− mice [t(10) = 1.839, p < 0.05]. While no significant effect of Tat was 
observed in PV+/SST− interneurons, there was a trend toward significance in 
PV+/SST+ interneurons in the stratum pyramidale [t(10) = 1.711, p = 0.059]. No effect 
of Tat was observed in PV+ interneuron groups in the SO. In contrast, the proportion of 
SST+ interneurons was reduced in the SO [t(10) = 2.664, p < 0.05], but not in the 
stratum pyramidale of Tat+ mice. While there were no significant differences in SO to 
suggest that subpopulations of SST+ neurons were reduced in the layer, there was a 
trend toward significant decreases in the proportion of PV−/SST+ [t(10) = 1.673, p = 
0.063]. These data indicate subregion-specific declines in interneuron populations, 
supporting the idea of selective vulnerability among hippocampal neuron 
subpopulations. 
 
PV+ and SST+ processes in CA1 appear unaffected by Tat 
ImageJ analysis of PV expression in the SR and SST expression in the SL-M 
showed no differences in fiber density between Tat+ and Tat− mice. There were also no 
differences in dendritic varicosity number or size in PV+ neurons (Fig. 7). 
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Discussion 
Given the great diversity in function, morphology, and localization of hippocampal 
interneurons, the highly localized reduction of Syt2+ fibers described by Fitting et al 
(Fitting et al, 2013) suggests selective vulnerability of distinct subpopulations of 
interneurons to HIV-1 Tat. We thus hypothesized that a subpopulation of hippocampal 
interneurons would be selectively vulnerable to HIV-1 Tat and used an 
immunohistochemical/morphological approach to identify neurodegenerative changes in 
cells within defined regions of CA1. We found that Tat+ animals exhibited aberrant 
learning behavior in both the Barnes maze and novel object recognition tests. Tat 
expression reduced the population of nNOS+/NPY− interneurons in both the SR and 
stratum pyramidale, SST+ cells in the SO, and PV + cells in the stratum pyramidale. 
nNOS+/NPY+ or nNOS−/NPY+ neurons remained unchanged.  
The pathology of specific interneuron subpopulations, and the hippocampal 
interneuron network as a whole, have been demonstrated in a number of neurological 
disorders (Korotkova et al, 2010; Toth et al, 2010; Antonucci et al, 2012; Fitting et al, 
2013; Levenga et al, 2013), some of which produce behavioral deficits in learning 
similar to the findings of Fitting et al (Fitting et al, 2013). Due to neuronal heterogeneity 
in the hippocampus (Bouilleret et al, 2000; Moga et al, 2002; Avignone et al, 2005), 
differential responses to Tat-induced excitotoxicity and neuroinflammation may be 
expected. In a kainate-induced model of excitotoxicity, a loss of GAT-1, a GABA 
reuptake protein, was greater in the stratum pyramidale than in the SO and the SR, 
suggesting regional variability in selective vulnerability of hippocampal interneurons 
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(Bouilleret et al, 2000). In HIV models, reductions in the number of cells expressing PV 
in CA3, and SST in CA1 were observed, although identification of the affected subtypes 
was incomplete (Masliah et al, 1992; Fox et al, 1997). The results of the present study 
indicate that there is at least one subtype of nNOS+ interneuron within CA1 that is 
selectively vulnerable to HIV-1 Tat. nNOS+ interneurons appear in all layers of the 
hippocampus, a majority of which are subpopulations of neurogliaform cells (NGFCs; 
nNOS+/NPY−) (Jinno et al, 1999; Tricoire et al, 2010). In addition to NGFCs, there are 
ivy (nNOS+/NPY+) and interneuron-specific interneuron type III (IS3; nNOS+/NPY−) 
cells. Ivy cells exist primarily in the stratum pyramidale, as well as the SR (Fuentealba 
et al, 2008; Lapray et al, 2012). nNOS+/NPY− cells have been found in the stratum 
pyramidale (IS3s) and SR (NGFCs) (Acsady et al, 1996a; Acsady et al, 1996b; Porter et 
al, 1998; Jinno et al, 1999; Jinno & Kosaka, 2002; Jinno & Kosaka, 2004; Tricoire et al, 
2010; Armstrong et al, 2012; Somogyi et al, 2012).  
Our findings suggest that the ivy cells (i.e., nNOS+/NPY+ neurons residing in the 
stratum pyramidale) are not vulnerable to HIV-1 Tat as previously hypothesized 
(Fuentealba et al, 2008). Rather, a significant decline was observed in the number of 
nNOS+/NPY− interneurons in both the stratum pyramidale and SR. In the stratum 
pyramidale, these vulnerable neurons are thought to be IS3s (given the lack of NPY). 
Additionally, these neurons are positive for vasoactive intestinal polypeptide (VIP), and 
calretinin (CR) (Acsady et al, 1996a; Acsady et al, 1996b; Porter et al, 1998; Jinno et al, 
1999; Jinno & Kosaka, 2002; Tricoire et al, 2010) and the expression of nNOS 
differentiates them as IS3s versus an IS1 subtype (Tricoire et al, 2010). Functionally, 
IS3s support feedback inhibition within CA1 (Gulyas et al, 1996; Chamberland et al, 
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2010; Chamberland & Topolnik, 2012; Tyan et al, 2014). Of particular interest, the 
selective vulnerability of multiple subsets of CR + cells in the hippocampus may occur in 
a temporal-lobe epilepsy model, a good predictor of neuronal vulnerability to 
excitotoxicity. Those cells that remain exhibit pathologic dendritic varicosities and a loss 
of dendritic complexity and synapses, as a result of excitotoxic injury (Toth et al, 2010; 
Toth & Magloczky, 2014). Patients with epilepsy can have fewer nNOS+ interneurons 
within CA1 (Leite et al, 2002).  
The population of nNOS+/NPY− cells affected by Tat in SR likely consists of 
multiple nNOS+ interneuron subtypes, including IS3s (Acsady et al, 1996a; Acsady et 
al, 1996b; Porter et al, 1998; Jinno et al, 1999; Jinno & Kosaka, 2002; Tricoire et al, 
2010) and NGFCs (Tricoire et al, 2010; Armstrong et al, 2012; Somogyi et al, 2012; 
Tricoire & Vitalis, 2012). Since IS3s represent a small proportion of nNOS+ cells in the 
SR, it is probable that NGFCs constitute a majority of nNOS+/NPY− cells lost (Jinno et 
al, 1999; Jinno & Kosaka, 2002; Tricoire et al, 2010; Armstrong et al, 2012). The 
presence or absence of CR, which is expressed in IS3s, but not NGFCs, might be used 
to further differentiate these interneuron subtypes in the future (Jinno & Kosaka, 2002; 
Armstrong et al, 2012; Somogyi et al, 2012). Considering the lack of cell death in the 
hippocampus observed at early time points following Tat induction (Fitting et al, 2013), 
we speculate that the affected interneuron subtypes are downregulating nNOS in 
response to excitotoxic injury in order to restore homeostasis (Hu et al, 2008; Di et al, 
2012). 
nNOS is required for the normal functioning of the hippocampal interneuron 
network and maintenance of related behavioral endpoints. In complete nNOS knockout 
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mice, there is an attenuation of contextual fear conditioning and spatial memory 
formation similar to what is observed in Tat transgenic mice (Kirchner et al, 2004; 
Weitzdoerfer et al, 2004; Kelley et al, 2009; Fitting et al, 2013). While nNOS is important 
for normal hippocampal function (Kirchner et al, 2004; Zanelli et al, 2009), research 
indicates that nNOS-induced neuronal damage occurs in pathological states (Cui et al, 
2007; Eugenin et al, 2007; Steinert et al, 2010; Wang et al, 2010; Drury et al, 2014; Hsu 
et al, 2014; Wu et al, 2014b). The role of nNOS in excitotoxicity, including HIV-1 Tat 
excitotoxicity, is reportedly linked to its activation of PSD-95 and NMDA receptor 
complexes (Christopherson et al, 1999; Eugenin et al, 2007; Fan et al, 2010; King et al, 
2010; Steinert et al, 2010). Exposure to excitotoxic levels of glutamate causes temporal 
dysregulation of nNOS activation-inactivation processes (Rameau et al, 2007). Thus, 
Tat-induced increases in the activation of nNOS may enhance NMDA receptor 
phosphorylation, the recruitment of additional AMPA receptors, and the generation of 
peroxynitrite resulting in greater susceptibility to excitotoxic damage in nNOS-
expressing interneurons (Yu et al, 1997; Grima et al, 2001; Rameau et al, 2007; 
Hossain et al, 2012). Lastly, we speculate that the proposed compensatory 
downregulation of nNOS may be absent or may be less prevalent in nNOS+/NPY+ 
neurons due to the neuroprotective effects of NPY, which can regulate neuronal 
excitability via paracrine/ autocrine signaling (Xapelli et al, 2006; Smialowska et al, 
2009).  
The present findings stand in contrast to prior studies that did not demonstrate a 
loss of PV+ interneurons in CA1 of HIV-infected patients or rodent models (Masliah et 
al, 1992; Guo et al, 2012). Herein, we differentiate the percentages of CA1 PV 
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expressing cells by CA1 layer and by SST co-expression, allowing for delineation of 
CA1 cell types (PV+ interneurons including bistratified and oriens-lacunosum-
moleculare (O-LM) cells) (Kosaka et al, 1987; Masliah et al, 1992; Buhl et al, 1994; 
Freund & Buzsáki, 1998; Jinno & Kosaka, 2000; Jinno & Kosaka, 2002; Klausberger et 
al, 2004; Klausberger & Somogyi, 2008; Muller & Remy, 2014; Yamada & Jinno, 2015). 
Bistratified cells were discerned from O-LM interneurons via the relative intensity of PV 
(high in bistratified) and SST (minimal in bistratified) immunoreactivity. In contrast, O-
LMs exert an opposing PV/SST profile, with a subset of O-LMs being entirely PV− 
(Chittajallu et al, 2013; Muller & Remy, 2014). Our data show a modest effect of Tat on 
the total PV+ population of the stratum pyramidale; however, this was not restricted to a 
particular PV+ cell type. Although we believe Tat may be selectively affecting bistratified 
cells based on a trend toward reduced PV+/SST+ interneuron numbers, additional 
information is needed for confirmation. Interestingly, while the loss of PV+ cells in CA1 
is not reported in patients with neuroAIDS, many of the PV+ interneurons were 
reportedly unhealthy with damaged neurites being the chief descriptor (Masliah et al, 
1992). Despite limitations in generalizing findings from Tat transgenic mice to HIV-
infected individuals, the collective findings suggest PV+ interneuron subsets are 
selectively vulnerable to HIV—perhaps through synaptodendritic injury and pruning. 
Reductions in SST gene expression in the brains of HIV patients are linked to the 
development of depression (Everall et al, 2006). Fox et al. (Fox et al, 1997) showed a 
reduction in SST+ interneurons in HIV patients, but did not differentiate between the 
layers of CA1. We observed a strong net reduction of SST+ interneurons in the SO, but 
not in the stratum pyramidale. The SR was not quantified due to the relative rarity of 
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SST+ cells in this region. Interestingly, there was a trend toward reductions in 
SST+/PV− interneurons in the SO following Tat induction. The loss of SST has been 
shown to have profound effects on LTP within CA1, with differential effects in the apical 
and basilar dendrites of pyramidal cells based on receptor subtypes and response to 
specific oscillation patterns (Fan & Fu, 2014). Considering the decline in SST+ neurons 
observed in this study and previous findings of reduced SST expression in HIV patients 
(Everall et al, 2006), it will be important to examine whether region-specific SST losses 
contribute to impairments in LTP and related behavior following Tat-exposure (Behnisch 
et al, 2004; Fitting et al, 2013). In support of this notion, ablating SST+ interneurons, 
focal to distal apical dendrites of pyramidal cells in SL-M (likely O-LMs), causes a loss 
of cue-based fear learning, while removal of PV+ neurons, focal to basal dendrites and 
proximal portions of apical dendrites in the SR, does not result in loss of fear learning. 
(Leão et al, 2012; Lovett-Barron et al, 2014; Lovett-Barron & Losonczy, 2014; Muller & 
Remy, 2014)}  While it is not possible to say with certainty which SST+ population is 
affected in the present study, the net loss in SST in the SO is most likely due to O-LM 
cell vulnerability. 
We and others have found that HIV-1 Tat can impair learning and memory, and 
the present study begins to advance our understanding of the limbic neuronal types that 
may underlie such effects. In the present study, Tat+ mice exhibited deficient 
performance on two hippocampally dependent tasks, the Barnes maze and novel object 
recognition tests, compared to their Tat− counterparts. Consistent with these results, 
stereotaxic injections of Tat directly to dorsal hippocampus have recently been 
demonstrated to increase the latency to find a hidden platform in a Morris water maze 
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and to impair novel object recognition among Sprague-Dawley rats (Harricharan et al, 
2015). Similar intracerebroventricular injections of Tat impaired radial arm maze 
performance concurrent with disrupted LTP in the hippocampus of C57BL/6J mice (Li et 
al, 2004). Additionally, similar impairment of Barnes maze performance and object 
recognition has been observed in a separate GFAP driven Tat-inducible mouse model 
(Carey et al, 2012). Considering that behavioral deficits similar to those seen in 
neuroAIDS can be traced back to the dysfunction of one or more of the interneuron 
types discussed here, it is reasonable to assume that imbalance in this complex circuit 
may contribute to the attenuation of spatial memory observed in HAND (Masliah et al, 
1992; Buhl et al, 1994; Acsady et al, 1996a; Fox et al, 1997; Sik et al, 1997; Ali et al, 
1998; Kirchner et al, 2004; Klausberger et al, 2004; Weitzdoerfer et al, 2004; Carey et 
al, 2012; Leão et al, 2012; Fitting et al, 2013; Lovett-Barron et al, 2014; Muller & Remy, 
2014; Sun et al, 2014; Tyan et al, 2014).  
Hippocampal interneurons interact as part of a functional network and it is clear 
that the removal of even one cell type from the network can have drastic effects on 
information processing, pyramidal cell excitation, and consequent behavioral outcomes 
(Moga et al, 2002; Dugladze et al, 2007; Goldin et al, 2007; Toth et al, 2010; Peng et al, 
2013; Long et al, 2014; Lovett-Barron et al, 2014; Lovett-Barron & Losonczy, 2014; Toth 
& Magloczky, 2014; Orban-Kis et al, 2015). Importantly, the susceptible nNOS+/NPY− 
interneurons of the stratum pyramidale and the SR, PV+ cells of the stratum pyramidale, 
and SST+ interneurons of the SO form a microcircuit known to be involved in a complex 
feedback loop/input gating mechanism that regulates network synchronization within 
CA1 (Fig. 8) (Buhl et al, 1994; Acsady et al, 1996a; Sik et al, 1997; Ali et al, 1998; 
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Klausberger et al, 2004; Chamberland et al, 2010; Chamberland & Topolnik, 2012; Leão 
et al, 2012; Muller & Remy, 2014; Sun et al, 2014; Tyan et al, 2014; Milstein et al, 
2015). Herein, we propose this microcircuit to be selectively vulnerable to HIV-1 Tat. 
Given clinical observations that implicate HAND- and psychostimulant-related 
neurocognitive deficits to be associated with interneuron losses in other brain regions 
(Chana et al, 2006), the present findings suggest that a proportionally small, 
interconnected ensemble of hippocampal CA1 interneurons may contribute to key 
functional and neurobehavioral deficits observed in HAND. 
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Figure 2. 1: Barnes  maze performance between Tat- and Tat+ mice 
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Representative traces of the movements of Tat− (a–c) and Tat+„ (d–f) mice 
exploring a Barnes maze on testing days 1 (a, d) and 4 (b, e), as well as the reversal 
probe trial [escape hole reversed 180° (c, f)]. Escape hole is noted as the black circle in 
each figure. Tat+ mice (n = 8) demonstrate significantly longer latencies to find the 
escape hole (g) and (h) spend a significantly lower proportion of time in the correct 
quadrant of the Barnes maze test, indicating impaired learning compared to Tat− control 
mice (n = 13). Neither the number of errors made (i) nor the distance traveled (j) differs 
between Tat− and Tat+ mice, but decreases among all animals from day 1 
performance. Tat+ mice have a reduced velocity compared to Tat− mice, and all mice 
show reduced velocity in the reversal probe trail compared to day 1 performance (j, 
inset). The asterisk indicates a main effect for Tat− and Tat+ mice to significantly differ. 
The dagger sign indicates performance significantly differs from day 1 performance. The 
double dagger sign indicates reversal probe trial performance significantly differs from 
all other testing days, except day 1 (main effects, repeated measures ANOVA, p < 0.05) 
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Figure 2. 2: Effects of Tat on novel object recognition task performance 
 
 
 
Tat+ mice (n = 14) spend a significantly lower proportion of time investigating a 
novel (vs. familiar) object in a novel object recognition test, indicating impaired cognitive 
performance compared to Tat− control mice (n = 14). The asterisk indicates a significant 
difference from the respective training trial exploration. The dagger sign indicates a 
significant difference between Tat− and Tat+ mice in the retention trial (interaction, 
repeated measures ANOVA, p < 0.05) 
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Figure 2. 3: Tat effects on nNOS and NPY expressing CA1 interneurons 
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Effects of HIV-1 Tat induction on neuronal nitric oxide synthase (nNOS) and 
neuropeptide Y (NPY) immunoreactive interneuron subpopulations in hippocampal area 
CA1. a–e Immunoreactivity for nNOS (c, c′), NPY (d, d′), and the neuronal marker, 
NeuN (b, b′), was co-localized in sections from Tat+ and Tat− mice counterstained 
using Hoechst dye (a, a′). e, e′ NeuN (blue), nNOS (green), and NPY (red) merged. f–j 
The percentage of labeled neurons in hippocampal area CA1 by layer and marker. The 
proportion of nNOS+ neurons in stratum pyramidale (Pyramidal) and stratum radiatum 
(Radiatium) is significantly decreased in Tat+ compared to Tat− mice (*p < 0.05, one 
tailed t test) (f), while the percentage of NPY+ neurons or neurons co-expressing nNOS 
and NPY in any layer is unaffected by Tat (g, h). The percentage of cells expressing 
nNOS in the absence of NPY is significantly reduced in stratum pyramidale and in 
stratum radiatum (*p < 0.05, one tailed t test) (i), while the proportion of NPY cells that 
lack nNOS was unaffected by Tat (j). Stratum oriens (Oriens), stratum lacunosum-
moleculare (L–M). Scale bar = 200 μm 
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Figure 2. 4: nNOS and NPY subcellular localization 
 
Subcellular localization of neuronal nitric oxide synthase (nNOS) and 
neuropeptide Y (NPY) immunoreactivity in interneurons in hippocampal area CA1 of 
Tat+ and Tat− mice. a–d Immunoreactivity for nNOS (green), NPY (red), and the 
neuronal marker, NeuN (blue), was co-localized in sections from Tat+ and Tat− mice 
counterstained using Hoechst dye (nuclei). a, c nNOS+/NPY− interneurons located in 
stratum pyramidale (sp). b, d nNOS+ and NPY+ interneurons of stratum pyramidale. 
Stratum oriens (so), stratum radiatum (sr). Scale bar = 10 μm 
 
 
65 
 
Figure 2. 5: Effects of Tat on PV and SST expressing CA1 interneurons 
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Effects of HIV-1 Tat induction on parvalbumin (PV) and somatostatin (SST) 
immunoreactivity in interneurons within hippocampal area CA1. a–d Low-magnification 
images of PV, SST, and NeuN immunoreactivity in sections from Tat+ and Tat− mice 
additionally counterstained with Hoechst dye. a–e Hippocampal sections from Tat+ and 
Tat–mice treated with DOX, probed with Hoechst (a, a′), NeuN (b, b′), PV (c, c′), and 
SST (d, d′). e, e′ NeuN (blue), PV (green), and SST (red) merged. f–j The percentage of 
labeled neurons in hippocampal area CA1 by layer and marker. A decrease in the 
percent of PV+ neurons is seen in stratum pyramidale (Pyramidal) (f), and a decrease in 
the percent of SST+ neurons is observed in stratum oriens (Oriens) (g). No significant 
decrease is observed for neurons expressing both PV and SST or for neurons that 
express either marker in the absence of the other (h–j). The asterisk denotes a 
significant reduction from Tat− control population percentage (one tailed t test, p < 
0.05). Scale bar = 200 μm 
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Figure 2. 6: PV and SST subcellular localization 
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Subcellular localization of parvalbumin (PV) and somatostatin (SST) 
immunoreactivity in interneurons in hippocampal area CA1 of Tat+ and Tat− mice. a–d 
High-magnification images of PV (red), SST (green), and NeuN (blue) immunoreactivity 
in sections from Tat+ and Tat− mice additionally counterstained with Hoechst dye (a–f). 
a, d PV+/SST− interneurons located in stratum oriens (so). b, e PV+ and SST+ 
interneurons of the stratum oriens. c, f PV+ neurons of stratum pyramidale (sp). Stratum 
radiatum (sr). Scale bar = 10 μm 
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Figure 2. 7: Tat does not affect amount of PV or SST+ neurites in CA1 
 
No evidence of changes to parvalbumin-immunoreactive (PV+) dendrites or 
somatostatin immunoreactive (SST+) axons is observed following Tat induction. a PV+ 
neurons and neurites in Tat− mice. No differences in the density of PV+ fibers or 
increases in the number of dendritic varicosities was seen in the stratum radiatum (sr). 
Scale bar = 20 μm. b Tat− SST+ axons in stratum lacunosum-moleculare (sl-m). No 
difference in fiber density of SST+ axons in the SL-M was observed. Stratum oriens 
(so), stratum pyramidale (sp), dentate gyrus (dg). Scale bar = 50 μm 
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Figure 2. 8: Interneurons affected by Tat are part of a memory microcircuit 
 
The interneurons affected by Tat form a microcircuit within the CA1 area of the 
hippocampus. CA1 pyramidal cells receive inputs from both hippocampal area CA3 and 
the entorhinal cortex. Oriens-lacunosum-moleculare (O-LM) cells gate inputs from the 
entorhinal cortex onto pyramidal cell distal apical dendrites. CA3 inputs are disinhibited 
by bistratified cells and Shaffer collateral-associated interneurons in the stratum 
radiatum (Sik et al, 1997; Klausberger et al, 2004; Leão et al, 2012). O-LMs receive 
excitatory inputs from CA1 pyramidal cells and the septum, and inhibitory innervation 
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from interneuron-specific interneuron type 3 (IS3) cells (Acsady et al, 1996a; Muller & 
Remy, 2014; Sun et al, 2014; Tyan et al, 2014). Bistratified cells receive excitatory input 
from Shaffer collaterals, CA1 pyramidal cells, and the septum (Ali et al, 1998; 
Klausberger et al, 2004; Muller & Remy, 2014) and innervate pyramidal cells (Buhl et al, 
1994; Sik et al, 1997; Klausberger et al, 2004). In addition to being inhibited by O-LMs, 
bistratified cells receive GABAergic inputs from the neuronal nitric oxide 
(nNOS)+/neuropeptide Y (NPY)− IS3s (Leão et al, 2012; Tyan et al, 2014). IS3s 
innervate O-LMs preferentially, as well as bistratified cells, in the stratum oriens (Acsady 
et al, 1996a; Tyan et al, 2014). Disruption of this circuit by Tat may disrupt the gating of 
inputs from CA3 and the entorhinal cortex and therefore produce aberrant pyramidal cell 
outputs, which could account for the behavioral phenotype observed following Tat 
exposure (Sik et al, 1997; Klausberger et al, 2004; Leão et al, 2012). CA1 pyramidal cell 
(yellow), bistratified cell (Bis, orange), O-LM (red), IS3 (light blue), Shaffer collateral 
input from CA3 (green), perforant path input from the entorhinal cortex (EC, purple). 
Glutamatergic synapses are noted with a plus (+) and GABAergic synapses are noted 
with a minus (−). 
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 Tat− n= 14 Tat+ n= 14 
Familiar Object Exploration (s) 12 ± 2 15 ± 2 
Novel Object Exploration (s) 24 ± 3 20 ± 3 
Total Distance Traveled (m) 13 ± 1 11 ± 1 
Frequency of Rearing 51 ± 8 44 ± 8 
Total Time Rearing (s) 43 ± 7 35 ± 6 
 
Table 2. 1: Raw exploration time and motor behavior among Tat- and Tat+ mice 
Raw exploration time and motor behavior among Tat− and Tat+ mice (n = 
14/group) that were assessed in a novel object recognition task (mean ± SEM). No 
significant differences were observed between Tat− and Tat+ mice. 
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Chapter 3: The effects of Tat and Morphine on the structure and function of CA1  
Parts of this chapter will be submitted for publication in the Journal of Neuroscience 
 
Clarification of contributions: Dr. Virginia McLane, Aaron Barbour, and Jean Moon 
assisted with morphological analyses 
 
Introduction 
 Infection of the CNS by the human immunodeficiency virus (HIV) results in a 
series of neurological impairments collectively termed the HIV associated 
neurocognitive disorders (HAND). The neurological effects of HIV have also been 
shown to be exacerbated by using opiates (Hauser et al, 2012). Diminished spatial 
memory, frequently associated with hippocampal dysfunction, is a hallmark of HAND 
and aggravated by opiate abuse (Maki et al, 2009; Keutmann et al, 2017).  Despite this, 
the mechanisms underlying the pathological effects of HIV and morphine alone or in 
combination within the hippocampus are incompletely understood. 
Both Tat (Kesby et al, 2016; Marks et al, 2016), and morphine (Zhu et al, 2011; 
Kitanaka et al, 2015) have been demonstrated to impair spatial memory in mice. 
Previous work identified HIV-1 Tat-induced reductions of long term potentiation (LTP) in 
CA1, which coincides with deficits spatial memory formation in HIV transgenic mice 
(Fitting et al, 2013).  However, reductions in LTP were accompanied by only modest 
reductions in the density of dendritic spines in CAI pyramidal cells and no change in the 
levels of excitatory synaptic proteins.  In contrast, Tat markedly reduced expression of 
synaptotagmin 2, while triggering presumably compensatory increases in gephyrin 
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postsynaptically, reflecting a disruption in inhibitory GABAergic transmission within CA1. 
Further investigation of the GABAergic cells within CA1 revealed that several distinct 
subgroups of GABAergic interneurons were preferentially vulnerable to Tat, while others 
were unaffected (Fitting et al, 2013; Marks et al, 2016). Many of the interneurons 
affected by Tat are known to be part of a microcircuit within CA1 that is involved in 
feedback regulation and input gating of pyramidal cells (Buhl et al, 1994; Sik et al, 1997; 
Klausberger et al, 2004; Leão et al, 2012; Muller & Remy, 2014; Tyan et al, 2014; Marks 
et al, 2016), making it likely that Tat will cause notable effects on the physiological 
activity of these targets as a consequence of disruptions in the supporting microcircuitry, 
even beyond any direct Tat effects on pyramidal cells themselves. Morphine generally 
decreases neuronal excitability (Liao et al, 2005; McQuiston, 2008; Xu et al, 2013; 
Fitting et al, 2015a; Fitting et al, 2016). However, because morphine disinhibits 
GABAergic interneuron inputs onto pyramidal cells, this may exacerbate Tat-induced 
excitotoxicity in pyramidal cells. This is all dependent on neuron type and opiate 
receptor distribution (Drake & Milner, 2002; Liao et al, 2005; McQuiston, 2007; 
McQuiston, 2008; Xu et al, 2013). Interestingly, Tat and morphine can exert effects in 
pathways which have converging processes (Sanchez-Blazquez et al, 2010; Garzon et 
al, 2011). Tat can also cause morphine to have differential effects on sodium channel 
activity in cultured neurons. Depending on morphine concentration, combined Tat and 
morphine can profoundly disrupt physiologic processes (Fitting et al, 2015a). 
With observed deficits in the GABAergic network of the hippocampus, 
accompanied by only slight morphological disturbances in the pyramidal cells, we 
hypothesized that the functional output of CA1 might be disrupted by HIV-1 Tat. We 
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also set out to examine whether the observation of reduced synaptotagmin 2 in SR 
results in loss of synaptic contacts on pyramidal cells. Additionally, the evidence that 
morphine exacerbates HIV effects in human patients as well as our Tat transgenic 
mouse model led us to hypothesize that the deleterious effects of Tat would be 
exacerbated by the presence of morphine, especially in the morphologic domain, 
considering the very modest effects previously observed.  To test these hypotheses, we 
used whole cell patch clamp to examine the firing frequency and other 
electrophysiological properties of CA1 pyramidal cells, as they represent the focal point 
of inhibitory and excitatory processed in the region before projecting out toward the 
entorhinal cortex, and perform morphological analyses on the cells recorded from 
afterward. Additionally, we sought to identify behavioral deficits in spatial memory 
formation, closely associated with the hippocampus associated with the combined 
effects of HIV-1 Tat and morphine exposure. 
Materials and Methods 
The use of mice in these studies was pre-approved by the Institutional Animal 
Care and Use Committee at Virginia Commonwealth University and the experiments 
were conducted in accordance with ethical guidelines defined by the National Institutes 
of Health (NIH Publication No. 85-23). 
Subjects and housing 
 Male mice between 8 and 12 weeks of age with or without the presence the HIV-
1 tat transgene (HIV-1 T Tat1-86) under the control of a doxycycline activated Tet-on 
expression system driven by glial fibrillary acidic protein (GFAP) were used in these 
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studies (Bruce-Keller et al, 2008). Doxycycline (Dox) was administered in a specially 
formulated diet (Dox Diet #2018, 6 g/kg, Harlan Laboratories, Madison, WI) to the mice 
for 10-11 days. On the last day, animals were sacrificed for electrophysiological 
experiments or tissue harvesting. All mice were housed 4-5/cage and maintained in a 
temperature- and humidity-controlled room on a 12:12 h light/dark cycle (lights off at 
18:00 h) with food and water available ad-libitum. On day 5 following Dox 
administration, animals had a morphine pellet (25 mg morphine sulfate, NIH) or placebo 
pellet implanted in beneath the skin in the subscapular region.   
Tissue preparation for electrophysiological experiments 
Following 10-11 days of Dox exposure, adult male mice were transcardially perfused 
with sucrose cutting media (in mM; 3 KCl, 4.12 MgSO4, 1.2 NaH2PO4, 206 sucrose, 25 
NaHCO3, 25 glucose) chilled to around 1-3°C and bubbled with a 5% CO2 balanced 
oxygen mix. Brains were extracted and halved along the sagittal sulcus, then cut 
horizontally in 350 µm sections from the ventral surface using a Leica VT1200 S 
vibratome (Leica Biosystems, Buffalo Grove, IL). Slices were cut in oxygenated sucrose 
cutting media held at 1-3°C by an external cooling apparatus (Huber, Offenburg, 
Germany). Following the cutting procedure, slices were transferred onto a nylon mesh 
submerged in oxygenated extracellular recording solution (in mM; 3 KCl, 1.2 CaCl2, 1.2 
MgSO4, 1.2 NaH2PO4, 125 NaCl, 25 NaHCO3, 25 glucose) maintained at 36.5°C for 30 
minutes. The beaker was then returned to room temperature and the slices allowed to 
rest for 30 minutes prior to recording. In some cases, both the cutting solution and 
extracellular solution were supplemented with 500nM morphine sulfate. 
Electrophysiological recording 
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Slices were continuously perfused with extracellular recording solution warmed to 
30-34°C with an external heating apparatus (Warner instruments, TC-344B, Hamden, 
CT). The CA1 subfield of the hippocampus was visualized using a 4x magnification 
objective on a Zeiss Axio Examiner A1 microscope (Zeiss, Oberkochen, Germany). 
Magnification was switched to a 63x fluid-immersion objective to identify putative 
pyramidal neurons in the CA1 pyramidal layer. Pipettes for whole cell patch clamp were 
pulled (Narishige PC-10 pipette puller; Narishige, Tokyo, Japan) from borosilicate glass 
pipettes (WPI #1B1505-4) to a resistance of 2-6 MΩ.  Pipettes were filled with an 
intracellular solution containing (in mM) 135 KMeSO4, 10 HEPES, 2 MgATP, 0.1 
MgGTP, 8 NaCl, 0.1 BAPTAK4, Biocytin 0.2% (pH 7.25). Membrane potentials were 
recorded using a MultiClamp 700B amplifier (Molecular Devices, Sunnyvale, CA), 
processed using a Digidata 1550A digitizer, and analyzed using Clampex 10.4 software 
(Molecular Devices, Sunnyvale, CA) a Windows-based computer. Membrane potentials 
were observed in response to step-wise, 25 pA current increases from −100 pA to 400 
pA. 
Histology: Upon termination of whole cell patch clamp configuration, slices containing 
biocytin-filled cells were moved into a 24-well plate and fixed with 4% paraformaldehyde 
in 1x phosphate buffered saline (PBS) for 4-7 days at 4°C. Following fixation, slices 
were rinsed in PBS 6 times for 10 min each on a rocking platform at 4°C. Slices were 
permeabilized for 30 min in a solution of 50% ethanol in 1x PBS, containing 0.02% 
Triton X100, then transferred into a similar solution containing 70% ethanol for 30 min, 
and returned to 50% ethanol for 30 min. Slices were rinsed as described earlier, and 
then blocked in PBS containing 2% chicken serum, 0.02% bovine serum albumin, and 
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0.02% Triton X100 for 30 min. Primary antibodies against gephyrin (goat polyclonal, 
1:1000, Santa Cruz, Sc-6411), and synaptotagmin 2 (Syt2; Rabbit polyclonal, 1:1000, 
Synaptic Systems, Goettingen, Germany; Cat. No. 105 123) were applied, and slices 
were incubated for 48 h on a rocking platform at 4°C. The slices were rinsed as before, 
and incubated in secondary antibodies (donkey anti-goat IgG-Alexa Fluor® 488 1:500, 
Invitrogen A-1055; goat anti-rabbit IgG-Alexa Fluor® 647 1:500, Invitrogen A-21244), as 
well as an Alexa Fluor® 594 Conjugated streptavidin probe (1:100, Invitrogen, S-32356) 
for 48 h, and then rinsed in PBS. Slices were incubated in Hoechst (0.5 μg/ml in PBS, 
Invitrogen, H3570) for 10 min, rinsed in PBS, and mounted on slides using ProLong 
Gold Antifade reagent (Invitrogen, P36930). 
Imaging and morphological analysis: 
Z-stack imaging of neurons was performed using a Zeiss LSM 700 (0.55 NA) at 20x 
(Plan-Apochromat 20x/0.8 NA, M27) and 63x (Plan-Apochromat 63x/1.40 NA Oil 
immersion DIC, M27) magnification (Zeiss, Oberkochen, Germany). Hoechst was 
visualized using a 405 nm laser with an SP 490 nm Filter, Alexa 488 using a 488 nm 
laser and a BP 490-555nm filter, and Alexa 594 using a 555nm laser with a BP 505-600 
nm filter. Z-Stack data was reconstructed into a 3-D image using Imaris Bitplane 7.6.4 
(Zurich, Switzerland). Primary dendrites were determined as dendrites that protrude 
from the cell body and dendritic order increased with every branching point. Dendritic 
spine analysis was performed with Imaris Bitplane 7.6.4 and regions selected for 
analysis were 20-30 µm in length and were selected at a 5-10 µm distance from the 
previous branch point and at least 5 µm from the next branch point. Dendritic spine 
densities are reported as the average number of spines per 10 µm length of dendrite. 
 
 
79 
 
Spine morphology was analyzed using uncompressed Z-stacks. Spines were counted 
along 20-30 µm long dendrite segments laying parallel to the plane of view. Three 
categories of spine morphology were quantified: thin, stubby, and mushroom (Harris et 
al, 1992; Ochs et al, 2015). Each spine type was counted and expressed as a 
percentage of total spines. Analysis of the co-localization of inhibitory puncta within 
neurite segments was performed using the co-localization module of Imaris Bitplane 
[version 9.0].  Briefly, background signal was filtered out of from the 488 channel 
(gephyrin), and the signal from the 594 channel (streptavidin tagged pyramidal cells) 
was used as a mask to create a co-localization channel for gephyrin puncta occurring 
within spaces occupied by filled pyramidal cells. The number of puncta within a 
measured length of approximately 10 µm along the identified neurite segment was then 
counted. Data is expressed as number of gephyrin puncta per micrometer.  Analysis of 
inhibitory contacts took place on the aspinous portions of the apical and basilar 
dendrites immediately adjacent to the cell body, as well as the spiny portions at the 
distal ends of dendrites terminating in SL-M, as these dendritic compartments are have 
the highest percentage of inhibitory contacts in the average CA1 pyramidal cell (Megıás 
et al, 2001). 
Barnes maze 
Tat− and Tat+ mice were implanted with either morphine (n = 15 Tat−, 15 Tat+) 
or placebo pellets (n = 17 Tat−, 18 Tat+) and assessed for spatial learning and motor 
function using a Barnes maze test (Barnes, 1979). Mice consumed DOX chow for 6 
days prior to 1 day of prehabituation (1 day following subscapular pellet implantation), 
followed by 4 days of testing. In the prehabituation phase, mice were placed in a 
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randomly positioned escape hole for 2 min, then were placed in the brightly lit center of 
the Barnes maze (91 cm diameter, 90 cm height, with 20 holes each 5 cm diameter; 
Stoelting Co., Wood Dale, IL). Mice were the guided to the same assigned escape hole 
where they remained for 2 min. Finally, the mice then were placed under a glass 
cylinder next to the escape hole, and allowed up to 3 min to volitionally enter (mice that 
did not enter the hole were guided in and remained for 2 min). On testing days (two 
trials per day over 4 days), mice were placed in the brightly lit center of the Barnes 
maze and were allowed up to 3 min to enter the escape hole. Mice that did not enter the 
hole were gently guided to the hole and allowed to remain for 2 min. Shorter latencies to 
find the escape hole, a greater proportion of time spent in the correct quadrant of the 
maze, and fewer errors were considered indices of greater learning (Camara et al, 
2013). On the final day, following the completion of training trials, a reversal probe trial 
was conducted in which the maze was rotated 180° from its original position such that 
the correct goal box was on the opposite end of the Barnes maze table. The proportion 
of time spent in the new target quadrant, latency to find the new escape hole, and 
number of errors made were assessed. Distances and velocities traveled were used as 
an index of motor behavior. Behavioral data were recorded and digitally encoded using 
the ANY-maze animal tracking system (Stoelting Co., Wood Dale, IL). 
Vision testing 
All mice were tested for visual function following conclusion of the Barnes maze 
test (Wersinger et al, 2002; Marks et al, 2016). Briefly, mice were suspended 
approximately 12 in. above a vertical ring-stand and were lowered with the ring-stand 
approximately 2 in. from the left or right visual field (close enough to allow visual, but not 
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whisker, contact with the ring-stand). The left and right visual fields were assessed for 
each mouse, with the starting side selected randomly. Visual responding was 
considered positive when mice reached with the forepaws for the rod when presented to 
both the left and right side. A response to only one visual field is considered a negative 
response. One male animal (Tat+/morphine) failed vision testing and was excluded from 
analysis. 
Statistical analysis 
 Behavioral data were assessed via repeated-measures analyses of 
variance (ANOVA) with Barnes maze testing trial (days 1–4 and reversal probe) as the 
within subjects factor, and both mouse genotype (Tat− or Tat+) and drug treatment 
(morphine or placebo) as the between subjects factors. Fishers PLSD post hoc tests 
were used to assess group differences following main effects. Interactions were 
delineated via simple main effects and main effect contrasts with alpha corrected for 
multiple comparisons. All electrophysiological data was collected and analyzed using a 
planned comparisons paradigm. Tat− and Tat+ animals treated with placebo pellets 
were compared against Tat− and Tat+ animals treated with morphine pellets and 
maintained in morphine containing solutions. As a separate comparison, Tat− and Tat+ 
animals treated with morphine pellets and maintained in morphine-containing solutions 
were compared against Tat− and Tat+ animals treated with morphine pellets and 
maintained in morphine-free solutions. Firing frequency was analyzed using a repeated 
measures ANOVA with current step as the within-subjects factor, and Tat genotype and 
drug treatment combination as the between-subjects factors. Intrinsic firing properties 
were performed with a standard two-way ANOVA.  In all cases, the threshold for 
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significance was considered p < 0.05, and post-Hoc testing was performed using 
Fisher’s PLSD except where the requirements of planned comparisons testing 
necessitated more stringent application of Bonferroni corrections for multiple 
comparisons. 
Results 
Barnes maze 
 A main drug effect was noted in latency to escape [F (1,61) = 15.708, p < 0.05], 
with morphine treated animals taking longer to escape in all trials than placebo treated 
animals, regardless of genotype [p = 0.0002] (Fig. 3.1A). A significant interaction was 
observed for the factors of time, genotype, and drug in a repeated measures ANOVA [F 
(1,61) = 2.704, p < 0.05] for the percentage of time animals spent in the correct 
quadrant. Tat−, placebo-treated animals outperformed Tat+, placebo-treated animals 
after four days of training trials. Morphine-treated animals were unaffected by genotype 
status (p = 0.0402), obviating the Tat effect (Fig 3.1B, 3.2) While no significant effects 
were noted in the number of errors made between groups, an overall effect of time was 
observed, in which all groups made fewer errors as testing progressed [F (1,59) = 
20.749, p < 0.05] from day 1 to day 4, and increased with the reversal trial [p = 0.0001 – 
0.0034] (Fig 3.1C). Similarly, the distance traveled (Fig 3.1D) was not significantly 
different between groups, but changed across all groups over time [F (1,61) = 22.036, p 
< 0.05], with decreasing distance from days 1 to four, and an increase in the reversal 
trial [p = 0.0001 – 0.0296]. While no significant interactions were noted in the average 
velocity of the animals, independent main effects of drug [F(1,61) = 5.366, p < 0.05] and 
time [F(1,61) = 4.116, p < 0.05] are present (Fig 3.1E). Placebo treated animals move at 
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higher velocity across all trials [p = 0.0239], and all groups move at a lower velocity on 
Day 4 compared to day 1, with a return to baseline velocity in the reversal trial [p = 
0.0142 – 0.002]. 
Electrophysiological analysis of Tat and drug effects on CA1 pyramidal cells 
  In order to assess the effects of Tat and morphine on physiological function of 
CA1 pyramidal cells as the functional output of CA1, a planned comparisons testing 
paradigm was designed to test the differences between six sets of conditions:  Groups 
A and B consisted of Tat− and Tat+ placebo-treated animals (n = 13 cells from 3 
animals, and 11-12 cells from 3 animals respectively).  Groups C and B consisted of 
Tat− and Tat+ morphine-treated mice in which the ex vivo slices were maintained in 500 
nM morphine-containing physiological solutions during recordings and referred to as 
‘morphine maintained’ (n = 19 cells from 4 animals, and 13 cells from 4 animals, 
respectively) and were compared to groups A and B.  Groups E and F consisted of Tat− 
and Tat+ morphine-treated mice in which morphine was withheld from the ex vivo slices 
that were maintained in physiological solutions lacking morphine during recordings and 
referred to as ‘morphine withheld’ (n = 29 cells from 8 animals, and 22 cells from 7 
animals).  Groups A and B were independently compared to groups C and D (‘morphine 
maintained’) or to groups E and F (‘morphine withheld’; Fig 3.3), but C and D and E and 
F were not directly compared to one another. 
In the comparison between Tat− and Tat+ placebo-treated animals vs. Tat− and 
Tat+ morphine maintained animals, several effects were observed. Assessments of 
firing frequency showed a significant interaction between current step and Tat genotype 
[F(1,52) = 3.037, p < 0.05]; however, no other interactions occurred (Fig 3.4A-D). One-
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way ANOVA revealed that between the 50 pA and 150 pA current steps, pyramidal cells 
from Tat+ mice fired at a lower frequency than those from Tat− mice [p = 0.0024 - 
0.0461] (Fig. 3.4C).  Intrinsic membrane properties were assessed by two-way ANOVA. 
An interaction between Tat and morphine exposure was observed in the resting 
membrane potential of the CA1 pyramidal cells [F(1,53) = 7.341, p < 0.05].  Pairwise 
comparisons using the Bonferroni correction for multiple comparisons (significance 
threshold set at p < 0.0083) revealed that only placebo-treated Tat− and Tat+ mice 
differed (Fig. 3.5A), with Tat+ placebo-treated animals having significantly more 
depolarized resting membrane potentials [p = 0.0057]. In addition, a main effect of 
morphine was observed on the firing threshold of CA1 pyramidal cells [F(1,53) = 15.812, 
p < 0.05], with morphine-treated cells firing at a more hyperpolarized potential than 
placebo-treated mice [p = 0.0001] (Fig 3.5C).  No significant effects were noted for 
rheobase, however, Tat treatment caused a trend toward increased rheobase compared 
to controls [F(1,53) = 3.367, p = 0.0622] (fig 3.5B).  Notably, no significant differences 
were seen between any groups in the values of input resistance or capacitance (Table 
3.3). 
To assess the effects of withholding morphine in our model, we compared the 
physiological response of CA1 pyramidal cells in Tat− and Tat+ placebo treated animals 
with those of Tat− and Tat+ morphine treated animals, in which physiological recordings 
took place in solutions lacking morphine, so as to induce a withdrawal-like state in the 
tissue slices. Assessment of firing frequency revealed two interactions, one between Tat 
and current step [F(1,71) = 3.465, p < 0.05], and another between drug treatment and 
current step [F(1,71) = 6.425, p < 0.05]. Tat and morphine treatment did not show any 
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interactions (Fig 3.6A-D). To independently test the effects the Tat induction and 
morphine on the firing rates pyramidal cells exposed to increasing amounts of current, 
the Bonferroni corrected significance threshold was set at p < 0.025. Collapsing across 
genotype and ignoring the effects of morphine, Tat exposure altered the firing rate of 
pyramidal cells depending on the amount of the stimulating current.  Tat+ pyramidal 
cells fired at a lower frequency than Tat− neurons [p = 0.0013 – 0.0208] (Fig 3.6C) at 25 
pA to 200 pA, but firing rates did not differ at other current levels. Collapsing across 
drug treatment, without considering the effects of genotype, showed that when 
morphine was withheld from slices from morphine-treated mice, pyramidal cells fired at 
a significantly lower frequency than those in placebo-treated mice when stimulated with 
275 pA to 375 pA [p = 0.0069 – 0.0204] (Fig 3.6D). Intrinsic membrane properties were 
again compared by using two-way ANOVA. An interaction between Tat and drug 
treatment was observed in the resting membrane potential [F(1,72) = 37.989, p < 0.05]. 
Pairwise comparisons using the Bonferroni correction for multiple comparisons 
(significance at p < 0.0083) revealed that only the resting membrane potential of Tat− 
and placebo-and Tat+ and placebo-treated mice differed (Fig 3.7A), with Tat+ placebo-
treated animals having significantly more depolarized resting membrane potentials [p = 
0.0031]. Additionally, a Tat effect was noted in the observed rheobase [F(1,72) = 7.704, 
p < 0.05], where Tat positive cells required more current to reach threshold [p = 0.0039] 
(Fig 3.7B). No significant effects were observed on the firing threshold CA1 pyramidal 
cells (Fig 3.7D). As in the previous comparison, neither the resistance nor capacitance 
was affected by Tat and/or morphine, suggesting that the effects of Tat and morphine 
on CA1 pyramidal cells are indirect (e.g., through alterations in presynaptic inputs 
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originating from interneurons, circuits outside CA1, and/or glial activity), rather than 
direct/intrinsic effects of Tat and/or morphine on the pyramidal cells themselves (Table 
3.4).  
Morphological analyses 
 The morphological effects of Tat on CA1 pyramidal cells have previously been 
analyzed as whole cells or larger segments without consideration to the sublaminar 
divisions within CA1 (Fitting et al, 2013), which may result in subtler effects of Tat being 
missed, as distinct structural and functional differences exist between, and within, the 
dendritic compartments occupying different CA1 sublamina (Megıás et al, 2001).  To 
better assess the regional variations within CA1 dendritic structure, analyses of 
morphology were broken down by sublamina (Figs 3.8, 3.9A, 3.10A, 3.11A). The cells 
and dendrite segments used for morphological analysis were all used in the 
electrophysiological analysis of Tat and morphine (n for all groups = 10-12; figs 3.8, 
3.9B, 3.10B, 3.11B). 
 The effects of Tat and morphine on the density of dendritic spines differed in 
each layer of hippocampal area CA1. In the SO, there was a main effect of morphine on 
spine density [F(1,41) = 8.402, p < 0.05], where cells from morphine treated animals 
had fewer spines per 10 µM segment [p = 0.0069] (Fig 3.9C). No effects on spine 
density were observed in SR (Fig 3.10C); however, a significant effect of Tat was 
observed in SL-M [F(1,38) = 5.015, p < 0.05], with Tat+ cells having a higher spine 
density than Tat- cells [p = 0.0252] (Fig 3.11C). A trend toward an interaction between 
Tat and morphine was also observed in SL-M [F(1,38) = 3.465, p = 0.0704]. With this in 
mind, the effects of morphine were examined further in pyramidal cells in Tat− and Tat+ 
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mice separately. Significant effects were observed in Tat- cells [F(1,20) = 7.075, p < 
0.05], but not Tat+ cells. Morphine-treated pyramidal cells in Tat− mice had fewer SL-M 
spines than in placebo-treated mice [p = 0.0150]. With the lack of change in pyramidal 
cells in the Tat+ mice by comparison considered with the trend toward interaction, it is 
likely that the main effect of Tat on SL-M spine density is actually driven by a reducing 
effect of morphine that is present only in Tat- cells.  
 As with regional spine density, the effects of Tat and morphine on the 
morphologic types of spines present on dendrites varied by sublamina. Significant 
interactions between Tat and morphine were observed in the SO (Fig 3.9D) for the 
percentage of mushroom spines [F(1,40) = 6.932, p < 0.05] and stubby spines [F(1,40) 
= 8.764, p < 0.05], and SL-M (Fig 3.11D) for the percent of mushroom spines [F(1,35) = 
6.140, p < 0.05]. SO mushroom spines were found to be reduced in Tat+ morphine-
treated animals compared to Tat− placebo-treated animals [p  = 0.0028], and Tat− 
morphine-treated animals [p < 0.0001]. Tat+ placebo-treated animals had more 
mushroom-type spines than Tat− morphine-treated animals [p = 0.0034], but only 
showed a trend toward increase from Tat− placebo-treated animals [p = 0.0865]. 
Additionally, Tat+ morphine-treated animals trended toward decreased mushroom 
spines in comparison to Tat− morphine-treated animals [p = 0.0563]. Stubby spines in 
the SO were reduced in Tat+ placebo-treated mice [p = 0.0115], as well as both Tat− 
and Tat+ morphine-treated mice [p = 0.0001 – 0.0062]. SL-M mushroom spines were 
reduced in Tat+ morphine-treated animals compared to all other groups [p = 0.0005 – 
0.0112]. In addition to interactive effects, main effects of morphine were observed on 
the mushroom-type spines of SR (Fig 3.10D) [F(1,43) = 7.027, p < 0.05], with morphine-
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treated animals having fewer mushroom-type spines than placebo-treated animals [p = 
0.0107], and on the stubby-type spines of SLM [F(1,35) = 5.867, p < 0.05], with 
morphine-treated animals having more stubby-type spines than placebo-treated animals 
[p = 0.0129]. Finally, a main of Tat was seen on the percentage of thin/filopodial type 
spines in SR  [F(1,43) = 5.043, p < 0.05], with an increase seen in Tat+ animals 
compared to Tat− animals [p = 0.0274]  
 Differing levels of dendritic damage were observed in SO, SR, and SL-M. Tat 
and morphine had an interactive effect on the percent of SO dendrites with varicosities 
[F(1,43) = 5.125, p < 0.05] (Fig 3.9E). This interaction was driven by all Tat+ groups and 
morphine-treated groups being higher than the Tat− and placebo-treated controls [p = 
<0.0001-0.0004]. In the SR, there were independent Tat [F(1,43) = 13.571, p < 0.05] 
and morphine effects [F(1,43) = 13.100, p < 0.05] on the percentage of dendrites 
exhibiting varicosities (Fig 3.10E), and a trend toward an interaction between them 
[F(1,43) = 3.093, p = 0.0857]. Pyramidal cells in Tat+ mice had more dendrites with 
varicosities than those in Tat− mice [p = 0.0006], and morphine-exposed pyramidal cells 
had more dendrites with varicosities than those in placebo-treated mice [p = 0.0005].  In 
addition to damage in the terminal dendrites, some degenerative effects were evident 
on the main axis dendritic shaft (Fig 3.10F). The nonparametric Kruskal-Wallis test was 
used because, unlike pyramidal cells in Tat+ mice, Tat− placebo-treated animals 
displayed no varicosities along the main axis of their dendrites.  Because of the lack of 
variance in the Tat− placebo-treated animals compared to other groups, the ANOVA is 
an improper test. A significant effect was observed between the four group medians (H’ 
= 16.993, p < 0.05]. Mann-Whitney testing (with significance threshold set at p < 0.0083) 
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revealed that Tat+ and placebo-treated animals and Tat+ or Tat– mice receiving 
morphine had more dendritic varicosities than control neurons [p < 0.0001-0.0025]. 
Additionally in SL-M, a significant effect of morphine was observed in the percentage of 
terminal dendrites with varicosities [F(1,38) = 11.142, p < 0.05], with morphine-exposed 
cells having more dendrites with varicosities than in placebo-treated mice [p = 0.0019] 
(Fig 3.11E). 
 Assessment of the number of inhibitory postsynaptic puncta within pyramidal 
cells was performed to further explore the loss of Syt2 expression and increase of 
gephyrin previously observed in the hippocampus (Fitting et al, 2013). The number of 
puncta was quantified along the aspinous portions of the basilar and apical dendrites as 
they emerged from the soma, as this is the region known to have the highest 
percentage of inhibitory contacts onto pyramidal cells (Megıás et al, 2001). The results 
show no significant interactions between or main effects of either Tat or morphine on 
the number of inhibitory puncta within the basilar [p = 0.3145-0.7208] or apical [p = 
0.1287-0.5430] dendritic shafts in the perisomatic region (Fig 3.12).  
Correlational analysis 
 A number of correlations were observed between morphological outcomes, and 
electrophysiological outcomes. Several noteworthy correlations between the 
morphological features in discrete dendritic compartments and electrophysiological 
function were observed, and are presented with statistical results in Table 3.3. Negative 
correlations between the density of spines in SR and the firing frequency of pyramidal 
cells between 50 and 300 pA were observed. SR spine density also positively correlated 
with rheobase. The percentage of mushroom spines in SO was seen to positively 
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correlate with firing threshold, and negatively with firing frequency at the 100, 125, and 
150 pA current steps. The percentage of mushroom spines in SL-M positively correlated 
with resting membrane potential, and the percentage of thin spines in SL-M positively 
correlated with firing frequency between the 275-300 pA and 350-400 pA current steps. 
Measures of dendritic damage did not correlate with electrophysiological function.  
Discussion 
In a variety of cell types, Tat is known to cause neuronal excitotoxicity (Yu et al, 1997; 
Mattson et al, 2005; Eugenin et al, 2007; Soulas et al, 2009; King et al, 2010). While 
Hippocampal pyramidal cells have been shown to be vulnerable to excitotoxic injury 
induced by excessive NMDA agonism (Avignone et al, 2005), the present study, and 
previous studies of CA1 pyramidal cell function and morphology, suggest that direct 
effects on CA1 pyramidal cells by Tat are minimal (Fitting et al, 2013) and that there is 
an effect on local circuitry that impinges on CA1 pyramidal cells (Marks et al, 2016). 
Indeed, there are more routes to excitotoxic injury than simple excess activation of 
NMDA receptors (Bouilleret et al, 2000; Avignone et al, 2005). The excitotoxic effects of 
Tat seem to mimic the syndrome caused in the kainite-induced injury model used to 
examine temporal lobe epilepsy rather than exposure to NMDA, as the effects appear to 
be more pronounced in subsets of CA1 interneurons rather than in CA1 pyramidal cells 
(Bouilleret et al, 2000; Avignone et al, 2005; Marks et al, 2016). This variation in 
excitotoxic disease could be due to interactions with multiple signaling pathways beyond 
NMDA receptor activation (Cossart et al, 2001; Oliva et al, 2002; Avignone et al, 2005), 
which is not surprising in the case of Tat considering how many interactions it can have 
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with intra- and extracellular targets (Eugenin et al, 2007; King et al, 2010; Debaisieux et 
al, 2012). 
 Physiologically, a Tat effect is seen in the analyses of Tat vs. morphine, and Tat 
vs. pyramidal cells in which morphine was withheld, in which firing frequency is 
significantly reduced al low current stimulation intensities. If direct excitotoxic activity of 
Tat on CA1 pyramidal cells was sufficiently great, or occurring in isolation, it could be 
expected that there would be an increase in their firing frequency, rather than a 
decrease, as has been shown in pyramidal cells isolated from upstream circuitry and 
exposed to excitotoxic insult (Avignone et al, 2005). Moreover, in the present study, the 
decrease in firing frequency was accompanied by an increase in the amount of current 
for pyramidal cells in Tat+ mice needed to reach their firing threshold. Although the firing 
frequency of pyramidal cells from Tat+ animals is decreased, the resting membrane 
potential of these cells is significantly elevated.  This finding suggests that while Tat-
exposed pyramidal cells may tend to be hyperexcitable, Tat may sufficiently 
overactivate the surrounding presynaptic inhibitory inputs to negate any intrinsic 
excitatory effects of Tat on the pyramidal cells themselves.  
 Disparate effects occurred when comparing the active presence of morphine 
against the effects of prolonged exposure followed by removal of morphine on CA1 
pyramidal cells. Most interestingly, the only measure on which Tat and a morphine 
paradigm interacted was the resting membrane potential, and in each case, the 
difference is largely driven by the difference between the Tat− and Tat+ placebo-treated 
population, with morphine exposure appearing to obviate the effect, as we observe in 
both the Barnes maze results, and in the cytokine data. When morphine is present 
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during recordings of animals previously exposed to morphine, there is no observed 
morphine effect on firing, and it appears again that the presence of morphine obviates 
the Tat effect. There is, however, a reduction in the firing threshold of morphine-treated 
cells. By contrast, however, when tissues from morphine-treated animals are tested in 
solutions lacking morphine the firing frequency of withdrawn CA1 pyramidal cells is 
lower at high current stimulations (275-375 pA), but there is no effect of withholding 
morphine on the firing threshold.  
HIV-1 Tat has been shown to cause changes in dendritic spines throughout the brain, 
indicating aberrations in normal patterns of plasticity. Reductions of spine density have 
been observed in the cortex, striatum, and hippocampus (Fitting et al, 2013; Raybuck et 
al, 2017; Schier et al, 2017), and alterations in the type of dendritic spines present on 
dendrites in the striatum have been observed (Schier et al, 2017). Decreased long term 
potentiation has also been seen in the hippocampus independently with Tat and 
morphine exposure (Bao et al, 2007; Fitting et al, 2013).  Additionally, HIV-1 Tat and 
morphine exposure have an interactive negative effect on spine density in the striatum 
(Fitting et al, 2010a). The present study shows morphine-driven reductions in the spine 
density of dendrites in SO that do not interact with Tat, and differential morphine effects 
in the SL-M on Tat− and Tat+ pyramidal cells, with no change in the SR. In comparison, 
an eleven percent reduction in CA1 pyramidal cell spines was described by Fitting et al 
(2013) and attributed to Tat alone, differences in the methodology and quantification are 
present in this study which may give a more nuanced view by looking at discrete 
dendritic compartments rather than the cell as a whole. The analysis of dendritic spine 
loss is complemented by observations of regional shifts in spine types, which reflect 
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region specific shifts in plasticity. The excitatory systems, however, do not act alone. 
Our data show no differences in the amount of gephyrin puncta within dendrites near 
the soma (fig 3.12), which could suggest that the previously-found increase in gephyrin 
expression is related to inhibitory contacts onto other interneurons (Fitting et al, 2013; 
Marks et al, 2016). In any case, it is likely that in each of the CA1 lamina, a subtle 
balancing between excitatory and inhibitory processes is occurring independently of the 
other layers. The changes observed in spine number and morphology, as well as 
measures of dendritic damage were more pronounced in SO and SL-M, while SR 
remained comparatively stable, indicating systems interacting within SR may be more 
stable or better able to adapt. Dendritic damage observed in this study did not appear in 
previous work (Fitting et al, 2013), which may indicate that added insults, such as the 
manipulations under the hours-long sectioning, patching recording, and immersion 
fixation processes employed here might expose underlying pathology that is not readily 
visible given the relatively acute exposure to Tat in the prior experiments. 
Results from previous studies have shown that Tat attenuates spatial memory as 
assessed by the Barnes maze task. This includes an increased latency to escape, a 
decreased time in the correct quadrant, and altered search strategies, as well 
decreased performance in working memory and phase dependent alterations in reversal 
learning (Kesby et al, 2016; Marks et al, 2016). The attenuation of spatial memory by 
Tat is still evident, with Tat+ placebo-treated animals performing significantly worse than 
Tat- placebo-treated animals according to post-hoc testing. Morphine treatment 
appeared to obviate the negative effects of Tat, with morphine treated mice performing 
at levels between the Tat- and Tat+ placebo-treated animals, regardless of genotype. 
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Interestingly, there is only an observed effect of morphine on latency to escape, with 
morphine-treated animals taking longer to escape than placebo-treated counterparts 
regardless of genotype. While both Tat and morphine independently can impair spatial 
memory function (Zhu et al, 2011; Kitanaka et al, 2015 ; Kesby et al, 2016; Marks et al, 
2016), the present study shows no interaction between these factors, and even points 
toward a morphine-based attenuation of the deleterious effects of Tat. Morphine has 
been shown to have both stimulating and depressive effects on motor behavior 
depending on dose, with higher doses generating a biphasic response in which activity 
first decreases, then increases before returning to baseline. Tolerance to the depressive 
effects, however, develops more rapidly than the stimulant effects with chronic high 
dose administration. (Vasko & Domino, 1978; Ling et al, 1989; Le Marec et al, 2011) 
raising the possibility of motor confound in the present study. Other studies, however, 
have suggested that the effect of morphine on spatial memory is not attributable to 
locomotor effects (Kitanaka et al, 2015). This is likely considering that there is an 
observed effect of morphine on the overall velocity of travel (but not distance travelled), 
and could be a consequence of the drug delivery method used in the present studies. 
Additionally, it is possible that post-surgical inflammation, which can be expected from 
any surgical procedure, may affect behavioral function (Chen et al, 2008; Vizcaychipi et 
al, 2014). Also of note is that the testing protocol employed here used 2 fewer training 
trials than in Marks et al (2016) to eliminate the problem of overtraining the animals, as 
in the previous study we observed that after four days of training trials, a number of the 
animals became habituated to the aversive stimulus used to drive the task and stopped 
performing. It is possible that the risk of overtraining was outweighed by the 
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confounding effects of morphine, and that the present study would have benefited from 
more training trials. Further studies should be directed towards examining the 
behavioral outcomes of Tat and morphine interactions 
 The results of this study suggest that despite the general observation that 
morphine exposure exacerbates Tat toxicity in the brain (Hauser et al, 2012), the 
hippocampus as a discrete region may not be as susceptible to this phenomenon. This 
might be related to the Tat induced reduction of MOR expression, which could result in 
a subtle shift between the deleterious effects of chronic MOR activation, and the counter 
effects of DOR or KOR activation (Fitting et al, 2010a; Fitting et al, 2015b).  
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Figure 3. 1: Effects of Tat and morphine on Barnes maze performance in mice 
 
  Barnes maze performance of Tat+ animals compared to Tat− animals, 
with either placebo or morphine pellets implanted. (A) Animals given morphine took 
longer to escape than mice given placebo pellets, regardless of genotype (p = 0.00002). 
(B) A significant interaction was observed between Tat and morphine in the percent of 
 
 
97 
 
time spent in the correct quadrant (p < 0.05), with placebo-treated Tat− mice performing 
better than placebo-treated Tat+ animals (p = 0.0402). Mice treated with morphine 
performed at an intermediate level regardless of genotype. No significant differences in 
the number of errors made (C), or the distance traveled (D), were observed between 
groups; however, these measures decreased from Day 1 to day 4, returning to Day 1 
levels during the reversal probe (p = .00001-0.0209). The velocity differed across all 
days between mice given placebo pellets and morphine pellets (E), with morphine 
pellet-treated mice moving more slowly than placebo-treated animals (p = 0.0142-
0.002).   
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Figure 3. 2: Representative Barnes maze track traces 
 
Representative track plots of the movements of male mice taken during 3 min (180 Sec) 
performance of the Barnes Maze spatial memory test. Track plots represented show the 
performance of Tat− and Tat+ mice, with either a morphine- or placebo-pellet implanted 
subcutaneously in the subscapular region.    
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Figure 3. 3: Visual representation of planned comparisons design for 
electrophysiological analysis 
 
  Visual representation of the planned comparisons design described in the 
methods section to assess the physiological activity of morphine naive Tat− and Tat+ 
CA1 pyramidal, and cells exposed to morphine in a morphine maintained state, and a 
morphine deprived state independently. Briefly, six separate groups of mice were 
generated contemporaneously for electrophysiological recordings. Intended 
comparisons were between pyramidal cells from Tat− and Tat+ placebo treated mice, 
and recorded in unsupplemented physiological solutions (A, B) and Tat− and Tat+ mice 
treated with morphine, and recorded in physiological solutions supplemented with 
morphine (C, D). The second intended comparison was between groups A, and B as in 
the first comparison, and Groups E and F (Tat− and Tat+ mice treated with morphine, 
but recorded in unsupplemented physiological solutions). 
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Figure 3. 4: Firing frequency of CA1 pyramidal cells after exposure to Tat and/or 
morphine-treated mice (in vivo) in which morphine is present during 
electrophysiological recordings (ex vivo) 
 
Analysis of the firing frequency of CA1 pyramidal cells from Tat– or Tat+ mice 
treated with either a placebo or morphine. Slices from morphine-treated animals were 
recorded in artificial CSF containing 500 nM morphine to continue to expose the 
hippocampal slices to morphine ex vivo. Patched cells were stimulated with escalating 
current pulses 500 ms in duration starting at −100 pA and escalating to 400 pA in 25 pA 
steps. Representative traces (A) for each group are depicted at the 100 and 350 pA 
current steps. An interaction between Tat genotype and the amount of current applied 
was observed in the repeated measures ANOVA (p < 0.05) (B). CA1 pyramidal cells 
from Tat+ mice fired at a lower frequency than those of Tat− animals at between 50 and 
150 pA (p = 0.0024 - 0.0461; C), but were unaffected by the sustained exposure to 
morphine during recordings (D).   
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Figure 3. 5: Membrane properties of CA1 pyramidal cells in Tat and/or morphine-
treated mice (in vivo) in which morphine is present during electrophysiological 
recordings (ex vivo) 
 
 
 Further analysis of the excitability of CA1 pyramidal cells from Tat– or Tat+ mice 
treated with either a placebo- or morphine-pelleted implants for 5 days in vivo.  Slices 
derived from morphine-treated animals were isolated and recorded in physiological 
solutions containing 500 nM morphine to maintain receptor occupancy and morphine 
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effects on the tissue. A significant interaction between Tat and morphine was observed 
for the resting membrane potential (VR) of CA1 pyramidal cells (A). Post hoc analysis 
showed that the differences were driven by a significant increase in the resting 
membrane potential of pyramidal cells from Tat+ and placebo-treated mice relative to 
those from Tat− and placebo-treated mice (p = 0.0057). Morphine treatment appears to 
obviate the effects of Tat. While no significant effects were noted in the rheobase, there 
was a trend (p = 0.0619) for pyramidal cells from Tat+ animals to require a greater 
amount of current (pA) to reach threshold for firing compared to cells from Tat− mice 
(B). A main effect of drug observed on firing threshold. The threshold for firing (mV) is 
significantly reduced in cells from morphine-treated animals (p = 0.0622; C). 
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Figure 3. 6: Firing frequency of CA1 pyramidal cells from Tat and/or morphine-
treated mice (in vivo) in which morphine is withheld during electrophysiological 
recordings (ex vivo) 
 
Analysis of the firing frequency of CA1 pyramidal cells from Tat– or Tat+ mice 
treated with either a placebo or morphine. Slices from morphine-treated mice and 
morphine naïve mice were recorded in physiological solutions which did not contain 
morphine. Patched cells were stimulated with escalating current pulses 500 ms in 
duration starting at −100 pA and escalating to 400 pA in 25 pA steps. Representative 
traces (A) for each group are depicted at the 100 and 350 pA current steps. Interactions 
between Tat and current step, and morphine withdrawal and current step were 
observed in the repeated measures ANOVA (p < 0.05; B). Tat and morphine removal 
did not interact at any level of the analysis. At stimulating currents between 25 and 
2,000 pA, CA1 pyramidal cells in slices from Tat+ mice fired at a lower frequency than 
those from Tat− mice (p = 0.0013-0.0208; C). Withholding morphine from pyramidal 
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cells slices isolated from morphine-exposed mice resulted in significantly lower firing 
rates at stimulating currents from 275 pA to 375 pA compared to morphine-naïve 
pyramidal cells (p = 0.0069-0204; D).  
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Figure 3. 7: Membrane properties of CA1 pyramidal cells from Tat and/or 
morphine-treated mice (in vivo) in which morphine is withheld during 
electrophysiological recordings (ex vivo) 
  
Analysis of the firing frequency of CA1 pyramidal cells from Tat– or Tat+ mice treated 
with either a placebo or morphine. Morphine-treated and morphine-naive mice in this 
analysis were recorded in physiological solutions that did not contain morphine. A 
significant interaction between Tat and morphine was again observed for the resting 
membrane potential (VR) of CA1 pyramidal cells (A). Post hoc analysis showed that the 
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differences resulted from a significant increase in the resting membrane potential in 
pyramidal cells from Tat+ than Tat− mice treated with placebo pellets (p = 0.0031).  
There was a significant effect of Tat on rheobase. Independent of morphine presence or 
withholding, pyramidal cells in Tat+ mice required a greater amount of current (pA) to 
reach the threshold potential for firing compared to Tat− mice (p = 0.0039; B), despite 
the fact that the firing threshold (mV) of CA1 pyramidal cells was unaffected by Tat or 
morphine exposure (C). 
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Figure 3. 8: Examples of a 3D-reconstructed biocytin-filled CA1 pyramidal cells 
 
  
 Reconstructions of Z-stack images of biocytin-filled pyramidal cells within 
hippocampal area CA1. Z-stack images were used for analysis of morphological 
characteristics following exposure to Tat and morphine.  Scale bars = 50 µM.  
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Figure 3. 9: Effects of Tat and morphine on the morphology of the portion of the 
pyramidal cell dendrite within the stratum oriens (SO) 
 
 Morphological effects of Tat and morphine on the portion of the CA1 pyramidal 
cell dendrite within the stratum oriens (SO) (A). (B) Sample SO dendrites and 3D 
reconstructions from each of the four experimental groups (C) An overall reduction in 
spine density was attributed to the effects of morphine (p = 0.0069). (D) There were also 
significant shifts in the morphologic types of spines present on SO dendrites. The 
percentage of stubby spines was reduced in Tat+/placebo-treated animals when 
compared to all other groups (p= 0.0001-0.0115). The percentage of mushroom spines 
was reduced in Tat+/morphine-treated animals compared to both placebo-treated 
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groups (p = 0.0034), and was trending toward being significantly lower that 
Tat−/morphine-treated animals (p = 0.0563). There was evidence of an increase in 
dendrites with varicosities in all groups compared to control animals (p = 0.0001-0.004; 
E). Multiple symbols are used in this figure for a p < 0.05 due to the complexity of panel 
D; (*) denotes a main effect of Tat, (†) denotes a main effect of morphine, (**) denotes a 
difference between Tat−/placebo and Tat+/placebo, (***) represents a difference 
between Tat−/placebo and Tat−/morphine, (††) represents significance between 
Tat−/placebo and Tat+ morphine, the difference between Tat+/placebo and 
Tat−/morphine is shown by (‡), Significance between Tat+/placebo and Tat+/morphine 
is denoted with (§), and finally The differences between Tat−/morphine and 
Tat+/morphine are denoted as (§§). 
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Figure 3. 10: Effects of Tat and morphine on the morphology of the portion of the 
pyramidal cell dendrite within the stratum radiatum (SR) 
 
Morphological effects of Tat and morphine on the portion of the CA1 pyramidal 
cell dendrite within the stratum radiatum (SR) (A). (B) Sample SR dendrites from each 
of the four experimental groups. No differences were observed in spine density in SR 
dendrites (C). (D) Tat and morphine caused shifts in the spine morphology on SR 
dendrites. The percentage of thin type spines was increased by Tat (p = 0.0107), while 
the percentage of mushroom-type spines was decreased by morphine (p = 0.0274). 
There were non-interacting effects of Tat (p = 0.0006) and morphine (p = 0.0004) to 
increase the amount of varicosity formation along peripheral SR dendrites (E). 
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Additionally, significant increases in the number of varicosities along the main axis of 
pyramidal cells were observed in all groups compared to controls (p = 0.0001-0.0025; F) 
,. Parametric statistics were used except where noted in parenthesis.  Multiple symbols 
are used in this figure for to denote significance; (*) denotes a main effect of Tat, (†) 
denotes a main effect of morphine, (**) denotes a difference between Tat−/placebo and 
Tat+/placebo (Mann-Whitney U test), (***) represents a difference between 
Tat−/placebo and Tat−/morphine (Mann-Whitney U test), (††) represents significance 
between Tat−/placebo and Tat+/morphine (Mann-Whitney U test), the difference 
between Tat+/placebo and Tat−/morphine is shown by (‡), Significance between 
Tat+/placebo and Tat+/morphine is denoted with (§), and finally The differences 
between Tat−/morphine and Tat+/morphine are denoted as (§§). 
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Figure 3. 11: Effects of Tat and morphine on the morphology of the portion of the 
pyramidal cell dendrite within the stratum lacunosum-moleculare (SL-M) 
 
Morphological effects of Tat and morphine on the portion of CA1 pyramidal cell 
dendrite within the stratum lacunosum-moleculare (SL-M) (A). (B) Sample SL-M 
dendrites from each of the four experimental groups. Morphine caused a reduction of 
dendritic spine density in pyramidal cells from Tat−, but not Tat+, mice.  In fact, there 
was a trend for Tat to reverse morphine-dependent reductions in dendritic spine density, 
albeit not significant (p = 0.07), suggesting that the Tat and morphine may uniquely 
interact to increase spine numbers on the SL-M (C). Spine morphology was observed to 
change with Tat and morphine exposure (D). Morphine caused an increase in the 
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percentage of stubby-type spines (p = 0.0129), and Tat+/morphine-treated animals had 
fewer mushroom-type spines than all other groups (p = 0.0005-0.0112). Increases in 
dendritic damage observed with the percentage of dendrites with varicosities increasing 
in morphine-treated animals (p = 0.0019; E). Multiple symbols are used in this figure for 
a p < 0.05; (*) denotes a main effect of Tat, (†) denotes a main effect of morphine, (**) 
denotes a difference between Tat−/placebo and Tat+/placebo, (***) represents a 
difference between Tat−/placebo and Tat−/morphine, (††) represents significance 
between Tat−/placebo and Tat+/morphine, the difference between Tat+/placebo and 
Tat−/morphine is shown by (‡), Significance between Tat+/placebo and Tat+/morphine 
is denoted with (§), and finally The differences between Tat−/morphine and 
Tat+/morphine are denoted as (§§). 
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Figure 3. 12: Assessment of gephyrin puncta within the aspinous portion of pyramidal cell basilar and 
apical dendrites 
 
 
 Assessment of gephyrin puncta within the perisomatic dendrites of CA1 
pyramidal cells. Biocytin filled pyramidal cells labeled with an Alexa 594-conjugated 
streptavidin probe (red) and gephyrin puncta (green) were analyzed in Imaris Bitplane 
9.0.0. (A, B, B’), and a third channel was created which contained only green voxels 
which overlapped in the space occupied by red voxels (A’, C, C’). The number of co-
localized puncta (B, C) was quantified in a region of interest of a defined length (B’, C’) 
to generate a value reflecting the number of co-localized puncta per 10µM. No changes 
in the number of gephyrin puncta were observed occurring on the aspinous portions of 
the basilar (D) or apical (E) dendrites in the perisomatic region following Tat expression 
or exposure to morphine.  
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 Tat- Placebo 
n = 13 
Tat+ Placebo 
n = 12 
Tat- Morphine 
n = 19 
Tat+ Morphine 
n = 13 
Capacitance 
(pF) 
29.42 ± 2.8 32.59 ± 3.65 30.77 ± 2.8 31.44 ± 2.72 
Resistance 
(MΩ) 
19.858 ± 2.2 22.86 ± 3.06 23.81 ± 1.96 21.98 ± 2.06 
 
Table 3. 1: Membrane properties of CA1 pyramidal cells after exposure to Tat and 
morphine 
 Table 3.1 lists the Capacitance and resistance values for the comparison of Tat− 
and Tat+ animals treated with placebo against those treated with morphine. No 
significant changes were observed. All values are shown as mean ± SEM. 
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 Tat- Placebo 
n = 13 
Tat+ Placebo 
n = 12 
Tat- 
Withdrawn 
n = 29 
Tat+ 
Withdrawn 
n = 22 
Capacitance 
(pF) 
29.42 ± 2.8 32.59 ± 3.65 43.13 ± 7.66 35.89 ± 3.5 
Resistance 
(MΩ) 
19.86 ± 2.2 22.86 ± 3.06 24.12 ± 1.54 22. ± 1.49 
 
Table 3. 2: Membrane properties of CA1 pyramidal cells from Tat- and Tat+ 
animals in a withdrawal like state 
Table 3.2 lists the Capacitance and resistance values for the comparison of Tat− 
and Tat+ animals treated with placebo against those treated with morphine and then 
forced into a withdrawal-like state. No significant changes were observed. All values are 
shown as mean ± SEM. 
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Morphological 
Data 
Physiological 
Data 
Correlation N Z p 
SO % Mushroom Threshold .348 43 2.298 0.0216 
 Frequency 100 pA -0.311 43 2.033 0.0421 
 Frequency 125 pA -0.313 43 2.045 0.0408 
 Frequency 150 pA -0.331 43 2.174 0.0297 
SR spine density Rheobase 0.422 45 2.918 0.0035 
 Frequency 50 pA -0.347 45 2.347 0.0189 
 Frequency 75 pA -0.433 45 3.001 0.0027 
 Frequency 100 pA -0.393 45 2.692 0.0071 
 Frequency 125 pA -0.403 45 2.771 0.0056 
 Frequency 150 pA -0.393 45 2.691 0.0071 
 Frequency 175 pA -0.407 45 2.803 0.0051 
 Frequency 200 pA  -0.382 45 2.611 0.0090 
 Frequency 225 pA -0.371 45 2.521 0.0117 
 Frequency 250 pA -0.351 45 2.376 0.0175 
 Frequency 275 pA -0.337 45 2.275 0.0229 
 Frequency 300 pA -0.319 45 2.142 0.0322 
SL-M % Mushroom VR .396 38 2.291 0.0219 
SL-M % Thin Frequency 275 pA .344 38 2.122 0.0339 
 Frequency 300 pA .326 38 2.004 0.0451 
 Frequency 350 pA .352 38 2.176 0.0295 
 Frequency 375 pA .375 38 2.330 0.0189 
 Frequency 400 pA .406 38 2.548 0.0108 
 
Table 3. 3 Correlations between morphological and electrophysiological findings 
Table 3.3 presents a selection of relevant correlations between morphological 
observations and electrophysiological data. The data presented here include samples 
from 4 groups: Tat− and Tat+ placebo-treated animals, and Tat− and Tat+ morphine-
treated animals that had been maintained in morphine containing physiological 
solutions. 
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Chapter 4: General Discussion and future directions 
Clarification of contributions: Dr. Virginia McLane performed the Bioplex assay. 
 
 
HIV infection and HIV-1 have been demonstrated as having profound effects on 
the hippocampus. There is also a preponderance of evidence that shows concurrent 
exposure to opiates exacerbates progression of HIV or HIV protein-related pathology 
immunologically and neurologically (Hriso et al, 1991; Anthony et al, 2005; Bruce-Keller 
et al, 2008; Fitting et al, 2010a; Byrd et al, 2011; Hauser et al, 2012; Xu & Fitting, 2016); 
however, few of these studies have been performed specifically in the hippocampus, 
and those that do tend to focus on biochemical or morphological effects rather than 
hippocampal function (Guo et al, 2012; Hauser et al, 2012; McLane et al, 2014). The 
collected aim of the studies discussed here is to determine the effects of HIV-1 Tat 
and/or morphine on the circuitry of the hippocampus morphologically, and to assess the 
disruptions to functional outputs of the hippocampus behaviorally and 
electrophysiologically in order to understand the etiology, and ultimately inform the 
development of treatment options, of the spatial memory deficits commonly seen in HIV 
patients suffering from HAND (Antinori et al, 2007; Stark, 2007; Byrd et al, 2011; 
Bilgrami & O'Keefe, 2014). 
While multiple inputs and outputs play a critical role in hippocampal function, the 
studies presented herein focus on the CA1 subfield as the final step in the hippocampal 
tripartite circuit before passing information to other brain regions (Ranson, 1932; Amaral 
& Lavenex, 2007; Stark, 2007). Particularly, the focus is on the CA1 pyramidal cells and 
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the circuitry affecting pyramidal cell function is important since this is a major excitatory 
output of the hippocampus. The pyramidal cells do not act alone, and are supported by 
a diverse array of network interactions (Acsady et al, 1996b; Ali et al, 1998; Klausberger 
et al, 2004; Klausberger & Somogyi, 2008; Kelley et al, 2009; Leão et al, 2012; Tyan et 
al, 2014; Pelkey et al, 2017). Both Tat and chronic morphine exposure impair spatial 
learning concomitantly where LTP is inhibited (McQuiston, 2008; Fitting et al, 2013; 
Zhou et al, 2015). Prolonged exposure to Tat and/or morphine have both been shown to 
impair LTP in CA1 with (Fitting et al, 2013; Heidari et al, 2013; Wen et al, 2014; Zhou et 
al, 2015) and the acquisition of spatial memory, which is closely associated with LTP 
(Carey et al, 2012; Kitanaka et al, 2015; Marks et al, 2016; Raybuck et al, 2017). The 
action of morphine within the CA1 system varies depending upon the context in which 
morphine is given, reflecting the adaptation of the hippocampus to chronic exposure to 
morphine (McQuiston & Saggau, 2003; Zhu et al, 2011; Fakira et al, 2014; Portugal et 
al, 2014; Kitanaka et al, 2015). Reductions in LTP caused by Tat and morphine 
independently (Fitting et al, 2013; Wen et al, 2014; Zhou et al, 2015) likely result from a 
shift in the functionality of the interneuron network and the disinhibition of discrete sets 
of interneurons (Pelkey et al, 2017). Over time, compensatory processes may occur as 
tolerance develops, or as Tat exposure continues, through alterations in the expression 
of ion channels, opioid and/or other receptor types, or other signaling events (Hall et al, 
1991; Fakira et al, 2014; Portugal et al, 2014; Sadegh & Fathollahi, 2014; Zhou et al, 
2015). GABAergic interneurons in the hippocampus are comparatively more susceptible 
to excitotoxic damage, one of the main hallmarks of HIV associated neurocognitive 
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damage, than pyramidal cells (Avignone et al, 2005; Chandra et al, 2005; Hoskison et 
al, 2007), and are often also a target for morphine (Drake & Milner, 2002). 
The net effect of morphine in CA1 is to decrease GABA release, resulting in 
increased pyramidal cell excitability under acute activation paradigms (McQuiston & 
Saggau, 2003), mediated through primarily GABAA receptors, but also through GABAB 
receptors (McQuiston & Saggau, 2003; McQuiston, 2007). It is important to note that the 
exposure paradigm can have a significant effect on the outcome of experiments, with 
acute, chronic, and withdrawal administration pattern effecting the results of 
experiments (McQuiston & Saggau, 2003). In our experiments, morphine administration 
via subscapular pellet implantation results in a continuous release of morphine over a 5-
day period, which is more than sufficient for development of tolerance in the 
hippocampus. In hippocampal slice physiology preparations, tolerance has been 
observed to develops within 2-6 hours of the initiation of morphine exposure (Lue et al, 
1999). Tolerance will develop to different aspects of morphine’s effects (e.g. analgesic 
first, locomotor second) at different rates (Vasko & Domino, 1978; Hall et al, 1991; 
Bodnar, 2012), and the development of tolerance has been shown to proceed at 
different rates for the different opioid receptors (Angelopoulos et al, 1995). The effects 
of tolerance in the present studies may be more pronounced, but harder to discern than 
in wild type mice; however, as Tat+ mice induced with doxycycline show increased 
tolerance to the analgesic and locomotor effects of morphine, while paradoxically 
exhibiting less pronounced withdrawal symptoms (Fitting et al, 2012; Fitting et al, 2016). 
This may be related to Tat-induced changes in the expression or activity of MOR and its 
cognate endogenous ligands (Fitting et al, 2010a; Hahn et al, 2016). The observations 
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of acute increases in excitability mediated both through loss of GABAergic inhibition and 
increase of extracellular glutamate levels (Wimpey et al, 1989; Farahmandfar et al, 
2011a; Farahmandfar et al, 2011b) give way to a re-established homeostasis In the 
pyramidal cells, as evidenced by the lack of difference between the firing rate of 
morphine-treated cells and placebo-treated cells shown in chapter 3. Subsequent 
removal of morphine likely releases the MOR expressing interneurons to re-inhibit the 
disinhibited pyramidal cells, which have become acclimated to a new homeostasis with 
lower inhibition. As a result, their excitability becomes reduced (Fig 3.3B). A similar 
effect has been observed in the reduction of LTP in animals following withdrawal of 
chronic morphine application during which tolerance is likely to have developed, which 
can be restored with reperfusion of the drug (Bao et al, 2007). 
The distribution of MOR expression in CA1 is mainly in the pyramidal layer. MOR 
expression is also observed on SO and SR, while the lowest levels are in the SL-M 
(Drake & Milner, 2002; McQuiston, 2008). MOR expression can be further localized to 
GABAergic interneurons (McQuiston, 2007), with differential expression and therefore 
morphine effects on different CA1 interneuron subsets. Morphine exposure increases 
excitatory post synaptic potentials (EPSPs) strongly in CA1 SO, SP, and SR; but weakly 
in SL-M, indicating the effects of MOR activation on local excitatory/inhibitory balance 
differs among hippocampal layers depending on differences in presynaptic inputs from 
MOR-expressing interneurons or from MOR-expressing afferents from other brain 
regions (McQuiston, 2008; Sadegh & Fathollahi, 2014). The laminar effects depend on 
the projections of varying interneuron subsets to other layers (McQuiston, 2007), where 
changes in GABA release act to increase excitation through diminished action at both 
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the GABAA and GABAB receptors (McQuiston & Saggau, 2003; McQuiston, 2007). A 
substantial portion of CA1 network interactions come from inhibitory interneurons, of 
which there is an ever-expanding classification of subtypes (Cenquizca & Swanson, 
2006; Klausberger & Somogyi, 2008; Wheeler et al, 2015; Hamilton et al, 2017b). I have 
found Tat exposure disrupts the hippocampal interneuron network which we believe is 
in part responsible for the behavioral and physiological deficits observed in our data and 
in previous publications (Fitting et al, 2013; Marks et al, 2016). Considering that 
morphine acts in part through the disinhibition of GABAergic inputs (Liao et al, 2005), 
and that Tat damages the interneuron network, it is reasonable to conclude that 
combining morphine with Tat will more strongly disrupt the normal functioning of the 
hippocampus, making the present findings more surprising. 
Of the 21+ types of interneurons found within the hippocampal area CA1 
(Cenquizca & Swanson, 2006; Klausberger & Somogyi, 2008; Wheeler et al, 2015), we 
have found selective vulnerability in two discrete subtypes and vulnerability within two 
other interneuron families that we have not yet fully defined. Induction of Tat expression 
in our mouse model resulted in losses of nNOS+/NPY− interneurons in the stratum 
pyramidale (IS3s) and in the SR (neurogliaform cells) (Acsady et al, 1996a; Acsady et 
al, 1996b; Chamberland et al, 2010; Tricoire et al, 2010; Armstrong et al, 2012; Tricoire 
& Vitalis, 2012; Tyan et al, 2014; Marks et al, 2016). We also observed reductions in the 
total population of PV+ interneurons within the pyramidal layer, and SST+ interneurons 
within the SO. While our data did not show conclusively which subsets are affected, 
they suggest that the major contributor to these losses are the bistratified cells and OL-
Ms, respectively (Buhl et al, 1996; Muller & Remy, 2014). The initial definition of Tat 
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effects in the hippocampus can now be used alongside what we know about the 
endogenous opioid system in the hippocampus to help inform our understanding of their 
potential interactions. MOR, DOR, and KOR are expressed with some, but not 
complete, overlap in subsets of GABAergic interneurons (Drake & Milner, 1999; Halasy 
et al, 2000; Pelkey et al, 2017), and are usually found presynaptically, with lower levels 
expressed postsynaptically on dendrites (Lambert et al, 1991; Drake & Milner, 1999; 
Pelkey et al, 2017). Pyramidal cells also express low levels of DOR (Stumm et al, 
2004).  While the hippocampus as a whole responds to morphine, there is differential 
sensitivity, with CA3 being more affected at low doses of morphine, and CA1 effects 
emerging with higher receptor occupancy (Jones et al, 1994). MOR immunoreactivity is 
found in PV+ and SST+ cells, including the OL-M cells and IS3s (Acsady et al, 1996a; 
Acsady et al, 1996b; Drake & Milner, 2002; Stumm et al, 2004), as well as Ivy cells and 
neurogliaform cells (Lafourcade & Alger, 2008; McQuiston, 2008; Krook-Magnuson et 
al, 2011). DOR expression occurs primarily in NPY+ and SST+ projections to the 
pyramidal layer, generally on cells originating in SO (Commons & Milner, 1996; Stumm 
et al, 2004). With KOR tending to overlap with DOR expression (Svoboda et al, 1999). 
The connectivity between interneurons and the localization of the opioid receptors on 
processes is critical to the way they modulate CA1 synaptic events. MOR and 
DOR/KOR systems appear to fill separate but complimentary roles, with MOR activity 
modulating feed-forward inhibition, and DOR/KOR modulating feedback inhibition 
(Pelkey et al, 2017). DOR activity appears to hyperpolarize both bistratified cells and 
OLMs, which can unbalance the normal gating of inputs to favor activation of pyramidal 
cells by the EC (Svoboda et al, 1999). MOR activity, by contrast, tends to regulate the 
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activity of terminals synapsing onto pyramidal cells rather than hyperpolarizing 
interneurons and reducing firing in that way, although this process still occurs in Ivy cells 
(Glickfeld et al, 2008; Krook-Magnuson et al, 2011).  
IS3s and OL-Ms play a stong role in spatial memory, which is affected in HAND 
(Antinori et al, 2007). Tat has been shown to worsen spatial learning and memory in the 
Morris water maze and Barnes maze tasks, and to limit memory in contextual fear-
conditioning and novel object recognition tasks, as has Gp120 (Sanchez-Alavez et al, 
2000; Carey et al, 2012; Fitting et al, 2013; Kesby et al, 2016; Marks et al, 2016). The 
diversity of interneurons and their interconnections underlie the processing power of the 
hippocampus, which is revealed in the complexity of integrated interneuronal input into 
CA1 pyramidal neurons (Buhl et al, 1994; Acsady et al, 1996a; Acsady et al, 1996b; Sik 
et al, 1997; Ali et al, 1998; Drake & Milner, 2002; Klausberger et al, 2004; Cenquizca & 
Swanson, 2006; Klausberger & Somogyi, 2008; Tricoire et al, 2010; Leão et al, 2012; 
Tricoire & Vitalis, 2012; Lovett-Barron et al, 2014; Muller & Remy, 2014; Sun et al, 
2014; Marks et al, 2016). It is the modulation of the complex interneuron-pyramidal cell 
interface that appears to be specifically affected by Tat, resulting in the observed 
behavioral deficits (Drake & Milner, 2002; Cenquizca & Swanson, 2006; Klausberger & 
Somogyi, 2008; Fitting et al, 2013; Lovett-Barron et al, 2014; Tyan et al, 2014; Marks et 
al, 2016).  For example, the vulnerable interneuron subsets we identified reportedly play 
a strong role in mnemonic and spatial memory processes (Sik et al, 1997; Cenquizca & 
Swanson, 2006; Leão et al, 2012; Lovett-Barron et al, 2014) and form a unique 
microcircuit (Tricoire & Vitalis, 2012; Muller & Remy, 2014; Tyan et al, 2014; Marks et 
al, 2016) within the larger CA1 subfield. We believe this microcircuit is critical in the 
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etiology of HIV-related mnemonic disorders (Buhl et al, 1994; Acsady et al, 1996a; 
Acsady et al, 1996b; Sik et al, 1997; Ali et al, 1998; Drake & Milner, 2002; Klausberger 
et al, 2004; Cenquizca & Swanson, 2006; Klausberger & Somogyi, 2008; Tricoire et al, 
2010; Carey et al, 2012; Leão et al, 2012; Tricoire & Vitalis, 2012; Lovett-Barron et al, 
2014; Muller & Remy, 2014; Sun et al, 2014; Kesby et al, 2016; Marks et al, 2016). The 
IS3s play a crucial role in setting the rhythm and tone in a key inhibitory circuit that 
regulates output from CA1 pyramidal cells, acting as a feedback control mechanism 
through control of other interneurons (Chamberland & Topolnik, 2012; Tyan et al, 2014). 
This feedback occurs by regulating the disinhibition of OL-M cells, which inhibit 
pyramidal cells and have significant cross interaction with bistratified cells 
(Chamberland et al, 2010; Chamberland & Topolnik, 2012; Tyan et al, 2014). The 
optogenetic activation of IS3s decreases OL-M cell firing and stimulating IS3s can 
produce activity in OL-Ms mimicking theta oscillations (Tyan et al, 2014). OL-Ms will 
have significant crosstalk with bistratified cells, which can also be inhibited by IS3s 
(Leão et al, 2012; Muller & Remy, 2014). This interaction defines a gating mechanism, 
in which dendrites receiving inputs from CA3 (in the SR) or entorhinal cortex (in the SL-
M) will be preferentially inhibited, while negating the effects of opposing inputs (Leão et 
al, 2012; Lovett-Barron et al, 2014; Muller & Remy, 2014). 
 Tat and opiate-induced functional imbalances in the interneuron network 
profoundly affect the output of pyramidal cells independently, but the question remains 
to what extent they will interact. The data seems to support the notion that despite Tat 
and morphine having the tendency to alter hippocampal function, the interactions 
between them from a functional perspective are limited (Figs 3.4-3.8). That does not 
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necessarily mean, however, that they do not interact at a deeper level which might 
mask a simple identification of the effect.  Tat has previously been shown to lower the 
expression of the mu opiate receptor in the hippocampus, while not effecting the 
expression of DOR or KOR (Fitting et al, 2010a), and MOR signaling activity in the 
striatum and amygdala also appear to be altered by Tat (Hahn et al, 2016). This shift in 
the balance of receptors/receptor activation could underlie a genuine interaction 
between Tat and morphine that would not manifest as an explicit worsening of function. 
It has been demonstrated that mild neuroprotective effects of morphine and other MOR 
antagonists can occur at low doses, or rather, with low level activation of MOR, likely 
due to the relative levels of MOR, DOR, and KOR activation (Zhao et al, 2006; Ammon-
Treiber et al, 2007; Fitting et al, 2010a; Kawalec et al, 2011). At the same time, it is 
known that the activation of DOR and KOR can have different effects on cellular 
processes and that the effects mediated by DOR and KOR often run counter to the 
effects of MOR (Loacker et al, 2007; Saboory et al, 2007; Lutz & Kieffer, 2013). 
Additionally, MOR and DOR/KOR systems appear to operate in separate but 
complimentary systems in the hippocampal GABAergic network (Valentino et al, 1982; 
Plager & Vogt, 1988; Drake & Milner, 2002; Loacker et al, 2007; McQuiston, 2008; 
Krook-Magnuson et al, 2011; Williams & Milner, 2011; Pelkey et al, 2017), and most 
importantly, many MOR agonists can also act at DOR and KOR with lower efficacy, but 
a non-zero effect (Beckman, 2014). It is a possibility that the reduced levels of MOR 
expression caused by Tat, coupled with the moderate neuroprotective effects 
achievable by activating the right combinations of opioid receptors, begins to explain 
why independent Tat and morphine/morphine withdrawal effects are evident, but 
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interactive effects are not.  it might be that a genuine interaction is occurring, but the 
effect is actually neuroprotective, and could explain why it appears that morphine 
treatment ameliorates or obviates the observed effects of Tat in Barnes maze 
performance and resting membrane potential. This question could be tested by 
administering MOR, DOR, and KOR antagonists to mice, and repeating the 
physiological studies performed in the presence of these same antagonists. Ideally, a 
dose response curve could be generated for each of these antagonist categories for 
physiological functionality and Tat interactions, with the degree of antagonism of DOR 
and KOR systems likely to reveal interactive functional pathology due to Tat and 
morphine interactions. 
Despite all of these observations in support of alterations in the GABAergic 
interneuron network by both HIV-1 Tat and by morphine, It is not possible to attribute 
this to an actual loss of inhibitory innervation.  Previous studies of the effects of Tat in 
the hippocampus showed that the amount of Syt2, the presynaptic organizer of 
GABAergic synapses was decreased in CA1.  The Syt2 loss was specifically in the SR, 
while the overall amount of gephyrin in CA1 was increased (Fitting et al, 2013). Our 
data shows that the density of gephyrin puncta within the regions of the pyramidal cell 
with typically high levels of inhibitory contacts do not change with Tat or morphine 
treatments (Fig 3.12). Nevertheless, this observation does not necessarily contradict the 
previous finding. One potential explanation is that the increase in gephyrin, believed to 
be compensatory for the loss of Syt2 expression, was sufficient to maintain inhibitory 
presynaptic contacts on the aspinous portions of pyramidal cell dendrites. Another 
potential explanation would be that the increase in gephyrin and loss of Syt2 is limited to 
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specific types of inhibitory presynaptic contacts, either local (ISI type 1, 2, or 3) 
interneurons or from extrahippocampal regions (septohippocampal projections). In 
either case, it would not necessarily be the lack of synaptic contacts onto pyramidal 
cells, but alterations in the network activity, that would be responsible for the observed 
physiological effects. 
Beyond questions about the contribution of damage to the inhibitory 
interneuronal network to the disturbances in functional output, mention also must be 
made about the observed structural and functional changes to the excitatory systems 
within CA1. In the present studies, there were differential effects of Tat and morphine on 
the spine density and spine types present across the dendrites occupying SO, SR, and 
SL-M.  Moreover, interactions between Tat and morphine were evident in SO and SL-M, 
where decreases as well as increases in different spine types were observed. Increases 
in spine density or a particular spine type can be just as disruptive to the overall balance 
of a complex circuit as a reduction. The excitatory presynaptic inputs onto pyramidal cell 
dendrites differ within each layer and region of the hippocampus. The degree to which 
spine density or spine type changes may reflect some alteration in the excitatory input 
being given or received by these areas. The largest contributors to excitatory input in 
CA1 pyramidal cells are the Shaffer collateral inputs onto SR and the temporoammonic 
inputs from entorhinal cortex that form presynaptic contacts throughout SL-M (Amaral & 
Lavenex, 2007; Agster & Burwell, 2013). Both the Shaffer collaterals and 
temporoammonic pathway possess collateral fibers that split from the main fiber tract 
and synapse onto the dendrites in SO, where their excitatory activity is directly 
modulated by cholinergic inputs from the septal nuclei (Seress et al, 2002; Buño et al, 
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2006; Zheng et al, 2011). In addition to cholinergic inputs from the septal nuclei, 
afferents from the diagonal band of Broca also modulate the activity of Interneurons in 
SO (Gulyás et al, 1991; Amaral & Lavenex, 2007; McQuiston, 2014; Bell et al, 2015). 
Although there is some evidence of direct excitation by septohippocampal inputs, the 
observation may simply be a reflection of the net disinhibition driven by GABAergic 
action of the septohippocampal inputs, resulting in increased pyramidal cell activity (Oka 
& Yoshida, 1985; Toth et al, 1993). Interestingly, some of the excitatory inputs from EC 
to SO appear to come from nNOS positive pyramidal cells (Seress et al, 2002), along 
with observations of the contributions of NO to excitotoxicity and morphine tolerance, 
might be a good target for further study (Lue et al, 1999; Eugenin et al, 2007; King et al, 
2010; Sanchez-Blazquez et al, 2010; Garzon et al, 2011; Marks et al, 2016). In addition 
to the intrahippocampal excitatory inputs, there are several extrahippocampal regions 
which send excitatory inputs onto CA1 pyramidal cells.  Afferents from the basomedial 
nuclei of the amygdala synapse onto dendrites throughout CA1 along the temporal 
hippocampus, and receive some input from CA1 (Pikkarainen et al, 1999; Amaral & 
Lavenex, 2007; Kim & Cho, 2017). More specifically, SL-M receives inputs from the 
accessory basal nucleus, while both SO and SR receive inputs from the caudomedial 
region of the parvicellular division (Pikkarainen et al, 1999). The Perirhinal cortex 
synapses onto the dendrites in SL-M, and receives inputs from CA1 resulting in 
synchronous activation under certain oscillation patterns (Supcun et al, 2012; Agster & 
Burwell, 2013; Vinck et al, 2015). The perirhinal cortex also interacts directly with the 
amygdala (Supcun et al, 2012). Finally, excitatory inputs from the nucleus reuniens 
(NR) synapse onto dendrites within SL-M, as well as SL-M interneurons (Dolleman-Van 
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der Weel et al, 1997; Amaral & Lavenex, 2007). The NR is part of a circuit involved in 
spatial memory consolidation in which (1) pyramidal cells in CA1 project to the PFC, (2) 
pyramidal neurons in the PFC project to the NR, and (3) the NR then projects back to 
CA1 (Cassel et al, 2013; Griffin, 2015). 
Alterations to any of these inputs to CA1 could profoundly change the net effect 
of hippocampal processing (Lee & Park, 2013; Newmark et al, 2013; Wu et al, 2014a; 
Benetti et al, 2015), and are likely to be directly affected by Tat and/or morphine (Table 
1.1 lists the large number of brain regions affected by Tat and morphine). However, 
even in the absence of direct neuropathology causing decreased excitatory input, the 
inputs to CA1 from each of these regions are likely disrupted by local disturbances in 
synaptodendritic structure and function depending on the combination of Tat and 
morphine. A general observation can be made that morphine is known to modulate 
spine shape. The endogenous opioid system plays a role in maintaining the integrity of 
dendritic spines; however, the application of morphine can overwhelm the normal 
function of the endogenous system, and result in a loss of spine stability (Liao et al, 
2005). More specific observations can be made, however, when considering the 
complexity of local microcircuits and inter-regional connections. First, it is notable that 
across all three regions, the least amount of change was seen in SR, where there was 
no observation of a shift in spine density following exposure to Tat or morphine, and 
comparatively fewer shifts in the type of spines present. The fact that the spines in SR 
remain comparatively stable despite the Tat and opiate insults is intriguing. There are 
some shifts in the types of spines seen in the region; yet, there is no evidence of 
interactive effects of Tat and morphine. A main effect of Tat to increase thin/filopodia 
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type spines, and a main effect of morphine to decrease mushroom-type spines are both 
observed in SR. The Tat-induced increases in the proportion of thin/filopodia type 
spines is unexpected, as LTP is known to be reduced in Tat+ animals (Li et al, 2004; 
Fitting et al, 2013).  Nonetheless, increases the filopodia are though represent newly 
formed connections and coincide with learning and plasticity (Rochefort & Konnerth, 
2012; Bailey et al, 2015). In the SL-M, there is an interesting occurrence where a 
statistically significant Tat effect upon further examination appears to be more due to 
differential effects of morphine to reduce spine density on pyramidal cells in Tat−, but 
not Tat+, mice (Fig 3.11C). This is of particular interest considering that the amygdala is 
known to send projections onto this layer, and that Tat has been seen to differentially 
modulate MOR activity in the amygdala, with Tat decreasing MOR signaling 
(Pikkarainen et al, 1999; Hahn et al, 2016). In this case, it makes sense that if Tat 
reduces MOR signaling, morphine itself will have less inhibitory activity on outputs from 
the amygdala to SL-M in Tat+ than Tat− animals, coinciding well with the observations 
of spine density in SL-M. While the amygdalar component is of note, it is also important 
to recall the existence of inputs from EC onto SL-M dendrites, and that the amygdala 
and perirhinal cortex have been shown to interact with each other and contribute to 
spatial memory processing with the perirhinal cortex and EC projections overlapping in 
the SL-M (Supcun et al, 2012; Agster & Burwell, 2013; Lee & Park, 2013). Beyond 
changes in the density of spines in SL-M, morphine treatment was observed to reduce 
the amount of thin spines in the layer, suggesting a shift away from stable connections 
toward formation of new synapses, a notion supported by the fact that Tat and morphine 
interacted to reduce the amount of mushroom spines in SL-M (Fig 3.11D) (Rochefort & 
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Konnerth, 2012; Bailey et al, 2015). In the SO, there was another differing pattern of 
spine morphology perturbation, with morphine reducing spine density regardless of Tat, 
and shifts in the amount of mushroom and stubby spines, but not thin spines. Like the 
SL-M, the SO also receives amygdalar inputs; however, the specific nuclei that project 
to these regions are different. More likely to be a contributing factor to SO morphology 
would be the modulation of septohippocampal inputs and their effects on the 
glutamatergic inputs from EC and CA3 (Seress et al, 2002; Amaral & Lavenex, 2007). 
Morphine has been shown to reduce the spontaneous firing of GABAergic neurons in 
the septum and diagonal band, which would then have an effect on the modulation of 
activity in the hippocampus and spatial memory formation (Alreja et al, 2000). This may 
explain in part the morphine-induced reductions in spine density. The change in 
morphologic types of dendritic spines is more difficult to draw conclusions from, as the 
shifts were between mushroom- and stubby- shaped spine types; both associated with 
stable synapses (Rochefort & Konnerth, 2012; Bailey et al, 2015). Variations in spine 
neck diameter may still have effects on the amount of calcium able to flow through the 
spine, allowing for subtle changes in input processing to occur with changes in the 
representation of stable spine types (Noguchi et al, 2005). Overall, while interesting to 
consider, the complexity of these local and regional networks makes pinpointing the 
exact cause of the changes in spinous morphology impossible given the current 
dataset, with further conclusions necessitating a more focused circuit based approach 
with a focus on extrahippocampal afferent projections. 
 Increased dendritic damage was seen across all three major dendritic 
compartments in response to Tat expression and to morphine, with SO and SL-M being 
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more affected than SR, mirroring the ways in which these regions changed or did not 
change spine density and spine types. The observation of damage (Figs 3.9B,E, 
3.10B,E-F, 3.11 B,E) stands in contrast to the notable lack of damage observed in 
pyramidal cells by Fitting et al (2013). It is possible that differences in the technique 
used to process the images made damage appear more evident in the present study. 
Alternatively, it is possible that the cellular trauma induced by the act of patching onto 
the cells themselves caused a strong enough perturbation to make damage appear in 
neurons that were already unhealthy or disrupted as a result of exposure to Tat and 
morphine, whereas the healthy control neurons were not damaged by the patching 
process.   
Future directions 
In light of the discovery of selectively vulnerable interneuron populations within 
the CA1, further studies on the physiological effects on these cells might be appropriate 
(Marks et al, 2016). When it is considered that previous studies in the hippocampus 
showed no increase in the number of apoptotic cells within the CA1 subfield following 
Tat exposure (Fitting et al, 2013), and that chromatolytic damage observed in the 
hippocampus with HIV infection is not necessarily lethal, and can in fact be reversible 
(Kim et al, 2008; Torres & Noel, 2014), it is reasonable to conclude that the missing 
interneurons observed in these studies may not be dead, but merely damaged; 
performing at sub optimal levels, and expressing various markers below the biochemical 
detection threshold of fluorescent immunohistochemical techniques. If this is the case, 
pharmacological rescue of these cells may be possible, in addition to more focused 
studies on their pathology. In the studies presented here, however, some interneurons 
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of the identified vulnerable subgroups remain in the tissue, which also begs the 
questions of why they are not affected as much as other cells of the same class, and 
what role the subtle variations in populations play in their resilience. Since the 
publication of the interneuron studies presented here, a broader understanding of the 
hippocampal interneuron complement was unveiled in the hippocampome project 
(Wheeler et al, 2015; Rees et al, 2016). The hippocampome is a compendium of cell 
types within the hippocampus based on gene expression patterns, with estimates of cell 
type categories which go far beyond the previously touted 21+ types of interneurons 
within the CA1. Recent improvements and additions to the hippocampome project have 
been aimed at clarifying disparate naming conventions of interneuron populations, 
identifying more subtypes of hippocampal principal cells, and exploring the network 
connectivity of the hippocampus (Rees et al, 2016; Hamilton et al, 2017a; Hamilton et 
al, 2017b; Rees et al, 2017). The idea that there are subtypes within existing 
interneuron groups is not new. Variations within the expression of proteins and of 
localization within the CA1 subfield have been noted within the bistratified cells, O-LMs, 
and neurogliaform cells (Tricoire et al, 2010; Chittajallu et al, 2013; Muller & Remy, 
2014; Pelkey et al, 2017), and in fact, many of the classifications that existed prior to the 
hippocampome project were based on one or two subtle differences, as in the case of 
IS3s (Acsady et al, 1996a; Acsady et al, 1996b; Tricoire et al, 2010). It is not 
unreasonable to expect that functional differences which were previously undetected, 
less defined, or unexplored within the cell types Identified as being vulnerable to Tat 
may play a causal role in that phenomenon. Our observation of putative losses of O-LM 
cells and bistratified cells might be better explained with this in mind. O-LMs have been 
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demonstrated to have 2 distinct subtypes, with one expressing 5HT3RA, and the other 
lacking. In addition, these subsets of O-LMs may either express parvalbumin at low 
levels, or not at all (Chittajallu et al, 2013). While the earlier discussed results did 
demonstrate a loss sof somatostatin positive cells in the SO, and while there was no 
significant reduction in cells that co-express somatostatin and parvalbumin in this 
region, there was a trend toward significance was observed when the population of 
somatostatin positive cells that lacked parvalbumin expression were examined. This 
suggests that the total loss of somatostatin positive interneurons, while containing 
individual neurons from both subpopulations, is mostly comprised of parvalbumin 
negative O-LMs.  A similar observation can be made regarding the loss of parvalbumin 
positive interneurons in the pyramidal layer which I have suggested are putative 
bistratified cells. The broad class of bistratified cells may or may not express 
somatostatin, and can even have some subtle variations in their relative depth within the 
CA1 subfield, and so may encompass several similar neuron varieties (Chittajallu et al, 
2013; Marks et al, 2016; Pelkey et al, 2017). 
A project to assess the firing properties of IS3 cells in the CA1 was begun, but 
terminated for technical reasons. Tat mice were bred with a live of tdTomato VIP 
reporter mice to enable targeted patch clamping of VIP positive cells, with the intention 
of identifying VIP+ IS3 cells within the pyramidal layer for physiological and 
morphological analysis. Several cells were successfully patched and subsequently 
identified as putative IS3s by confirming morphological and basic physiological 
properties (Tyan et al, 2014). This project had to be terminated due to a problem with 
the TdTomato construct association with the VIP promoter, which caused TdTomato to 
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be expressed constitutively in the mice (Fig 4.1), rendering it impossible to identify any 
one cell under excitation. Necropsy revealed that the only materials/tissues that did not 
glow under excitation were the fur, bones, and blood. This project is a logical next step 
in continuing the exploration of the effects of Tat and morphine on the functionality of 
the CA1, and is in fact commonly asked for by individuals who learn of the study on the 
effects of Tat on the interneuron network. A few additional components that should be 
added to the study for comprehensiveness include the expansion of the scope to 
include multiple subtypes of interneurons beyond the IS3s, and the inclusion of MOR, 
DOR, and KOR agonists/antagonists to determine the role of opioids in the functionality 
of these interneurons following Tat exposure. Additionally, a paired recording system in 
which recordings are made from pyramidal cells and identified interneurons 
simultaneously under these conditions would further clarify the interactions between Tat 
and the presence of opioids in the CA1 system.    
Further mechanistic studies of the physiology of the pyramidal cells themselves 
would be beneficial in which pyramidal cells are systematically isolated from the 
surrounding circuits by sequential application of specific antagonists This study was 
attempted with inhibition of AMPA and NMDA with AP5 and CNQX respectively,  
CGP55845 was added to the AP5 and CNQX containing solutions to inhibit GABAB 
receptors, and finally Bicuculline was added to the other antagonists to inhibit GABAA 
receptors, with a final goal of isolating the pyramidal cells from glutamatergic and 
GABAergic neurotransmission. While this study was attempted, technical errors resulted 
in the failure of the experiment. Moving forward, some alterations to the design would 
be useful in clarifying the outcomes further. First, in the original experiment, application 
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of the GABAB antagonist CGP 55845 always occurred before application of bicuculline 
to antagonize GABAA. It would be better to alternate which GABA antagonist is applied 
first in case there is any additive effect of GABA receptor types. This would be important 
moving forward, and both GABAA and GABAB receptors are involved in the functionality 
of CA1 regional circuitry (McQuiston, 2007; Pelkey et al, 2017). Additionally, this study 
would benefit greatly from the acquisition of mini EPSPs/IPSPs and paired pulse 
facilitation experiments in conjunction with the isolation of pyramidal cells from the 
surrounding circuitry and various morphine exposure/withdrawal paradigms. In order to 
better investigate the link between circuit function and behavior, it would also be useful 
to observe the effects of Tat and morphine/morphine withdrawal on LTP in the 
hippocampus (Bao et al, 2007; Fitting et al, 2013; Portugal et al, 2014). 
Behaviorally, additional studies into the effects of Tat and morphine on spatial 
memory acquisition would be worth pursuing. In the present studies (Figs 3.1, 3.2), 
Morphine administration is achieved by the implantation of an indwelling pellet resulting 
in continuous morphine release over several days. This presents a few confounding 
factors, including the potential for peripheral inflammation resulting from the pelleting 
surgery itself affecting behavioral outputs, even with proper post-surgical care (Chen et 
al, 2008; Vizcaychipi et al, 2014). Additionally, continuous morphine application does 
not adequately mirror the usage pattern of opioid abusers, who will go through a series 
of highs and lows in their pursuit and use of opioid drugs (Eitan et al, 2017). The results 
of this experiment may be easier to interpret, and more translational if a paradigm of 
repeated morphine injections were used rather than the implantation of a morphine 
pellet. While this is not without its own problems, including confounds from the 
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repetitious injections and the increased amount of handling that would be necessary, 
contrasting these data with the continuous administration might yield valuable insight. It 
may also be useful to isolate MOR, DOR, and KOR effects by including their respective 
antagonists through the duration of treatment to see if the effects of the differential 
contribution hypothesis I have laid out here are indeed observable in behavioral 
outcomes (Ammon-Treiber et al, 2007; Fitting et al, 2014; Fitting et al, 2015b; Hahn et 
al, 2016). 
A pilot study was performed to examine the degree of hippocampal inflammation 
associated with HIV-1 Tat and morphine. The effects of Tat and morphine on cytokine 
levels were examined in hippocampi isolated from randomly selected mice following 
behavioral analysis discussed in chapter 3, with 3 to 4 animals in each of four groups 
(Table 4.1) utilizing the Bioplex cytokine assay (Bioplex, Catalog #M60009RDPD). A 
main effect of Tat was observed for levels of GM-CSF [F(1,9) = 6.525, p < 0.05], with 
Tat+ mice having lower levels of this cytokine than Tat− mice. Similarly, there was a 
trend for Tat+ animals to display reduced levels of CCL2 that Tat− animals [Main effect; 
F(1,10) = 4.718, p = 0.055]. Of the 23 cytokines assayed, no other cytokines were 
significantly affected by Tat and/or morphine. G-CSF, was unable to be analyzed due 
several samples being excluded for errors in data aquisiton (table 4.2). The observation 
that Tat+ animals had a decreased expression of GM-CSF was surprising, as the 
expression of this cytokine tends to increase with inflammatory insult rather than 
decrease (Choi et al, 2014). GM-CSF is usually considered a pro-inflammatory cytokine 
because it acts as a growth factor for macrophages, it is involved in the differentiation of 
immune cells, and it’s levels increase with inflammation (Bhattacharya et al, 2015). The 
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reasons why GM-CSF is not elevated in the hippocampus of Tat+ mice is uncertain, 
although it may due to timing or perhaps result from the development of innate immune 
tolerance in response to unrelenting Tat exposure (Gonek et al, 2017).  Alternatively, 
some elevation in baseline levels of cytokines might occur in our control mice during 
surgical implantation of the placebo pellets. It has previously been shown that peripheral 
inflammation can trigger the inflammation in the CNS (DiSabato et al, 2016) .  
 A study in progress is further examining the interactive effects of HIV-1 Tat and 
the effects of morphine withdrawal on cytokine levels. Tat transgenic animals are being 
exposed to doxycycline for 5 days, prior to receiving either a placebo or 25-mg 
morphine pellet implant, which remains in place concurrently with doxycycline 
administration for an additional 5 days. On the last day, animals are given a 
subcutaneous injection of either saline, or 10 mg/kg naloxone 1 hour before harvesting 
the tissue to induce precipitated withdrawal in morphine-treated mice, yielding a 
balanced study design with 8 groups; placebo/saline, morphine/saline, 
placebo/naloxone, and morphine/naloxone in both Tat- and + mice.  It is difficult to 
predict the outcome of this study due to several potentially opposing observations in our 
mouse model. HIV-1 Tat may directly effect the function of the endogenous opioid 
system. Notably, in the hippocampus, MOR transcript levels are reduced, but not DOR 
and KOR (Fitting et al, 2010a), which may result in alterations in morphine 
responsiveness in the region (Fitting et al, 2010a; Razavi et al, 2014). Tat+ mice have 
been shown to develop greater tolerance to morphine, and less severe withdrawal 
behaviors. These effects coincide with the temporal expression of Tat (Fitting et al, 
2012; Fitting et al, 2016). While the withdrawal behaviors in Tat+ mice may be 
 
 
140 
 
diminished, the severity of functional effects within specific brain tissues are likely to be 
more heterogenous (Fitting et al, 2010a; Fitting et al, 2010b; Gelman et al, 2012; Nath, 
2015). MOR expression is observed in astrocytes, and there are astrocyte specific 
splice variants (Dever et al, 2012), and similar to the broader CNS expression of MOR, 
HIV can cause a shift in the expression levels of different splice variants, likely causing 
alterations in the normal balance of functions modulated by those receptors by the 
endogenous opioid system (Fitting et al, 2010a; Dever et al, 2012).  Fitting et al (2010b) 
showed that HIV Tat increased in the production of cytokines and chemokines in culture 
from multiple regions of the brain, while neither gp120 or morphine affected cytokine 
release; however, the hippocampus was not included in that study. Interestingly, there 
was no interaction between Tat and morphine on the production of cytokines and 
chemokines. Alternatively, the pilot data shows that most cytokines did not change 
when assayed from the entire hippocampus from Tat+ mice, nor was there any 
observed effect of morphine. The only cytokine that did change (GM-CSF) was 
decreased. Although there is no extant hippocampal screen to compare this data 
against, the near global effect of Tat on cultured astrocytes from varying CNS regions 
makes this possibility very unlikely (Fitting et al, 2010b). This could indicate that the 
sample size in the pilot data was not sufficient, but more likely suggest that the pattern 
of cytokines released from an intact, adult hippocampal system treated over time with 
Tat and morphine differs from pattern of cytokines seen in an artificial in vitro system in 
which neonatal astrocytes are cultured in isolation and treated acutely with Tat and 
morphine (Fitting et al, 2010b). Since the mice used for the withdrawal component of 
this project had been exposed to morphine for several days, it is not expected that any 
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morphine effect will be seen in light of the pilot data as the 5 day exposure period is 
long enough for tolerance to develop. Nevertheless, there is a chance that the 
inflammatory cytokine response to spontaneous withdrawal, which is less abrupt than 
precipitated withdrawal caused by giving an opioid receptor antagonist such as 
naloxone, may qualitatively differ from the cytokine response after 5 days of chronic 
morphine exposure.  
An added layer of complexity to all the above-mentioned future directions would 
come with adjustments to the timing of experiments and treatment periods. The studies 
presented and proposed in this document all have a relatively acute Tat exposure 
paradigm, with experiments occurring after 10-12 days of DOX administration, and any 
morphine exposure happening within the last 5 days of that 10-12 day window. With the 
consideration of the temporal component of neuroinflammatory processes (Schwartz & 
Baruch, 2014), and the effects of HIV in aging populations (Ances et al, 2012), Many 
more questions relevant to discrete populations of both HIV+ individuals and opioid 
users can be addressed, and questions regarding the timing of the development of 
observable behavioral effects vs underlying circuit pathology can be addressed in 
greater detail (Norman et al, 2007; Vander Jagt et al, 2008; Schier et al, 2017). 
Concluding remarks 
 The effects of HIV infection and more specifically the Tat protein in the 
hippocampus are less well studied than other regions of the CNS like the striatum or the 
cortex, and relatively few studies have focused on the effects of HIV infection on the 
neural circuitry and resultant functional activity of the hippocampus or any other region 
of the brain. The studies performed here are among the first observations of the effects 
 
 
142 
 
of HIV infection on the physiological activity of the hippocampus, and the first studies of 
their kind exploring interactions of Tat and morphine on the physiological outputs of the 
hippocampus. The results of these studies have revealed selective vulnerability of 
interneuron subsets to HIV-1 Tat, shown electrophysiological deficits related to HIV-1 
Tat, and perhaps most importantly, suggest that HIV-1 Tat and morphine do not 
synergistically interact to worsen pathology in the hippocampus despite the prevailing 
wisdom that morphine exposure exacerbates the progression of HIV induced 
neuropathology throughout the brain. These new data open the door to circuitry-based 
inquiry in the context of both neuroAIDS and opiate abuse, form a starting point for 
many new questions to be studied, and ultimately stand as a novel insight into the 
etiology of HAND development that will hopefully be useful in informing the treatment of 
these disorders in patients. 
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Figure 4. 1: TdTomato x VIP expressing mice 
 
 
 Images depicting transgenic mice expressing TdTomato under the control of the 
VIP promoter (A, D, E), or constitutively (B-E) under excitation under blue light using the 
Nightsea fluorescence visualization system (Nightsea, Bedford, MA). 
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Cytokine Tat- Placebo 
n = 3 
Tat+ Placebo 
n = 3-4 
Tat- Morphine 
n = 3-4 
Tat+ Morphine 
n = 3-4 
IL-1a 5.17 ± 0.16 5.93 ± 0.46 6.74 ± 1.07 6.08 ± 0.87 
IL-1b 25.97 ± 0.2 32.58 ± 2.65 31.57 ± 3.12 30.69 ± 3.08 
IL-2 51.01 ± 3.1 67.91 ± 7.21 70.78 ± 9.65 65.41 ± 7.85 
IL-3 3.56 ± 0.3 3.3 ± 0.48 3.923 ± 0.46 2.662 ± 0.78 
IL-4 1.84 ± 0.32 1.26 ± 0.04 1.76 ± 0.16 5.34 ± 4.23 
IL-5 2.5 ± 0.41 2.58 ± 0.33 4.06 ± 0.73 2.85 ± 0.28 
IL-6 4.2 ± 0.27 4.63 ± 0.22 4.1 ± 0.79 4.29 ± 0.67 
IL-9 27.99 ± 2.5 24.52 ± 1.47 28.83 ± 4.26 21.81 ± 4.67 
IL-10 10.33 ± 0.83 8.87 ± 0.11 12.15 ± 1.56 9.54 ± 1.58 
IL-12 p40 11.25 ± 0.88 11.45 ± 1.74 11.93 ± 1.36 11.85 ± 2.24 
IL-12 p70 228.14 ± 3.59 211.56 ± 41.4 228.26 ± 14.43 240.92 ± 19.09 
IL-13 90.21 ± 7.76 142.34 ± 20.23 138.27 ± 31.25 138.16 ± 24.43 
IL-17 61.22 ± 6.22 55.34 ± 4.65 69.92 ± 5.13 50.78 ± 10.84 
Eotaxin 130.13 ±18.23 128.53 ± 4.99 136.16 ± 12.14 121.38 ± 13.12 
GM-CSF 27.12 ± 1.58 15.91 ± 4.96* 26.46 ± 1.77 22.377 ± 3.11* 
IFN-γ 120.23 ± 13 135 ± 45.54 141.88 ± 16.16 132.64 ± 27.46 
KC 3.56 ± 0.3 3.2 ± 0.48 3.92 ± 0.46 2.66 ± 0.78 
MCP-1 46.05 ± 3.81 35.01 ± 4.91b 45.73 ± 2.36 39.44 ± 5.4b 
MIP-1α 2.12 ± 0.27 1.75 ± 0.41 2.26 ± 0.26 1.56 ± 0.58 
MIP-1β 30.56 ± 3.48 37.1 ± 0.95 30 ± 2.73 29.97 ± 4.13 
RANTES 12.91 ± 1.28 12.81 ± 0.33 14.81 ± 1.64 11.74 ± 1.37 
TNF-α 404.12 ± 61.59 495.42 ± 104.82 386.32 ± 96.27 553.38 ± 8.93 
 
Table 4. 1: Effects of Tat and morphine on hippocampal cytokine levels 
 Table 4.1 lists the levels of multiple cytokines assayed using the Bioplex 
analysis. * indicates a significant main effect of Tat (p < 0.05). bindicates a trend toward 
a main effect of Tat (p = 0.055). Values are expressed as mean µg/ml ± SEM. 
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Sample 
ID# 
Tat Drug 
Concentration 
(µg/mL) 
Desired Final 
Concentration 
(ug/mL) 
Volume 
Sample 
(µL) 
Volume IP 
Buffer 
(µL) 
Final 
protein 
content 
1 - Placebo 4099.92 500 15.244 47.26 62.5 
2 - Placebo 5476.04 500 11.41 51.09 62.5 
3 - Placebo 4658.41 500 13.417 49.08 62.5 
4 - Morphine 2000.93 500 31.23 31.26 62.5 
5 - Morphine 3982.01 500 15.7 46.8 62.5 
6 - Morphine 5028.84 500 12.428 50.07 62.5 
7 - Morphine 5375.62 500 11.627 50.87 62.5 
8 + Placebo 365.66 200 68.37 -5.87 50.8 
9 + Placebo 2858.09 500 21.87 40.632 62.5 
10 + Placebo 4568.35 500 13.68 48.82 62.5 
11 + Placebo 3163.41 500 19.76 42.74 62.5 
12 + Morphine 3320.84 500 18.82 43.67 62.5 
13 + Morphine 4798.52 500 13.025 49.48 62.5 
14 + Morphine 4040.32 500 15.47 47.03 62.5 
15 + Morphine 3088.98 500 20.23 42.27 62.5 
 
Table 4. 2: Protein extracted from hippocampal samples 
  Records of the amount of protein extracted from hippocampal tissue 
samples as recorded by the BCA analysis. Dilution factors to achieve the desired 
protein concentration, the amount of additional buffer needed, and the final protein 
concentration for each sample are listed. Sample 8 (Tat+ / placebo) was excluded from 
all analyses due to low protein yield. 
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